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Abstract
Background
The common argument used against the implementation of tobacco control policies is that
revenue from tobacco duty is considerably higher than the health care costs smoking imposes
on society. This point is true as revenue in the United Kingdom (UK) totalled £9.1 billion
while recent costs estimates for the treatment of smoking-attributable disease totalled £5.2
billion to the UK National Health Service. However, this argument becomes unclear when
indirect costs such as productivity loss or cost of absenteeism are incorporated. In the UK,
there were 29.2 million employed adults in 2011 of which 20% were current smokers. This
equates to approximately 5.84 million employed adult smokers. There are currently no
studies which have quantified the economic impact of smoking-attributable indirect costs to
both employers and the wider society in the UK. These costs are suspected to impose a large
economic burden to society but the best practice methodology for estimating indirect costs
and the magnitude of these costs are still unknown. Therefore, the aims of this thesis were to
quantify the economic impact of smoking-attributable indirect costs due to productivity loss
from premature mortality and absenteeism of workforce and to evaluate workplace
interventions which could potentially decrease the burden of smoking in the workforce in the
UK.
Methods
A number of methods were used along with a range of data sources which provided the
information to quantify the economic impact of smoking in the workforce. Cost-of-illness
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methodology based on the human capital method was utilised to quantify the monetary
burden of smoking in the workforce due to premature mortality in the UK. Systematic review
and meta-analysis was used to examine the epidemiological association between smoking and
absenteeism while also providing the necessary parameters to estimate costs of absence in the
UK. Finally, decision analysis and Markov simulation modelling was used to conduct both
cost-benefit analysis and cost-effectiveness analysis from the employer's perspective for
evaluating workplace smoking cessation interventions of brief advice, individual counselling
and nicotine replacement therapy with individual counselling.
iii
Results
Cost-of-smoking modelling estimated that smoking was responsible for 96,105 deaths (58%
male) in adults aged 35 years and over (17% of all deaths) in the UK annually, resulting in
1.2 million years of total life lost and 357,831 years of productive life lost valued at £4.93
billion in 2010. From the systematic review of 29 longitudinal studies, current smokers had a
33% increase in risk of absenteeism and were absent for an average of 2.74 more days per
year compared with non-smokers. Compared with never smokers, ex-smokers had a 14%
increase in risk of absenteeism; however, no increase in duration of absence could be
detected. Indirect comparison meta-analysis showed that current smokers also had a 19%
increase in risk of absenteeism compared with ex-smokers. Consequently, smoking was
estimated to cost UK employers £1.46 billion in 2011 from absenteeism in the workplace.
Workplace interventions for smoking cessation provide a possible method for reducing the
burden of smoking in the workforce. Cost-benefit analysis of workplace interventions
resulted in brief advice being the optimal decision strategy for women while brief advice and
individual counselling both were optimal decision strategies for men in terms of minimising
total costs and maximising return on investment for the employer. If the employer valued
maximising quitting instead, cost-effectiveness analysis showed that nicotine replacement
therapy with individual counselling would be the optimal strategy given a maximised budget
constraint.
Conclusion
This thesis has provided the first indirect cost-of-smoking study quantifying the productivity
loss due to premature mortality and absenteeism in UK; the first systematic review and meta-
analysis which has explored the association between smoking and absence from work; and
the first cost-benefit and cost-effectiveness analyses of workplace interventions for smoking
cessation in the UK. The implications of this research have particular relevance for UK
policy makers and employers to justify stronger tobacco control policy which promotes
smoking cessation. However, these findings are not unique to the UK. The thesis has
provided the framework and methodology for studies that can strengthen the evidence-base
around the economics of smoking in other countries as well ..
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Chapter 1
Introduction and Background
/'
1.1 Health effects of smoking
1.1.1 Mortality
Tobacco use is the leading cause of preventable death and disease in the world.' In the 20th
Century, tobacco use from smoking caused 100 million deaths.' Smoking-attributable
diseases are currently responsible for one in ten' adult deaths worldwide resulting in the
deaths of 6 million people per year.' On the basis of current consumption patterns, 450
million adults will be killed by smoking between 2000 and 2050 where over half of these
deaths will occur prematurely between the ages of 30 and 69 years." Latest estimates show
that the overall number of deaths in the UK has declined from 106,0005 per annum in 1998-
2002 to 96,1056 in 2010 due to a decrease in the adult smoking prevalence from 27%5 from
1998-2001 to 20%7 in 2010. Despite this decline, smoking is still responsible for one in six
deaths" in the UK. In men, lifetime smokers are expected to die on average 10 years earlier
than never smokers." In women, lifetime smokers are expected to die on average 11 years
earlier than never smokers.9 The shortened life span is due to the causal link that has been
established between smoking and a number of smoking-related diseases.' This section
summarises the primary causes of mortality and morbidity from smoking.
1.1.2 Cancer
Since the 1950s, there has been evidence that tobacco smoking is associated with an
increased risk of lung cancer (from case-control studies ).10 11 In 1986, the International
Agency for Research on Cancer (IARC) established a significant causal association between
tobacco smoking and cancers of the lung, oral cavity, pharynx, larynx, oesophagus, pancreas,
urinary bladder and renal pelvis from epidemiological studies.V Since then, new
epidemiological evidence has established that smoking also causes cancer of many other
organs including nasal cavities, paranasal sinuses, nasopharynx, liver, stomach, kidney,
uterine cervix, adenocarcinoma of the oesophagus and myeloid leukaemia.v' Compared to all
other cancers, the risk of developing lung cancer is extremely high in smokers and increases
with the number of cigarettes smoked.l" Controversy exists as to whether women are more or
less susceptible to the carcinogenic effects of cigarette smoke. Some biological studies have
suggested women may be more predisposed than men to molecular aberrations resulting from
the carcinogenic effects of tobacco smoke." However, observational studies 1617have not
found a significant difference in lung cancer risk between men and women.
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From 2010-2011 in England, a total of 160,300 primary diagnoses (11% of all diagnoses) of
cancer were found to be attributable to smoking; of which lung cancer accounted for 66,200
diagnoses (41% of smoking-attributable cancersj.i Smoking-attributable bladder cancer
accounted for the second largest number of cancer diagnoses with 33,400 diagnoses (21% of
smoking-attributable cancers).
1.1.3 Respiratory disease
There has been evidence since the 1960s that cigarette smoking was associated with a
doubling of the risk of chronic bronchitis and chronic obstructive pulmonary disease (COPD)
compared to non-smokers." 19There also has been early evidence to show that patients with
COPD have an increased risk of developing lung cancer.20 A recent study21 has suggested
that long-term oxygen depletion stimulates signals that promote tumour growth. It has been
estimated that 21% of smokers will develop moderate COPD and 4% of smokers will develop
severe COPD.22 However, evidence has also shown the majority of smokers will get COPD
but it is routinely under-diagnosed due to smokers dying from co-morbidities.f Evidence
from meta-analyses has shown that current smoking significantly increases the overall risks
of COPO (RR 3.51,95% Cl 3.08 to 3.99, N = 129 studies), chronic bronchitis (RR 3.41, 95%
Cl 3.13 to 3.72, N = 114 studies) and emphysema (RR 4.87, 95% Cl 2.83 to 8.41, N = 28
studiesj.i" From 2010-2011 in England, a total of 126,200 diagnoses of respiratory disease
were due to smoking; of which COPD accounted for 88,500 diagnoses (70% of smoking-
attributable respiratory disease),"
1.1.4 Cardiovascular disease
There is strong evidence that supports the association between smoking and cardiovascular
disease (CVD) including ischemic heart disease25, cerebrovascular disease/", atherosclerosisf
and aortic aneurysms", In addition, smoking is also associated with acute myocardial
infarction28 and stroke", Smoking is associated with a two to four-fold increase in risk of
ischemic heart disease, an increase in excess rate of death by 70% from ischemic heart
disease and elevated risk of sudden death.25 In a multicentre study in 52 countries, smoking
was associated with an increased risk of myocardial infarction (Odds Ratio [OR] 2.95, 95%
Cl 2.77 to 3.14) compared with never smoking." In a meta-analysis of 32 studies, the overall
relative risk of stroke associated with cigarette smoking was 1.5 (95% Cl 1.4 to 1.6).26 In a
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systematic review of 10 studies, the risk of aortic aneurysms was between three to six-fold
greater in current smokers than in non-smokers.i
From 2010-2011 in England, a total of 135,400 diagnoses of cardiovascular diseases (15% of
all CVO diagnoses) were found to be due to smoking; of which ischemic heart disease
accounted for 64,700 diagnoses (48% of smoking-attributable CVO), other heart disease
accounted for 37,600 diagnoses (28% of smoking-attributable CVO) and cerebrovascular
disease accounted for 16,700 diagnoses (12% of smoking-attributable CVO).7
1.1.5 Passive smoking
In addition to the harmful effects smokers pose to their own health, tobacco smoke also
generates considerable health threats to those who are exposed to second-hand smoke (SHS)
or environmental tobacco smoke_29 Passive smoking is the inhalation of SHS or ETS by
persons other than the intended active smoker which occurs when tobacco smoke permeates
any environment.
Systematic review evidence has shown that exposure to second-hand smoke significantly
increases the overall risk of lung cancer (RR 1.29, 95% Cl 1.17 to 1.43, N = 43 studiesr'",
heart disease (RR 1.25, 95% Cl 1.17 to 1.32, N = 18 studies)" and stroke (RR 1.25, 95% Cl
1.12 to 1.38, N = 20 studies)32 in lifelong non-smokers. There is also some evidence to
suggest that exposure to as little as an hour of second-hand smoke in adults is linked to an
acute decline in lung function while longer term exposure can induce asthma and COPO.33
While the health risks of passive smoking are small in comparison with the effects of active
smoking, the overall health impact is large due to the outcomes being common." In the UK,
passive smoking at work is estimated to be responsible for 617 deaths per year while the
burden is even greater in domestic settings." Each year passive smoking in the home is
estimated to account for another 2,700 deaths in persons aged 20-64 years and 8,000 deaths
among people aged ~ 65 years.35
Since a large proportion of passive smoking occurs in the home, children are particularly
vulnerable. Systematic review evidence has shown that second-hand smoke exposure in non-
smoking pregnant women is associated with an increased risk of low birth weight (OR 1.32,
95% Cl 1.07 to 1.63, N = 23 studies)." Additionally, second-hand smoke exposure to
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children in the home increases the risks of sudden infant death syndrome " (OR 2.08, 95% Cl
1.83 to 2.38, N = 19 studies), asthma in childhood " (OR 1.37,95% Cl 1.15 to 1.64, N = 14
studies) and bacterial meningococcal disease39 (OR 2.02, 95% Cl 1.52 to 2.69, N = 16
studies). Each year in the UK, second-hand smoke exposure leads to 20,000 cases of
respiratory infections; 120,000 cases of middle-ear disease; 22,000 cases of wheezing and
asthma; 200 cases of bacterial meningitis and 40 sudden infant deaths/"
1.1.6 Smoking in pregnancy
Second-hand smoke exposure is not the only means in which smoking can harm others.
Smoking in pregnancy can cause harm to the unborn child. Maternal smoking in pregnancy is
known to be associated with an increased risk of low birth weight" 42,pre-term delivery43 44,
certain congenital malformations45-47, spontaneous miscarriage" and placenta abruption'",
Recent review evidence has also shown that maternal smoking in pregnancy has also been
linked to an increased risk of being overweight in childhood (OR 1.47, 95% Cl 1.26 to 1.73,
N = 7 studiesj." Even though maternal smoking in pregnancy may result in growth
restriction in utero resulting in low birth weight infants, some studies have found that
affected infants exhibit extremely high rapid postnatal weight gain.51 52 It is also likely that
maternal smoking in pregnancy is a proxy for other social and lifestyle characteristics. In a
US study of low income children and their parents, children of smokers were found to have
poor diet quality with high levels of saturated fat, high levels of cholesterol intake and low
levels of fibre intake.53
1.1.7 Other diseases
Smoking is also suspected to be associated with other conditions such as hypertensiorr",
female infertility5 , gastric ulcers'", declining bone-mineral density'", rheumatoid arthritis'",
abdominal aneurysms'" and subarachnoid haemorrhage'", Although most of these conditions
are established as being associated with smoking through observational evidence, the exact
casual mechanisms are not entirely known compared to other more well-established casual
relationships (e.g. lung cancer, CVD, COPD).
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1.2 Smoking trends in the UK
1.2.1 Gender
Cigarette smoking had become extremely common in the UK in the first half of the 20th
Century in which an estimated 80% of men and 40% of women smoked.?' The Office for
National Statistics (ONS) started collecting official smoking prevalence data from 1948 in the
General Lifestyle Survey (GLS). The trends in smoking prevalence and lung cancer incidence
are shown from 1948 to 2010 in Figure 1.
Figure 1.Cigarette smoking prevalence and lung cancer incidence in the UK 1948-2010
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Since the start of data collection, smoking prevalence in men was already declining from
65% in 1948 to 54% in 1966. Inwomen, smoking prevalence increased from 41% in 1948 to
45% in 1966. It was not until the 1970s after the highly publicised Royal College of
Physicians report'" and US Surgeon General report'" on the harmful effects of smoking were
there sharp declines in smoking prevalence. Smoking prevalence fell rapidly from 55% to
31% in men and from 44% to 29% in women from 1970 to 1990. The rate of decline slowed
from the mid-1990s despite increased government legislation on tobacco control and
increasing pressure from the public health community. From 2000 to 2010, smoking
prevalence declined from 29% to 21% in men and from 25% to 20% in women. The trends
have shown that this decline has started to stagnate in recent years. Interestingly, the trends
in lung cancer (recorded from 1975 onwards) have shown a 20-year lag in following gender-
specific smoking prevalence rates (Figure 1). The 20-year lag was due to the harmful effects
of lung cancer usually occurring later in life. In men, the consistent decline in smoking
prevalence has followed the decrease in incidence of lung cancer. In women, lung cancer
incidence trended upwards as a result of smoking prevalence increasing from 1948 to 1966.
1.2.2 Age-groups
Smoking prevalence historically has been high in all age-groups. In 1974, smoking
prevalence was highest in the middle-age-groups (25-59 years) with relatively low levels of
youth smoking (16-19 years) and older adult smoking (60+ years) (Figure 2). Since then, the
largest declines in smoking prevalence have occurred in the middle-age-groups. In 1974,
more than half of adults aged 35-49 years smoked cigarettes. In 2010, the prevalence declined
to 24% in adults aged 35-49 years. Smoking prevalence in 2010 was lowest in individuals 60
years or older (13%) and youths aged 16-19 years (19%). Smoking prevalence was relatively
higher in 2010 for adults aged 20-24 years (27%) and 25-29 years (26%).
One group that Figure 2 does not show is the prevalence in children under the age of 16
years. The majority of UK smokers begin smoking before the age of 16 years.65 In 2011,
approximately 25% of pupils aged 11-15 years had tried smoking at least once and about 5%
were regular smokers (smoking at least one cigarette per week)." Evidence has also shown
that an earlier age of initiation leads to a decrease in success for smoking cessation later in
life.6667
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Figure 2. Cigarette smoking prevalence by age in the UK 1974-2010
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1.2.3 Socio-economic groups
Smoking has been established as having the single largest impact on heaJth inequalities.I"
Before the associations between smoking and lung cancer were first reported in the 1950s,
there was little difference in smoking prevalence between socioeconomic groups. The rate of
decline in smoking prevalence from the 1970s onwards is now known to differ by socio-
economic status.70 Figure 3 illustrates the differential decline of adult smoking prevalence in
manual and non-manual occupational groups from 1992 to 2010. In 1992, the prevalence of
smoking in manual workers was 33% while the prevalence of smoking in non-manual
workers was 23%. After 18 years, the prevalence of smoking in manual workers declined by
only 5% to 28% in 2010 while the prevalence of smoking in non-manual workers declined by
10% to 13% in 2010. The discrepancies in smoking prevaJence by socio-economic status are
likely due to higher uptakes rates and less successful quit attempts in more disadvantaged
groups.i'
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Figure 3. Prevalence of cigarettes smoking by occupational group,
adults aged 16 and over, UK 1992-2010
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Studies have also suggested that disadvantaged groups have reduced social support for
quitting, low motivation to quit, stronger addiction to tobacco, lack of self-efficacy and
increased likelihood of not completing smoking cessation interventions." As a result, large
survey studies 73 74 in the UK have shown that smoking rates are significantly higher in
deprived groups than in more affluent groups.
1.2.4 Maternal smoking in pregnancy
In 2005, nearly 33% of mothers in the UK smoked at some point in the 12 months
immediately before or during their pregnancy while 17% of mothers continued to smoke
throughout their pregnancy." The latest figures from the Infant Feeding Survey" showed a
decrease in smoking in pregnancy. In 2010, around 26% of mothers in the UK smoked
directly before or \during their pregnancy while 12% of mothers continued to smoke
throughout their pregnancy." The Department of Health has identified a national target to
reduce smoking during pregnancy to 11% or less by 2015 measured at the time of delivery."
The target is likely to be achieved as 54% of smoking mothers in the UK currently give up
smoking at some stage before birth." However, there is a strong association between
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smoking levels and socio-economic status. Mothers in routine and manual occupations were
five times more likely than those in managerial and professional occupations to have smoked
throughout pregnancy (20% and 4% respectivelyj."
1.3 Economic consequences of smoking
1.3.1 Nicotine addiction and individual costs
The addictive properties of nicotine are well known. Nicotine, a major component of tobacco
smoke, acts in the brain by stimulating nicotinic acetylcholine receptors (nAChRs). One of
the fastest ways to absorb nicotine is through cigarette smoking. A study of volunteers
comparing different methods of absorption found peak arterial concentrations of nicotine
were similar whether inhaled or injected intravenously.i" The smokers in the study achieved
almost 90% of all nicotine present in the mainstream smoke proving that smoking is a fast
and efficient way to absorb nicotine." However, nicotine is not the only addictive property of
cigarettes. Smokers rely on many non-nicotine components (i.e. the 'act' of smoking,
'scratchy' throat) that reinforce smoking behaviour. A more recent literature review of
smoking cessation interventions found that smokers also relied on the non-nicotine
components of the smoking to provide many of the rewarding effects, often surpassing the
direct effects of nicotine itself.79 As a result of the physical and psychological dependency on
smoking, an individual who smokes 20 cigarettes a day will spend about £2,600 a year (2011)
on cigarettes.t'' The total household expenditure on tobacco has decreased since 1980 to 2.0%
of total household expenditure in 2011.7 Despite this decline, the total amount spent on
tobacco in the UK remains substantial ranging from estimates of £15.3 billion to £18.3 billion
in 2011.80
1.3.2 Societal costs of smoking
The costs of smoking to society can come in the form of direct healthcare costs and indirect
costs. Globally, net economic loss amounts to $200 billion (1998) USD (£132 billion) per
year attributable to health care costs and lost productivity. I The health consequences of
addiction and smoking-related morbidity and mortality can be directly attributed to between
6% and 15% of total healthcare expenditures in high-income countries. I To date, most
economic studies evaluating the cost of smoking have focused only on healthcare costs.
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While many of these studies81-83 have found that the lifetime healthcare costs of smokers
(taking account of shorter life expectancy in smokers) are higher than those of non-smokers,
other studies84-86 have found the opposite. In the case of the UK, the direct healthcare costs to
the UK National Health Service (NHS) remained high at £5.2 billion (2005).87 However,
indirect costs are more difficult to quantify. Some expert commentaries from the UK have
suggested that approximately 50 million working days are lost each year due to smoking
valued at £1,710 million (1998).88 Another study of employers in Scotland found that the
annual cost of employee smoking was estimated to be about £450 million (2000) from lost
productivity." The sheer scale of the finances suggests that decreases in smoking prevalence
may result in huge gains in productivity.
1.4 Smoking cessation
1.4.1 Health benefits
The most obvious benefits of smoking cessation are the improvements in life expectancy and
prevention of disease. Smoking cessation at any age has been shown to result in a gain of life
years; those who stop at the age of 60, 50, 40, 30 years gain on average 3, 6, 9, 10 years
respectively.i The gain in life years is due to the overwhelming health benefits of quitting
smoking. When an individual quits smoking, the benefits are seen immediately." 91 These
immediate benefits will lead to longer term benefits from sustained quitting. Evidence has
shown that heart rate and blood pressure drop approximately 20 minutes after quitting'" and
blood carbon monoxide levels drop to normal after about 8 hours.9o Smoking cessation also
leads to significant medium term health benefits in the first year.9293 From 2 to 3 months after
quitting, circulation improves and lung function increases.92 From 1 to 9 months after
quitting, coughing and shortness of breath decrease and individuals start to regain normal
function of the lungs which increases their ability to handle mucus, clean the lungs and
reduce the risk of infection." From one year after quitting, the excess risk of coronary heart
disease is reduced by 50% compared to the risk in continuing smoking.93
The major decrease in the risk of smoking-attributable disease is seen in the long_term.9394
From about 5 years after quitting, the risk of cancers of the mouth, throat, oesophagus and
bladder are decreased by 50% while the risk of cervical cancer and stroke decrease to the
level of a non-smoker.f From about 10 years after quitting, the risk of death from lung
II
cancer is about half that of continuing smokers.t" The risk of cancers of the larynx and
pancreas decrease by slightly less.93 The evidence on the decrease in risk of other types of
cancers are inconclusive." After about 15 years since quitting, the risk of coronary heart
disease drops to the level of risk in a non-smoker." As a result of the short, medium and
long-term health benefits, cessation can improve an individual's quality of life as smokers
tend to have lower self-reported health status than non-smokersr"
1.4.2 Interventions
There is substantial evidence that self-help materials such as books and brochures (RR 1.21.
95% Cl 1.05 to 1.39. N = 12 studies)", brief advice (RR 1.66, 95% Cl 1.42 to 1.94, N = 17
studiesj'", individual behaviour counselling (RR 1.39,95% Cl 1.24 to 1.57, N = 22 studiesj'"
and group behaviour therapy (RR 1.98,95% Cl 1.60 to 2.46, N = 13 studies)" can improve
the chances of quitting. In addition, pharmacological interventions can be used to
complement self-help or counselling therapies. Pharmacotherapy for smoking cessation can
increase the chance of successful quitting more than self-help, brief advice or behavioural
therapy alone.l'" The three forms of pharmacotherapy that are licensed to be used in smoking
cessation in the UK are nicotine replacement therapy (NRT), bupropion (Zyban) and
varenicline (ChampixlChantix).
Nicotine replacement therapy (NRT) is licensed to be the only nicotine-based medication in
the UK. Several forms of NRT are available: gum, tablet, inhalators, nasal spray and
lozenges. NRT aims to reduce the motivation to smoke and withdrawal symptoms during a
quit attempt and therefore increase the likelihood of quirting.l'" Meta-analytic studies 101 have
shown that nicotine gum increases the likelihood of quitting by 43% (95% Cl 1.33 to 1.53, N
= 53 studies); nicotine patch increases the likelihood of quitting by 66% (95% Cl 1.53 to
1.81, N = 41 studies); nicotine inhaler increases the likelihood of quitting by 90% (95% Cl
1.63 to 2.45, N = 4 studies); oral tablets or lozenges increase the likelihood of quitting by
100% (95% Cl 1.53 to 2.45, N = 6 studies); and nicotine nasal spray increase the likelihood
of quitting by 102% (95% Cl 1.49 to 3.73, N = 4 studies). The recommended length of usage
of NRT is around 8 to 12 weeks with gradual reductions in dosage through the latter part of
the course. NRT can be obtained over-the-counter (OTC) or by prescription through the
NHS. Common side-effects of NRT include heart palpitations, chest pains, nausea, vomiting,
gastrointestinal complaints and insomnia.102
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Unlike NRT, bupropion and varenicline are prescription medications that do not contain any
nicotine. Bupropion is an antidepressant medication licensed for smoking cessation usage by
prescription only. Review evidence has found that bupropion increased the odds of quitting
by 97% (95% Cl 1.67 to 2.34, N = 16 studies) compared to placebo.l'" Studies have observed
that depression is more frequently found in smokers than non-smokers, smoking cessation
may precipitate depression and nicotine is suspected to have antidepressant effects.I04 105
Serious side-effects from bupropion use are rare. The major adverse effect is the risk of
seizures (estimated 0.1%) and therefore it is not recommended for patients with current
seizure disorders or a history of seizures.l'" Other less serious side-effects include allergic
reactions, dry mouth, headaches and insomnia.I06
Varenicline is the latest prescription medication used to aid smoking cessation. Varenicline is
a nicotine receptor partial antagonist which works by maintaining moderate levels of
dopamine to counteract withdrawal symptoms (acting as an agonist) while simultaneously
reducing smoking satisfaction (acting as an antagonist). Evidence has shown that varenicline
increases the likelihood of sustaining smoking abstinence for six months compared to placebo
(RR 2.33, 95% Cl 1.95 to 2.80, N = 6 studies).I07 Furthermore, varenicline has also been
shown be more effective in maintaining long-term abstinence for one year compared to
bupropion (RR 1.52,95% Cl 1.22 to 1.88, N = 3 studies) and NRT (RR 1.31,95% Cl 1.01 to
1.71, N = 1 study).107 Post-marketing safety data suggests that varenicline may be associated
with depression, agitation, suicidal behaviour or ideation.l07 More recent analysis of clinical
trials found no evidence that varenicline was associated with psychiatric disorders other than
sleep disturbances. lOS However, previous trials may not have been powered to detect a
significant relationship. Ongoing research is currently being conducted to evaluate this
relationship.
1.4.3 Economic benefits
The health consequences of addiction and smoking-related morbidity and mortality can be
directly attributed to between 6% and 15% of total healthcare expenditures in high-income
countries. I For instance, latest figures show that the cost of smoking to the UK NHS was £5.2
billion.s7 Therefore, there are potential economic benefits to individuals and society from
smoking cessation such as reducing the effects of passive smoking and decreasing
expenditures of the health service and employers.f These benefits can be short-term or long-
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term benefits as seen in several studies. A study in California estimated that a 1% decrease in
smoking prevalence resulted in 924 fewer hospitalisations for acute myocardial infarction and
538 fewer hospitalisations for stroke resulting in an immediate savings of $44 million (1995)
USD (£28 million).I09 A 7-year program that reduced smoking prevalence by 1% per year
would result in $3.2 billion (1995) USD (£2.1 billion) in cost savings preventing
approximately 13,100 deaths resulting from acute myocardial infarction.l'" A study in
Denmark found that the total lifetime cost-savings (1999 costs) associated with smokers who
quit before 35 was €24,800 (£21,085) per male smoker and €34,100 (£28,940) per female
smoker in terms of health care costs and lost productivity.J''' Another US modelling study
had found that an annual 1% drop in maternal smoking prevalence would prevent 1,300 cases
of low birth weight and save $21 million (1995) USD (£14 million) in direct medical costs in
the first year of the programme; the programme would prevent 57,200 cases of low birth
weight and save $572 million (1995) USD (£375 million) in direct medical costs in 7
years. III
It must also be acknowledged, however, that tobacco provides a large source of revenue for
the government from taxation of sales and imports. In the UK, the revenue generated from
tobacco duties totalled £9.1 billion in 2010-2011.112 Controversially, some studies84-86 have
suggested that a decline in population smoking prevalence may actually result in cost savings
in health care costs in old-age due to smokers dying prematurely. Despite revenue from
taxation and potential old-age cost-savings due to premature mortality, the human cost (loss
of life, quality of life, impact on family and friends) due to smoking from mortality and
morbidity has no true measurable value. When the human costs are considered with direct
health care costs and indirect costs, smoking cessation increases the overall health, social and
economic welfare of society. 88
1.5 Tobacco control policy
1.5.1 International influence
The previous sections have highlighted the harmful health effects of smoking, smoking trends
in the UK, the economic costs of smoking and the clear benefits of individually targeted
smoking cessation. The evidence favours strong tobacco control policies which encourages
smokers to quit and prevent new smokers from starting. In the UK, tobacco control policy is
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determined by the government. However, wider international influences of European
legislation and the WHO Framework Convention on Tobacco Control (FCTC)1I3 have also
influenced UK tobacco control.
While health policy, management, financing and legislation are the responsibilities of
individual member states, EU policy does in fact exert some influence over tobacco control
policy in the UK. Most notable is Article 168 of the Lisbon Treaty'" which highlights the
importance of cooperation between Member States in coordinating health policy. Tobacco is
specifically mentioned in Section 5 of Article 168114stating that the European Council may
'adopt incentive measures designed to protect and improve human health and in particular to
combat the major cross-border health scourges, measures concerning monitoring, early
warning of and combating serious cross-border threats to health, and measures which have as
their direct objective the protection of public health regarding tobacco and the abuse of
alcohol, including any harmonisation of the laws and regulations of the Member States'. 114
These are non-binding agreements between Member States but the direct effects of the treaty
can be seen in the implementation of the Tobacco Products Directive (TPD)lIS across the EU
which bans tobacco advertising of products, covers the use of health warnings on packets,
prohibits the use of 'mild' or 'light' descriptions on cigarette packets and prohibits the sale of
tobacco for oral use (except for Sweden). Legislation such as the TPD is extremely important
as it harmonises prohibitions around the sale of tobacco products within a single EU market
giving the UK and other EU countries the legal justification to implement these policies. In
2012, there has been a proposal to review (ongoing) the TPD to include regulations on plain
packaging, smokeless tobacco, hand-rolled tobacco, cross-border internet sales, oral tobacco,
electronic cigarettes, herbal products, pictorial health warnings and illicit trade.!"
UK tobacco control policy is also influenced by the WHO global guidelines due to the UK
government's signing, ratification and enforcement of the Framework Convention on
Tobacco Control (FCTC).113 The FCTC is an evidence-based public health treaty developed
as a response to the global tobacco epidemic. All signatories to the convention are
responsible for the implementation of several provisions'Y:
• Price and tax measures to reduce the demand for tobacco
• Protection from exposure to tobacco smoke
IS
• Regulation of the contents of tobacco products
• Implement health warning labels on tobacco products
• Regulation of tobacco product disclosures
• Packaging and labelling of tobacco products
• Education, communication, training and public awareness
• Prohibition of tobacco advertising, promotion and sponsorship
• Demand reduction measures concerning tobacco dependence and cessation
• Combat illicit trade and sales to minors
• Provision for support of economically viable alternatives
These FCTC and EU policies have largely influenced UK government policy on tobacco
control in recent years.
1.5.2 UK tobacco control policy
The comprehensive framework on tobacco control which the UK has developed has been
consistent with EU and FCTC priorities. In 1998, the government published its first White
Paper117 'Smoking Kills' detailing comprehensive tobacco control strategies. The objectives
of the strategy were to reduce smoking in children and young people, help smokers give up
smoking, reduce smoking-related inequalities and reduce smoking in pregnancy. In order to
achieve these objectives, a variety of policy measures were enacted:
• Ban on tobacco advertising and sponsorship and reduction of point-of-sales
advertising
• Increase taxation on tobacco products
• Enforcement of under-age sales
• Restrictions on cigarette vending machines
• Introduce NHS smoking cessation services
• Facilitate easy access to pharmacotherapy
• Combat illicit trade
Many of these measures are still in place today while others have evolved. The 1998
'Smoking Kills' White Paper':" had noted the harmful effects of passive smoking, however
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concluded that a ban on smoking in public places was not possible to implement. This view
changed when the government released another White PaperliS in 2004 with a proposal to
ban smoking in cafes, restaurants, pubs, workplaces and factories. After many government
consultations, the smoking ban came into force 1 July 2007.
The most recent tobacco control strategy was detailed in 2011 in the White Paper'!" 'Healthy
lives, healthy people'. The report detailed that in addition to continuing the enforcement of
existing tobacco control legislation; there were several objectives to implement over the next
few years:
• Legislation to end point-of-sales displays in shops
• Evaluate the possibility of plain packaging as an effective means to reduce uptake of
smoking by young people and to support adult smokers in trying to give up
• Maintain the high price of tobacco products through taxation
• Encourage smokers to quit using the most effective forms of smoking cessation
through local stop smoking services
• Effective enforcement of tobacco control policies at the local level
These objectives can be achieved through regulation, service provision, legislation and
enforcement. The specific strategies of tobacco control policy in the UK are described in this
section. In addition, evidence is provided on the effectiveness of each measure.
1.5.3 Age restrictions and availability
Age restrictions are common measures used to reduce the availability of tobacco products to
youths. In October 2007, the minimum age for the legal purchasing of tobacco products was
raised from 16 years to 18 years in England, Wales and Scotland (the minimum of possession
remains 16 years). In Northern Ireland, the minimum age for the legal purchasing of tobacco
products was raised from 16 years to 18 years in 2008.
There is evidence showing that age restrictions decrease the ability of tobacco purchases by
youths from legal vendors!20-122 Review studies'r" 122have found that age restrictions can
significantly reduce the rate of illegal tobacco sales to youth. However, both studies
concluded that lack of enforcement and the ability of youths to acquire cigarettes from social
17
sources can undermine the effectiveness of age restrictions. This fact is supported by a
community intervention study in the US which found that communities with strict
enforcement had reduced illegal sales to minors compared to communities without strict
enforcement.V'
1.5.4 Smoke free legislation
Due to harmful effects of passive smoking and the large number of individuals exposed as
described in Section 1.1.5, there is strong rationale for legislation imposing smoke-free
public places. In July 2007, smoking was banned in cafes, restaurants, pubs, workplaces and
factories in England. Smoke-free legislation was imposed in Scotland in March 2006 while
Wales and Northern Ireland imposed a smoking ban in April2oo7.
There has been substantial evidence attributing the decline of passive smoking exposure to
the decrease in negative health effects as a result of the smoking ban. In a sample of bar staff
in Ireland, salivary cotinine concentrations dropped by 80% after the smoke-free laws were
imposed while respiratory symptoms declined.123 In another study, air nicotine concentrations
were tested at city centre bars and the results showed that concentrations were reduced by
83%.124A study in Scotland found that the percentage of bar workers with respiratory and
sensory symptoms declined by 32.5% approximately 2 months after the ban while lung
function increased.125 In addition, the smoking ban was also found to be associated with
significantly reducing the number of emergency admissions for myocardial infarction after
the implementation of smoke-free legislation.F" Time-series analyses conducted in the US
have also found significant reductions in number of hospital admissions and incidence of
myocardial infarction after smoking bans were imposed.127128
A potential unintended consequence of the smoking ban was the displacement of smoking
into homes. A cross-sectional survey in Hong Kong found a significant increase in passive
smoking exposure in young children at home.129 This led to a large EU-wide study of five
countries (Ireland, France, Germany, Netherlands, UK) which found that smoke-free
legislation did not result in more smoking in homes and in fact encouraged many parents to
enforce their own smoking ban inside the home.13O
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1.5.5 Health warnings
The requirement for all tobacco products sold in the UK to display health warnings is due to
the EU Tobacco Products Directive (TPD).115 The TPD requires all tobacco products to
display general health warnings covering at least 30% of the front of the pack and health
warnings covering at least 40% of the back of the pack.115 This requirement has since been
enforced in the UK from 2002. There is a good body of evidence to suggest that health
warning labels are an effective means of communicating the health risks of smoking and
influencing quitting behaviour.l3l-l33 The studies also found that larger and clear health
warnings labels across packs of cigarettes tended to be more effective than smaller warning
labels, 131-133In addition, there is a growing body of research on the effectiveness of pictorial
or graphic warning labels on cigarette packs. Studies on graphic or pictorial warning labels
have shown that picture warnings improve smokers' recall of health risks and are more
effective than text-only warnings to influence quitting behaviour.134-136As a result of the
growing evidence, more than 60 countries now require pictorial health warnings on cigarette
packets. Canada was the first country to implement pictorial health warning labels in 2001
while Belgium became the first EU country to implement pictorial health warnings in 2007.
In 2008, the UK was the third EU country (behind Romania and Belgium) to implement
pictorial health warning labels. Due to the number of EU countries adopting pictorial health
warnings, there is a planned proposal for the mandatory use of picture warnings on all
tobacco products for sale in the EU.116
1.5.6 Tobacco promotion, advertising and sponsorship
Cigarettes are one of the most heavily advertised and promoted products in history.l37 From
1975 to 1983, the amount of money spent to promote cigarettes increased 288% from $490
million USD (£324 million) to $1.9 billion USD (£1.3 billion) in the United States alone.':"
The primary purpose of tobacco promotion, advertising and sponsorship is to encourage
uptake of smoking by young people and discourage current smokers from quitting as
specified directly in tobacco industry documents.138-140 Evidence has shown that adolescents
with high exposure to cigarette advertising are significantly more likely to be smokers than
those with low exposure to cigarette advertising.l" 142Time-series analysis has shown that
advertising bans may have some impact of reducing consumption; however this effect is
marginal in countries without comprehensive tobacco control pOlicies.143144In other words,
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advertising bans in one area may lead to the tobacco industry diverting resources to other
areas or media outlets, thus undermining the initial advertising ban.14s
Advertising of tobacco products on television was banned in the UK in 1965 under the
Television Act of 1964. Other forms of advertising in the press, billboards and films were
governed by a self-regulatory agreement with the UK government. After the release of the
White Paperll7 'Smoking Kills', the government proposed and passed the Tobacco
Advertising and Promotion Act of 2002 which banned tobacco advertising in the press and
billboards along with direct marketing of tobacco products. Subsequently, all tobacco
sponsorship was prohibited in Member States under the EU Tobacco Products Directive
(TPD) I IS which was enforced from 2005 onwards in the UK.
One of the media outlets where tobacco imagery still occurs is in films. Although tobacco
imagery in films has declined substantially in the past 20 years in the UK, older yet popular
films with tobacco imagery are easily accessible to children. A study on the most popular
films viewed in the UK from 1989 to 2008 found that tobacco imagery occurred in 70% of all
films, with over half of those containing tobacco imagery being rated by the British Board of
Film Classification (BBFC) as being suitable for children.l'" Observational evidence from the
US has suggested that increased exposure to smoking in movies is independently associated
with teenage smoking uptake.147-149 The current government tobacco control plan has a
proposal to work with media regulators and the entertainment industry around the portrayal
of smoking in the entertainment media.119
1.5.7 Mass media campaigns
Mass media interventions use a range of methods to reach large numbers of people without
being reliant on face-to-face contact often times involving local, regional or national
television, radio, newspaper, leaflets, booklets, mobile phones, social networking and the
internet. The National Institute for Health and Care Excellence (NICE) guidance on mass
media suggests that mass media may have an influence on changing health behaviour;
however it is not clear whether mass media independently prevents smoking uptake or
encourages quitting behaviour. ISO Evidence about the effectiveness of mass media on quitting
behaviour is mixedlsl-ls4 and there is almost no evidence evaluating the effectiveness of mass
media on preventing smoking uptake in youths. Most developed countries which have the
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resources to conduct mass media campaigns usually also have comprehensive tobacco control
policies, thus isolating the true effects of mass media on quitting behaviour or smoking
uptake is extremely hard to quantify.
In the UK, mass media campaigns influencing smoking behaviour are funded by the
government, charities or pharmaceutical companies. Although the pharmaceutical industry's
primary goal is to increase pharmacotherapy sales by triggering quit attempts, this does
complement the government's aim of increasing smoking cessation. The Department of
Health 2009-2010 budget for smoking related marketing and communication totalled £38
million. ISS Due to budget cuts, the amount was decreased to £15 million in 2011-2012.155 As
a result, the Department of Health has prioritised the money to be spent on four key areas
which includes smoking-related marketing and communication. However, more evidence is
needed to evaluate the efficacy and cost-effectiveness of mass media campaigns on changing
smoking behaviour.
1.5.8 Taxation
Taxation of tobacco products is the single most effective measure for influencing
consumption. Most standard goods behave in a manner that if price increases then demand
will decrease. It was once thought that the addictive nature of tobacco precluded it from a
downward sloping demand curve. This was largely due to early arguments about smokers
lacking self-control due to the addictive properties of nicotine and therefore the decision to
smoke was not rational.F" Consequently, taxation of cigarettes would result in little or no
impact on consumption.P" As empirical evidence on the effects of taxation on cigarette
consumption developed, demand was shown to be negatively correlated with price. Estimates
vary but international studies have shown that price elasticity (response in cigarette
consumption to changes in price) of cigarettes range from -0.3 to -0.5 (1% increase in price
results in between 0.3% to 0.5% fall in consumptionj.F" Price elasticity in the UK was
previously thought to be _0.5158 which was within the range of the international estimates.
However, a recent econometric analysis159 conducted by the HMRC producing eight models
using time-series data from 1982 to 2009 found price elasticity to be much larger than
previously thought ranging from -1.17 to -0.92 after taking into account the effects of the
smoking ban (2007) and the inception of the single EU market (1992).
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Currently (2012), the UK has the second highest levels of cigarette taxation in the EU
(Ireland has the highest levels of taxation) with a pack of 20 cigarettes typically costing
£6.28; of which £4.82 is tax (77% of the total cost).I60 This generated £9.1 billion 112 from
tobacco duties in 2010-2011. Under the current tobacco control plan, the government has
proposed to maintain a high level of taxation but do not specify any specific increases in price
on tobacco products.i'"
1.5.9 Illicit tobacco
One of the possible consequences of high tobacco prices is the rise in illicit tobacco.
However, there is no evidence to directly attribute the rise in tobacco taxation to an increase
in tobacco smuggling.l'" Tobacco smuggling grew in the mid-1990s after the integration of
Member States into a single EU-market. In 2000, more than one in five cigarettes smoked in
the UK was smuggled which cost over £3 billion per year in lost revenue.162 Government
efforts to combat illicit trade have since led to a decline but illicit tobacco is still a major
problem. From 2007-2008, illicit tobacco accounted for £1.8 billion in lost revenue due to
10% of cigarettes and 47% of hand-rolled tobacco being smuggled.l'" Due to cheaper prices,
illicit tobacco is most prevalent among youths from 14-17 years (one in three youths admit to
buying illegal tobacco) and individuals from lower socio-economic classes (61% of illegal
tobacco consumersj.l'" Because poorer smokers are disproportionately more likely to buy
illicit tobacco, combating illicit tobacco smuggling will also help reduce health
inequalities.162 Studies have also shown that smokers of illicit tobacco have significantly
worse health outcomes and more likely to have financial difficulties than smokers of legal
tobacco.l'" Economic analysis has shown using resources to combat illicit tobacco is
extremely cost-effective generating a net monetary benefit of £5.7 billion (2007) and averting
760 deaths annually.162 The current government's tobacco control plans calls for revising a
work protocol between HMRC and local authorities as well as the development of a global
protocol under the WHO FCTC.119 These measures include marketing campaigns to reduce
illicit tobacco use in certain communities, training local authorities to identify illegal products
and examining the feasibility about restricting the amount of cheap tobacco products
individuals can bring to the UK from abroad.119
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1.5.10 NHS stop smoking services
For individuals that would like to quit smoking, the NHS offers stop smoking services free at
the point of use. NHS stop smoking services were first introduced after the 1998 White
Paper1l7 'Smoking Kills' as part of the first comprehensive tobacco control strategy. These
services are provided locally in primary care, pharmacies or community centres. The
counsellors provide a range of services such as brief advice, behavioural counselling and
access to pharmacotherapy, From April2011 to May 2012, there were 816,444 quit attempts
in England made through NHS stop smoking services; of which 49% of the quit attempts
were successful at 4 weeks follow-up (though longer term abstinence is unknown)," Total
expenditure of the services in the same period was £88.2 million amounting to £220 per
quitter (excluding costs of pharmacotherapyj.' The service has been shown to be extremely
cost-effective in a study of 92 specialist smoking cessation services in England.l64 However,
the service has limited reach. In 2008, 67% of all smokers had reported that they wanted to
give up smoking but only 26% had actually made a quit attempt.165 Only 15% of those who
had made a quit attempt sought professional advice while only 8% had been referred to a stop
smoking service.165 The majority of smokers who try to quit are unsupported. This is
problematic as only an estimated 3% to 5% are successful with unaided quit atternpts.P" This
is one of the key areas laid out in the UK tobacco control strategy to improve: methods in
which NHS stop smoking services can maximise accessibility and outreach, particularly in
groups with high rates of smoking prevalence.l "
1.5.11 Point-of-sale displays
Tobacco companies have relied on point-of-sale displays as an effective means of branding
and communicating affordability to youths. Studies have shown that tobacco companies have
used large store displays to market cigarettes, often times behind counters and near other
convenience items such as candy and magazines.167 In addition, survey studies on school
children have found children perceived stores with large point-of-sale displays to be less
likely to ask for proof-of-age, recalled displayed cigarette brands more and increased
susceptibility to smoke in the future.168169There is also review evidence to suggest that point-
of-sale promotion undermines smoking cessation attempts and promotes relapse among ex-
smokers.170 As a result, point-of-sale legislation in England prohibiting the display of
cigarette packs came into effect in larger shops from April 2012 and will come into force for
smaller shops from April 2015, effectively eliminating all visibility of cigarettes in retail
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shops. In Northern Ireland, regulations have been issued to ban point-of-sale displays in the
latter half of 2012 for large shops and in 2015 for smaller shops. The Welsh Government has
also confirmed bans on point-of-sale displays from December 2012 in large stores and in all
other businesses by April 2015. In Scotland, legislation to prohibit point-of-sale displays has
passed but implementation is currently hindered by legal challenges by the tobacco industry.
1.5.12 Plain packaging
One of the last forms of brand advertising and promotion by the tobacco industry is through
the cigarette pack itself. Austra~ia was the first country in the world to implement plain
packaging for products manufactured since October 2012 and on sale since December 2012.
Brand logos and colours have been replaced by a standard size olive green pack with a
common font for all brand variants. Health warnings in text and pictures will still remain on
the majority of the packet surface area. There is no direct evidence that plain packaging will
be effective in reducing smoking consumption and uptake as the empirical case in Australia
had just come into force at the end of 2012. However, tobacco industry documents have
revealed that companies view cigarette packs as integral to brand promotion supported by
marketing studies carried out by the companies themselves which found that pack branding is
designed to appeal to select target groups such as youths and women.V' Tobacco field
experts believe the most likely outcomes would be a reduction in smoking prevalence in
adults and a greater reduction in the number of children trying smoking (although there is
substantial variability in the estimated size of these impacts).I72 Recently, the Department of
Health funded a systematic review on the impact of plain packaging which found that plain
packaging reduced pack and product appeal, increased the salience of health warnings,
improved recall of health warnings and reduced confusion about product harm.173 The review
also found some evidence that plain packs may have a deterrent effect for the onset of
smoking in young people and may encourage existing smokers to quit.173 The UK
government has launched a public consultation in the spring of 2012 which has since ended
in August 2012. The consultation report is expected to be released sometime in the near
future.
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1.5.13 Harm reduction
While pharmacotherapy can increase the probability of quitting significantly'?' 103 107,
successful smoking cessation is still low due to a low starting baseline of 3_5%166 for
unassisted quitting. Although the ideal for all smokers is to quit completely, a substantial
proportion of smokers do not want to stop smoking or have not been able to do so despite
many attempts.174 For these heavily-addicted individuals, switching to alternative forms of
nicotine without the major health risks of smoking may be a more positive option than
continuing to smoke cigarettes. Two types of products that are currently being researched are
electronic cigarettes and smokeless tobacco. Evidence has shown that smokeless tobacco
(snus, chewing tobacco, snuff) confers about 0.1% to 10% of the overall risk of cigarette
smoking.l " There is evidence that suggests smokeless tobacco users have an increased risk of
oral cancer but these results are due to discrepancies in product types from different
locations.!" Epidemiological data in Asia have shown an increased risk of oral cancer but the
results are not confirmed in Swedish studies.176 This i~ most likely due to the fact that the
smokeless product snus used in Sweden has fewer contaminants than the chewing tobacco
used in India.l77 Despite the mixed evidence, all smokeless tobacco products are banned
throughout the EU with the exception being Sweden where there is a long history of
smokeless tobacco use in the form of snus.
Electronic cigarettes are battery powered devices that deliver propylene glycol and nicotine in
vapour form through inhalation which simulates the act of smoking. The device was first
introduced. on the Chinese domestic market in 2004 and later exported to the international
market from 2005 onwards. The popularity of electronic cigarettes has risen in recent years
due to an increase in internet marketing and product exposure. Little is known about the
safety of electronic cigarettes. The WHO reported that there is currently no evidence or
rigorous peer-reviewed studies that have been conducted showing that the electronic cigarette
is safe but did not discount the possibility that the electronic cigarette could be useful as a
smoking cessation aid.l78 Some online surveys have found that a large percentage of the
smokers either cut-down or abstained from smoking altogether which suggests that electronic
cigarettes may have the potential to act as a smoking cessation aid.179 However, laboratory
tests of electronic cigarettes by the US Food and Drug Administration had found in some
products carcinogens and toxic chemicals such as diethylene glycol (compound used in
antifreezej.P" Debate about the safety and effectiveness of electronic cigarettes is ongoing in
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the absence of peer-reviewed evidence. NICE is scheduled to release guidance around harm
reduction mid-2013. Current UK tobacco control policy has suggested a review of the
evidence around harm reduction before policy proposals will be made.
1.6 Smoking in the workforce
The previous sections have shown that tobacco use is an extremely complex issue.
Comprehensive tobacco control involves a multifaceted approach involving the treatment of
smoking-attributable disease, the treatment of the nicotine addiction, the evaluation of the
economic consequences of smoking, government legislation and industry restrictions.
Consequently, there are many research gaps which have been identified. In Section 1.1.5,
there are no clear or effective policy solutions which would reduce the effects of passive
smoking in children. In Section 1.2.3, smoking prevalence in low SES groups remains high
and tobacco control policy seems ineffective to promote cessation in these groups. In Section
1.5.12, most tobacco control field experts believe that standard packaging will in fact reduce
uptake and promote cessation; however, there is no direct evidence which has shown this
effect. In Section 1.5.13, the safety and effectiveness of harm reduction products in aiding
with smoking cessation is unclear. In Section 1.3.2, little is known about the economic
impact of smoking in the workforce. Many of these research gaps highlighted require
different approaches and addressing all of these gaps is beyond the scope of this thesis.
However, the thesis does address the gap highlighted in Section 1.3.2 as the evidence
surrounding the economic impact of smoking in the workforce is extremely limited. The
following sections describe why this is an important area to research.
1.6.1 Thesis rationale: The economic arguments
The WHO FCTC states that ultimately 'health and not economic arguments are the reason for
tobacco control but economic arguments are raised as an obstacle to tobacco control
policies,.ll3 Government have raised three items!" of concern over the negative economic
consequences of tobacco control:
i. Lower tax revenues via reduced demand and increased illicit activities
11. Decreasing employment in the manufacturing and retail sectors
iii. Impoverishing smokers with higher prices
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Existing evidence from developed countries have suggested that economic fears over tobacco
control policies are largely unfounded. I In Section 1.5.8, taxation was shown to be the most
effective means to reducing consumption and there is no direct evidence that links increased
illicit activities to increased taxation as described in Section 1.5.9.
There is little impact of effect of 182 decreasing employment in the manufacturing and retail
sectors as employment in the UK tobacco industry has been falling over the past few
decades/" There is little evidence to suggest that tobacco control policies are the reason for
this decline. There is, however, evidence to show that the reduction in workforce is largely
the result of mechanisation and rationalisation.P'' A study conducted in the UK found that
19,400 tobacco manufacturing jobs were lost between 1963 and 1985 in which 16,000 (82%)
could be attributed to the improvement in productivity.P" According to the Office for
National Statistics, only 5,000 people were employed in UK tobacco manufacturing in
2010.185
Governments have raised the concerns over (iii) impoverishing smokers with higher prices
due to the regressive nature of taxes on poor smokers. As the tax increases, the share of
tobacco expenditure on household income also increases creating an extra burden on family
budgets. lSI The counter-argument can be made that by implementing taxes to the level
beyond the purchasing threshold of poor families, many simple will not be able to afford to
smoke. Evidence has shown that poor smokers and young smokers are more responsive to
price in which a 10% increase in price may reduce consumption by 4% or more.!" In respect
to poor smokers, the benefits of quitting are proportionally greater as there will be lower
lifetime health costs and more resources for other essential goods such as food and
education.i'"
Despite largely unfounded fears of negative economic consequences, there is still
considerable difficulty in the legislation of tobacco control policies which promote cessation
due to legal challenges by the tobacco industry. From 2009 to 2011, there were legal
challenges by the tobacco industry in 18 countries on tobacco control legislation using the
fear of negative economic consequences as part of the argument against measures such as
point-of-sales displays, standard packaging and graphic warning labels.!" One common
argument against these measures is the reduction in tax revenue as described in the first item
(i). However, the expectation of lower tax revenues due to stronger tobacco control policies
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has not held true. From the period from 2002 to 2011, UK tobacco control policy has
implemented health warning labels, introduced smoke-free public places, banned point-of-
sales displays and increased taxation. In the same period, adult smoking prevalence has
declined from 27% to 20%7 while tax revenue has actually increased from £8.1 billion to £9.1
billion 188.
The common 'smoking pays for itself argument used against implementation of tobacco
control policies is that revenue from tobacco duty is considerably higher than the health care
cost smoking imposes on society.s8 This point is true as tobacco revenue in the UK totalled
£9.1 billion188 while recent costs estimates of the treatment for smoking-attributable disease
totalled £5.2 billion'" to the NHS. However, this argument becomes unclear when indirect
costs are incorporated. Indirect costs are costs resources which are not directly accountable to
the cost object (smoking) but rather represent an opportunity cost or foregone benefit.189
Indirect costs of smoking commonly include but are not limited to productivity loss, effects
on other services and impact on patients, family and other stakeholders. This thesis has
focussed on quantifying the indirect costs of productivity loss in the workplace in the UK due
to smoking. The thesis uses the definition of productivity loss which can be described as lost
ability to work as a result of the ill health caused by smoking. These costs are suspected to
contribute substantially to the total cost smoking imposes on society.
In the UK, there were 29.2 millionl90 employed adults in 2011 of which 20%7 were current
smokers. This equates to approximately 5.84 million employed adult smokers. As described
in Section 1.1, there are significant health effects from smoking which are independent of
employment status. However, there are no studies which have quantified the economic
impact of smoking-attributable indirect costs such as productivity loss or absenteeism to both
employers and the wider society in the UK. These indirect costs impose a large cost burden to
society yet are difficult to quantify accurately. The sheer scale of the finances suggests that
decreases in smoking prevalence may result in huge gains in productivity, possibly offsetting
or even outweighing revenue generated by tobacco duties. Therefore. it is extremely vital for
this research gap to be addressed in order to inform tobacco control policy at the national
level.
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1.6.2 Research gap
A literature review was conducted to identify and evaluate any previous studies that had
reviewed the topic of smoking and indirect costs. The search for literature regarding smoking
and indirect costs was conducted broadly through electronic database searches and cross-
referencing between studies. The goal was to find any previous literature, narrative or
systematic reviews on smoking and indirect costs. There were only six studies found that
reviewed literature related to smoking and indirect costs; of which four studies were literature
reviewsI91-194;one study was a narrative review'"; and one study was a quantitative reviewl95.
There were three primary findings of the literature search:
• There is no standard methodology in which to quantify indirect costs due to smoking.
• Indirect costs were predominantly due to premature mortality or sickness absence.
• It is unknown whether interventions that promote smoking cessation are cost-effective
in the workplace.
In order to address the economic arguments against stronger tobacco control, it is necessary
to strengthen the evidence-base around these research gaps using robust and rigorous
methods. This will help move forward tobacco control policy and improve both the economy
and public health.
1.6.3 Aims and objectives
The aims of this thesis were to quantify the economic impact of indirect costs of smoking
from productivity loss due to premature mortality and absenteeism in the UK and to evaluate
possible solutions to decrease the burden of smoking in the workforce. These findings will
complement existing direct cost-of-smoking studies conducted in the UK to better inform
tobacco control policy at the national level. This is accomplished through seven specific
objectives:
• To review all cost-of-smoking studies to inform best practice methodology for the
estimation of population-level indirect costs (Chapter 2).
• To quantify productivity loss due to smoking using best practice cost-of-smoking
methodology for the UK (Chapter 3).
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• To evaluate the epidemiological association of smoking and absence from work by
systematic review and meta-analysis of worldwide studies (Chapter 4).
• To quantify the cost of absenteeism in the UK (Chapter 4).
• To validate the indirect costs estimates derived from this thesis using an ecological
model from worldwide studies (Chapter 5).
• To evaluate the cost-benefit of workplace smoking cessation interventions from an
employer-based investment perspective using decision analysis and Markov
simulation modelling (Chapter 6).
• To explore if the employer's decision strategy changes if the employers primarily
valued maximising quitting using cost-effectiveness analysis (Chapter 6).
1.6.4 Study methods
The methods utilised in this thesis involve a number of statistical, epidemiological and health
economic techniques drawing on multiple data sources. Outlined below are brief descriptions
of the study methods used. More detailed information on methodology and data sources are
provided in the individual methods sections of subsequent chapters and appendices.
1.6.4.1 Regression analysis
Regression analysis is a common statistical technique for estimating the relationship among
variables. This technique was used in Chapter 2 when examining the ecological association
between indirect costs and smoking prevalence and in Chapter 5 when exploring the
ecological validity of UK cost estimates. In Chapter 2, stepwise linear regression was
specifically used to determine the best ecological predictor model between indirect costs and
smoking prevalence taking into account population-level covariates.
1.6.4.2 Cost-or-illness
Cost-of-illness methodology is commonly used to quantify the direct or indirect costs of
particular diseases which are then reported as monetary values. As the focus of this thesis was
on indirect costs, the methodology around the quantification of these costs was reviewed in
Chapter 2. Subsequently, the methodological review informed the best practice technique for
estimating productivity loss due to smoking in the UK in Chapter 3. There are two types of
costing methods: prevalence and incidence approaches.l'" In this thesis, the prevalence-based
approach was employed to calculate smoking-attributable mortality using population
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fractions derived from smoking prevalence and smoking mortality risks. These figures were
then combined with UK earnings data to estimate the annual value of lifetime income lost
due to premature mortality.
1.6.4.3 Systematic review
Systematic review methodology was utilised in Chapter 4 to identify, appraise, select and
synthesize longitudinal evidence evaluating the association between smoking and absence
from work. This thesis adhered to all PRISMA guidelines 197 to ensure a high level of quality
assurance with regards to selecting and extracting data for the systematic review. Electronic
searches were conducted using several databases for published studies while conference
proceeding were searched for in grey literature. In addition, reference lists were assessed for
potential studies. Quality assessment of the studies was carried out using a standardised form
which evaluated important aspects of epidemiological quality such as study selection,
minimisation of bias and attrition.
1.6.4.4 Meta-analysis
Meta-analysis methodology was used to synthesize the quantitative results from studies
identified from the systematic review in Chapter 4. This thesis adhered to MOOSE
guidelines'" for meta-analysis of observational studies. The random effects model was used
to determine the effect sizes for the smoking and risk or duration of absenteeism due to
smoking. The random effects model was used to take into account heterogeneity in study
location, study length, study year, workforce characteristics and other unknown factors. In
addition, meta-regression was used to the test for differences in risk between subgroups.
1.6.4.5 Decision analysis
Decision analysis was used in Chapter 6 for both cost-benefit and cost-effectiveness analysis
of workplace interventions for smoking cessation. The decision analytical framework
provides a formal technique to assessing and ranking workplace interventions for smoking
cessation which maximise quitting and minimise absenteeism. From the employer's
perspective, the outcomes were total costs (TC) incurred and return on investment (ROn of
interventions which reduce absenteeism and labour turnover. Additionally, some employers
may choose to base their decision strategies on maximising quit rates. Therefore, Chapter 6
used cost-effectiveness analysis to determine the optimal intervention strategy based on
incremental cost-effectiveness ratios (leERs) for maximising quitting.
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1.6.4.6 Markov model
Representation of complex interventions may be difficult using conventional decision trees
and often times requires simplifying assumptions. Instead, Markov models can be used to
model complex interventions which involve risk that is continuous over time, incorporate
time dependency and simultaneous events. In this thesis, workplace smoking cessation
interventions were evaluated using a Markov state transition model which simulated a cohort
of employed adult current smokers from 35 years to the age of retirement (Chapter 6). The
Markov model was embedded in a decision tree to evaluate the cost-benefit and cost-
effectiveness of multiple smoking cessation interventions (Markov-cycle tree).
1.6.4.7 Probabilistic sensitivity analysis
The incorporation of uncertainty into Markov models uses a Bayesian process by fitting prior
probability distributions to model parameters. Probability distributions can be randomly
sampled using the Monte Carlo method to generate posterior distributions of costs, effects,
cost-effectiveness ratios, net monetary benefits or net health benefits. In Chapter 6,
transition probabilities which govern the movement between Markov states were fit with
appropriate probability distributions based on prior study information. The Monte Carlo
method was used to simulate multiple trials of each Markov cohort simulation. This
procedure tested for the robustness of the findings by incorporating all parameter uncertainty.
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Chapter 2
Indirect costs of smoking: Comparison of
methodology and results from population-level
studies
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2.1 Introduction
Smoking in the workplace has become an increasingly important public health issue in recent
years. Although smoke-free workplaces have been implemented in many countries,
employee smoking still remains a problem. Smoking is thought to contribute towards
productivity loss and increased absenteeism due to ill health, death and early retirement.l'"
Smoking may also reduce productivity as a result of smoking breaks and presenteeism
(reduced productivity while at work).198 Other costs include cleaning and fire damage to
property and business.l'" All these components contribute substantial economic costs to
society. One way of enhancing the awareness of the magnitude of these economic costs is to
transform the health related consequences of smoking-related diseases to monetary values.
Globally, the World Bank estimates that tobacco use results in a net economic loss of $200
billion (1998) USD (£132 billion) per year attributable to health care costs and lost
productivity. I Due to the magnitude of these costs, governments have recognised the impact
of smoking in the workplace. However, there is no consistent method used to measure
indirect costs to facilitate informed decision making. Indirect costs of smoking are most
commonly measured in terms of costs incurred from mortality, morbidity, absenteeism or
reduced productivity at work.199 Less frequently measured indirect costs include lost leisure
time, lost household production, effects on family and friends or damage to business and
property. The valuation of these costs depends on the perspective the study takes. Most cost-
of-illness studies utilise either the human capital model2OO or friction cost method_201Human
capital theory takes an individual (employee) perspective where indirect costs are estimated
as foregone earnings and lost leisure time. Friction cost methodology takes the employer's
perspective where indirect costs are presumed to be short-term or medium-term due to a
firm's ability to restore the initial level of production depending on labour market conditions.
These differences in perspective have a profound impact on indirect cost estimates. For
example, an Australian study (2008 costs) found that an absolute reduction in smoking
prevalence of 8% from 23% resulted in workforce production gains of either AUD $415
million (£267 million) using the friction cost method or AUD $863 million (£556 million)
according to the human capital mode1.202There have been a growing number of economic
studies in the past decade on the cost of smoking, including the cost of absenteeism and
reduced productivity due to illness. However, there have been no comparisons of results and
methodologies of these studies.
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2.2 Aims and Objectives
The aim of this chapter was to systematically examine the methodology and analyse the
results from population-level studies which have quantified indirect costs due to smoking.
This process informed the best methodology to conduct an indirect cost-of-smoking study for
the UK in Chapter 3. A secondary aim was to explore the consistency among studies by
examining the relationship between indirect costs and adult smoking prevalence. The results
from the secondary aim allowed for the comparison of total indirect costs in the UK with
other population-studies which formed the basis for a validation study in Chapter 5. These
aims were achieved by completing the following objectives:
• Review of the international literature on indirect costs or productivity loss due to
smoking
• Describe the cost components which contribute towards smoking-related indirect
costs
• Summarise the methodology and compare the results of the indirect costs
• Carr out quality assessment of the included studies
• Investigate the ecological relationship between smoking and indirect costs using
regression analysis
2.3 Methods
2.3.1 Data sources
Studies were identified (by SFW) through database searches of MEDLINE (1948 to
December 2012), EMBASE (1974 to December 2012), Centre for Reviews and
Dissemination (up to December 2012), Science Direct (1950 to December 2012) and EconLit
(1980 to December 2012). In addition, reference lists from identified articles were reviewed
for relevant literature. Keywords relating to 'smoking', 'indirect costs' and 'productivity loss'
were used to search for all relevant publications (Appendix 9.1). Where available in the
database, medical subject headings (MeSH) were used to identify related terms.
3S
2.3.2 Inclusion criteria
The studies obtained from the electronic database search were screened for duplicates (by
SFW). Titles and abstracts were assessed based on subject matter. Full-text articles were
subsequently retrieved from the remaining studies. There were several key criteria for
inclusion in the review:
(1) The designs considered in this review were economic cost-of-illness studies at the
population-level. Population-level studies were classified as national, state or regional
studies.
(2) The studies estimated the monetary value of indirect costs or productivity loss due to
active smoking.
(3) Indirect costs of smoking could be made of several cost components: productive life
lost due to mortality and morbidity; absenteeism due to sickness or behavioural
issues; time spent on smoking breaks; reduced productivity at work due to
presenteeism; or other smoking-related indirect costs reported in the study.
2.3.3 Data extraction and data synthesis
Studies were extracted (by SFW) for descriptive characteristics (study year, location, cost
methodology, cost components and primary findings). In addition, underlying methodologies
were described and compared. Only data pertaining to smoking-related indirect costs or
productivity loss were extracted for this review. Results pertaining to direct costs (healthcare
costs) of smoking were not extracted.
In order to compare monetary values of productivity loss across studies, a common unit of
annual cost per capita was calculated. Size of the population was obtained in the study year
using data from the World Bank Development Indicators (WDI)203, US Census Bureau'?',
General Register Office for Scotland2os and National Statistics Republic of China
(Taiwani06• Cost per capita was exchange rate adjusted to US dollars by annual rates
provided by the International Monetary Fund (IMF)207 in the study year. Subsequently, the
monetary values of costs were inflated to 2010 levels using a constructed earnings inflation
index from data on annual average earnings from the Organisation for Economic Co-
operation and Development (OECDio8, Census and Statistics Department of Hong Kong209
and National Statistics Republic of China (Taiwan)2Io. The year 2010 was selected as the
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base year as this was the study year of the most recent studies identified. The costs were
adjusted by the following equation:
Average annual earninBs2010 .
Cost per capita2010 = x Cost per capLtaStudAverage annual earninBSstudy year y year
2.3.4 Quality assessment
To assess the methodological quality of selected studies, a scale was developed based on the
Consensus on Health Economic Criteria (CHEC)211 checklist. CHEC is a 19-point scale
developed solely for clinical-effectiveness studies; thus the original scale was not appropriate
to use for cost-of-smoking studies at the population-level. Therefore, an 8-point scale
(Appendix 9.2) was adapted from the cost-side criteria of the CHEC checklist. The primary
domains of the developed scale covered methodological quality of study objectives, study
design, valuation of costs and sensitivity analysis. The quality assessment was conducted by
one reviewer (SFW).
2.3.5 Statistical analysis
The association between cost per capita and smoking prevalence in the study year was tested
by linear regression. Smoking prevalence rates for the included studies were obtained from
multiple data sources: The WHO Tobacco Control Country Profiles212-214;The WHO Report
on the Global Tobacco Bpidemici" 216;CDC MMWR217 218;Canadian Report on National
Strategy for Tobacco Controli'"; Hong Kong Thematic Household Survey220; Scottish
Household Survey221; Taiwan National Health Interview Survey222; and Tobacco and Health
in the European Union223. The smoking prevalence figures obtained from the data sources
were the rates of current adult smoking in the study year.
For the regression analysis, non-inflated cost per capita amounts in US dollars were used
instead of inflated cost per capita amounts. This was because all covariates were study-year
variables to take into account study year differences. Study-year covariates were obtained
from various official sources203 208-210224-232.It was hypothesized that costs per capita or
smoking prevalence may be associated with population size, earnings index (ratio of average
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earnings in 2010 to earnings in the study year}, GDP per capita, average monthly earnings,
life expectancy at birth and age of the study. Initially, univariate associations between cost
per capita or smoking prevalence and population-level covari ate s were explored.
Associations giving p-values < 0.1 were included in a multivariate model. P-values < 0.1
were used as the cut-off as power of the analysis was expected to be relatively low (few
studies). A smaller p-value would avoid missing potential univariate associations. Stepwise
regression analysis was utilised to determine the best possible multi variable model
incorporating smoking prevalence and cost per capita. Logarithmic and exponential
transformations were made due to potential non-linear associations between smoking
prevalence and covariates. The "best fit" model was determined by statistically significant P:
values < 0.05. Two separate models were presented in the analysis: (1) Modell including all
studies regardless of cost methodology; (2) Model 2 including only studies using the human
capital model. The analyses were conducted in STAT A 11 (Stata Corporation, College
Station, Texas, USA).
2.4 Results
2.4.1 Description of included studies
Twenty-seven full-text articles were deemed potentially eligible (based on titles and
abstracts) from a total search yield of 1,089 articles based on the inclusion criteria (Figure 4).
Of the 27 studies, ten were excluded after full-text versions of the studies were obtained.
Monetary costs of smoking were not reported in three studies233-235;five studies 182236-239were
epidemiological studies which explored productivity loss in a specific sample of workers; and
two subgroup studies240 241overlapped with another included study in this review where
duplicate data were used. After excluding these studies, 17 population-level studies" 110202
242-255were identified as fulfilling all the inclusion criteria and thus included in the review.
Table 1shows the characteristics of the studies including location, study year, method, study
currency, cost components, total indirect cost of smoking and quality score.
Nine studies89 110242244249250252-254were from Europe.Jour studies243245-247were from North
America, three studies248 251255were from East Asia248 251255and one study02 was from
Australia. All of the included studies were published within the last 15 years. The overall
quality of studies was high with scores ranging from the lowest of six to the maximum of
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eight. Most of the studies obtained a score of either six89243-246250251255points or seven247-249
252253points. These studies most commonly lost quality points for not providing detailed
descriptions of the study population or not conducting sensitivity analysis on reported cost
estimates. There were four studies 1JO 202242254which obtained the maximum quality score by
fulfilling all elements of the quality criteria.
Figure 4. Search process and exclusion criteria
Database search of 'smoking' and
'indirect costs' terms
(n=I,089)
Excluded based on title and abstracts I- _ _ _ _ _ _ _ _ _ _ _
(n=I,053)
Excluded duplicate studies
(n=9)
,
Full-text articles retrieved
(n=27)
Excluded
(Based on eligibility criteria)
----------
Indirect costs not estimated (n =3)
Non-population level study (n = 5)
Overlap with included study (n = 2)
Included in review
(n= 17)
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2.4.2 Human capital versus friction cost
The most common method of quantifying indirect costs of smoking was by the human capital
model used in 15 studies'" 110242-252254255.Grossman's human capital model2°O 256provides a
modelling framework for health and education and their relationship to labour supply,
earnings and productivity. The theory is based on the notion that an increase in an
individual's stock of knowledge and health increases his or her productivity in both market
and non-market activities257. In health-related studies, the human capital model takes the
perspective that an employee's income is related to their general health stock. The human
capital accounts for all future income lost from an individual that leaves the workforce as
result of death or disability. Therefore, negative behaviours such as smoking will likely have
an impact on health and transitively, income and earnings.
Two studies202 253were identified which utilised the friction cost method. The friction cost
method developed by Koopsmanschap et al.201 is an alternative to the human capital model
which takes into account the productivity loss from the employer's perspective. Taking the
friction cost perspective, indirect costs estimated using the human capital approach are seen
as potential lost production (or lost income) as a consequence of disease. Potential lost
production can be calculated as the total income lost in the case of disability or premature
death at a specific age until the potential age of retirement. The friction cost method considers
that actual lost production is much smaller because employers will tend to reduce the impact
of productivity loss from employee illness. This can be done through temporary or permanent
replacement, redistribution of the workload or the ability for employees to make up work
once they return. Therefore, the amount of lost production depends on the time-span
employers need to restore the initial level of production known as the 'friction period,.20I
2.4.3 Cost components
Seven cost components were identified in the 17 included studies (Table 1): future foregone
earnings from productive life lost; foregone wages from absenteeism; reduced output from
presenteeism; lost output due to smoking breaks; lost leisure time or household production
due to smoking-related illness; damage to property due to smoking-related fires; and
occupational injuries related to smoking. Future foregone earnings due to productive life lost
was the most common component measured in 14 studies 110242-250252-255.This component was
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an estimate of discounted future earnings lost which were attributable to premature mortality.
The estimation procedures routinely utilised smoking-attributable risk fractions (derived from
the prevalence of smoking in the population and relative risk of mortality) for common
disease classifications in combination with life expectancy data to calculate years of
productive life lost. Years of productive life lost were translated into monetary amounts by
age and sex-dependent wage data. Estimated future forgone earnings as a result of productive
life lost from smoking ranged from 12%253to 100%242243246255of total indirect costs with a
median proportion of 78%. This was the single largest component of indirect costs in the
majority of studies.
The absenteeism component of indirect costs was reported in 13 studies" 110202244245247-254.
Absenteeism was a direct measure of forgone income due to short-term sick leave or
temporary disability over the course of the study year. The monetary value of absenteeism
was calculated from average hourly earnings and duration of illness absence found in survey
data or previous literature. The cost of absenteeism ranged from 6%248 to 88%253 of total
indirect costs with a median proportion of 22%. This was the second largest component of
indirect costs in the majority of studies.
There were only two studies89251 that quantified the impact of smoking breaks at work. The
method in which the costs of smoking breaks were estimated was similar in both studies.
Assumptions were made on the time it took to smoke cigarettes based on previous literature
and number of cigarettes smoked on a normal work day. Less commonly measured cost
components were presenteeism/", fire damage89245, lost leisure or household production202
and occupational injuriesf", Data on presenteeism and lost leisure or household production
were quantified using questionnaire instruments. The costs of smoking-related fire damage to
property were estimated based on insurance claims data. The cost of occupational injuries
was based on relative risk estimates from previous epidemiological literature.
From the summary of the cost components, the two primary components of indirect costs
which were estimated were future forgone earnings from productive life lost and foregone
wages due to absenteeism (Table 1).
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2.4.4 Indirect cost per capita due to smoking
For comparison across studies, indirect cost per capita due to smoking was exchange rate
adjusted to US dollars and inflated to 2010 levels using a constructed earnings index. Figure
5 shows in descending order cost per capita according to study location. Canada in 1991245
had the highest cost per capita due to smoking at $694 USD (£455) while Hong Kong in
1999248 had the lowest cost per capita at $28 USD (£18). The median cost per capita was
$292 USD (£191). The friction cost studies202 253provided cost estimates on the lower end of
the spectrum. There were two studies252 253 conducted in Germany in 1999 by the same
author. However, the first studl52 computed indirect costs using the human capital method
while the latter stud/53 used the friction cost method. Using the human capital method, the
cost per capita of smoking in Germany in 1999 was $233 USD (£153).252 Using the friction
cost method, the cost per capita of smoking was $66 USD (£43).253 There was a stark contrast
in costs even though the populations were identical; the only difference being an assumption
that workers on long-term disability were replaced by new labour in the latter study.
Figure 5. Comparison of indirect costs per capita due to smoking inflated to
2010 US dollars by location
Canada 1991
Denmark 1999
Missouri 2004
USA2001
Germany 1999
Germany 1993
California 1999
Germany 2003
Scotland 1998
Germany 2005
Poland 2010
Sweden 2001
Germany 1999
Taiwan 2001
Taiwan 2000
Australia 2008
Hong Kong 2004
• Friction Cost • Human Capital
...
-...
...
$0 $100 $200 $300 $400 $600 $700 $800$500
Indirect Costs Per Capita (2010 USD)
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2.4.5 Relationship between indirect cost per capita and smoking prevalence
The ecological relationship between indirect cost per capita and smoking prevalence was
examined using a regression model (Figure 6). The slope of the regression line was found to
be $8.57 (95% Cl -$6.60 to $23.59, p = 0.24) [£5.62 95% Cl -£4.33 to £15.48) for every 1%
increase in adult smoking prevalence. The overall Ji1 was 0.09 which meant a large variation
was unexplained by the linear model. Although there seemed to be an overall positive
relationship between adult smoking prevalence and cost per capita. this relationship was not
necessarily linear. The non-linear association was explored further in the subsequent section.
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Figure 6. Ecological relationship between smoking prevalence and indirect cost
per capita for population-level studies
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2.4.6 Cost-prevalence elasticity
In Table 2, cost per capita (USD) is shown without adjusting for inflation along with
additional covariates in the reported study year. The adult smoking prevalence rates ranged
from 15%220in Hong Kong (1998) to 43%223in Germany (1993) with a median of 30%. In
Table 3, univariate analysis was conducted to test the relationship between indirect cost per
capita and covariates. Since the variables appeared to have non-linear associations with cost
per capita, logarithmic transformations were applied to all variables except for age of the
study where an exponential transformation was used. Logarithmic and exponential
transformations are routinely used to smooth continuous or time-element variables.258 The
regression coefficient of smoking prevalence was given as the cost-prevalence elasticity
interpreted as a 1% change in smoking prevalence results in a Y% change in indirect cost per
capita. In Models 1 and 2 (Table 3), indirect cost per capita was found to be significantly
associated with smoking prevalence in univariate analysis (Modell: P = 1.60, P = 0.03;
Model2: P = 1.76, p = 0.02). In addition, the covariates of earnings inflation, GDP per
capita, average monthly earnings and life expectancy were associated with indirect cost per
capita at the 10% level in both models (Table 3). Only the covariates of unemployment rate
and life expectancy were associated with smoking prevalence at the 10% level in both models
(Table 3).
Table 3. Regression coefficients from univariate analysis between population-level
covariates and indirect cost per capita or smoking prevalence
Modell Model2
All Studies Included (N=17) Human Capital Studies Only (N=15)
Variables
Log(Cost Per Log(Smoking Log(Cost Per Log(Smoking
Capita) Prevalence) Capita) Prevalence)
Log(Smoking Prevalence) 1.599* 1.762*
Log(Population Size) 0.105 0.086 0.146 0.075
Log(Earnings Inflation Index) 3.124* 0.497 2.776* 0.458
Log{GDP Per Capita) 0.382+ -0.123 1.219+
-0.037
Log(Unemployment Rate) 0.660 0.484* 0.695 0.458*
Log{Average Monthly Earnings) 1.209* 0.292 1.657* 0.331
Log(Life Expectancy) -21.85* -5.809+ -19.53+ -6.479+
Age of Study 0.059 0.012 0.040 0.006
Age of Study" 0.003 0.001 0.002 0.001
Reported P Coefficients, *p < 0.05, "P < 0.10
46
Following stepwise model fitting (Table 4), the final regression model included only one
covariate of GDP per capita when all studies were included and found that a 1% increase in
smoking prevalence resulted in a 1.7% (95% Cl 0.21 to 3.16, p = 0.028) increase in cost per
capita (Modell). The final regression model for human capital studies only included both
GDP per capita and unemployment rate and found that a 1% increase in smoking prevalence
resulted in a 2.1% (95% Cl 0.46 to 3.81, p = 0.017) increase in cost per capita (Model 2).
Model 2 which included only human capital studies had better fit (If = 0.540) than Modell
which included all studies (R2 = 0.313). In monetary terms (back-transforming), the results
show that on average a 1% increase in smoking prevalence results in a $5.42 USD (£3.55)
increase in cost per capita across all population level studies and an $8.17 USD (£5.36)
increase in cost per capita across human capital model studies only.
Table 4. Stepwise regression analysis for the relationship between the log of the indirect
cost per capita and adult smoking prevalence with the addition of covariates
Step Covariates Beta 95% Confidence
p.
Coefficient Interval Value
Modell-All Studies (N=l7)
1
GDP Per Capita, Inflation, Unemployment,
-0.91 -3.21, 1.38 0.396Monthly Earnings, Life Expectancy
2
GDP Per Capita, Unemployment, Monthly
-1.22 -3.47, 1.03 0.257Earnings, Life Expectancy
3 GDP Per Capita, Unemployment, Life -1.08 -3.29,1.12 0.306Expectancy
4 GDP Per Capita, Unemployment 1.91 -0.14,3.96 0.065
5 (Final) GDP Per Capita 1.69 0.21,3.16 0.028
Model2 =Human Capital Studies Only (N=lS)
GDP Per Capita, Inflation, Unemployment,
-0.36 -3.07,2.35 0.766Monthly Earnings, Life Expectancy
2 GDP Per Capita, Unemployment, Monthly -0.47 -3.13,2.18 0.696Earnings, Life Expectancy
3 GDP Per Capita, Unemployment, Life -0.55 -3.32,2.22 0.666Expectancy
4 (Final) GDP Per Capita, Unemployment 2.13 0.46,3.81 0.017
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2.5 Discussion
2.5.1 Summary of findings
In this literature review of health economic studies, 17 studies'" 110202 242-255 on the indirect
costs of smoking were identified from a comprehensive database search. The most common
method of estimating indirect costs of smoking was by the human capital model. There were
two studies202 253 which used the friction cost method. There were a total of seven cost
components identified: productive life lost, absenteeism, smoking breaks, presenteeism, lost
leisure or household production, fire damage and occupational injuries. The most common
component measured was foregone earnings due to productive life lost.
There was a positive and significant correlation between cost per capita and smoking
prevalence after adjusting covariates. On average, a 1% increase in smoking prevalence
resulted in a 1.7% increase in cost per capita across all population-level studies and a 2.1%
increase in cost per capita across human capital studies only; with the latter model showing a
better fit because the included studies used more similar study designs and methodology.
Friction cost studies tended give more conservative cost estimates of smoking due to the
model allowing for the firm's ability to find replacement work; thus foregone earnings due to
productive life lost are minimised or negated altogether. In monetary terms (back-
transforming), the results show that on average a 1% increase in smoking prevalence results
in a $5.42 usn (£3.55) increase in cost per capita across all population level studies and an
$8.17 usn (£5.36) increase in cost per capita across human capital model studies only.
2.5.2 Methodological implications
Although there were methodological differences in the estimation of cost components among
studies, the transformed association between cost per capita and smoking prevalence was
statistically significant. This suggests that there is a degree of consistency across population-
level studies. As a result, the association between smoking prevalence and cost per capita
could be utilised to validate future indirect cost-of-smoking studies at the population-level.
This validation approach was taken in Chapter 5 using UK indirect cost estimates derived
from this thesis. In terms of comparability of other smoking-related studies, the human
capital model offers the most comparable method of smoking-related costs and is relatively
straightforward to conduct. The human capital approach was the approach used for UK
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indirect costs estimates in Chapter 3 due to having more comparability to existing studies
and providing a theoretical basis consistent to neoclassical economic theory. The theoretical
basis for the model lies in the concept of health capital, where an employee's stock of health
determines the total amount of time he or she can spend producing money, earnings and
commodities.i" Broadly speaking, health defined by longevity and illness-free days in a
given year is both produced and demanded by individuals. Therefore, behaviours such as
smoking that have an impact on health will decrease health capital accumulation which will
in tum affect an individual's ability to produce money, earnings and commodities. Most cost
studies on smoking based on human capital theory capture productivity loss in terms of
foregone earnings from the individual's perspective. The sum of all the individuals within a
population or sample equals the total productivity loss due to smoking. There are criticisms
of the human capital model and its ability to provide accurate estimates for the consequence
of disease. When an employee becomes ill, several scenarios can potentially occur:201
I. The level and costs of production are unaffected due to the firm's ability to
make up unperformed work when the employee returns or if the firm has
internal labour reserves to make up for the loss.
II. The level of production remain unchanged but at higher costs due to
colleagues working overtime or the firm hiring temporary workers.
III. The level of production falls while costs remain unchanged due to the firm
not attempting to make up for the lost production.
IV. The level of production falls despite higher costs due to the firm attempting to
make up for lost production but not able to achieve the levels of the ill
employee.
Scenario III is representative of the human capital model where production is permanent
wealth lost while scenarios I, II, IV are representative of the firm's ability to adjust
production levels via the labour market. By valuing lost production as wealth lost to society,
the human capital model overestimates the burden of disease in society as the method
measures potential lost production and not actual lost production. This certainly has been
suggested by several authors259-261that real production losses may in fact be much smaller.
Alternatively, the friction cost method201 takes into account the short-term and medium-term
effects of illness by the firm's ability to make up or draw on internallabour resources to
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make up the level of production. Long-term costs are minimised by an employer's ability to
replace ill employees. Koopmanschap et al.201 suggests that the friction cost method better
reflects the economic impact of the disease from the employer's perspective as firms will
drive to maximize profits by reducing costs through worker replacement.P'' Empirically,
friction cost studies utilise a variable of friction period (average time a firm takes to replace
long-term vacancy due to illness). In addition, the friction cost approach takes into account
macro-economic labour market conditions. If unemployment is low, then the friction period
is longer than when unemployment is high. The friction cost method is relatively new (1995)
compared to human capital model (1972) and there is substantial difficulty in obtaining valid
data on both the frequency and length of friction periods. The friction cost model authors
have themselves suggested that necessary labour parameters for the model are extremely
scarce and a combination of data from time-surveys and patient questionnaires are needed to
provide reliable estimation parameters. The main criticism of the friction cost model262263is
that there are assumptions which contradict neoclassical economic theory. According to the
friction cost model, short-term and medium-term productivity losses are lower than the
estimates provided by the human capital model due to diminishing returns to labour, internal
labour reserves and sick employees restoring the level of work when they return from a
period of absence. Consequently, to estimate productivity loss this way assumes that the price
of labour (Le. the opportunity cost of labour) is set close to zero after the friction period and
is reduced during the friction period which is an implausible assumption.263 If the same
assumptions of the price of labour being set close to zero were consistently applied to direct
healthcare cost estimation, then the costs of health care programmes would be drasticall y
reduced. The friction cost method also takes into account diminishing returns to labour in the
estimation procedure. However, this may actually be unnecessary as the human capital
approach expects that a firm will hire labour until the marginal cost of labour equals the
marginal value of the products produced by the worker. When the worker is absent, this
represents a marginal loss of labour whose value of the firms equals the gross income of the
worker. Therefore, the human capital model would correctly estimate the productivity loss
according to neoclassical economic theory.
The friction cost model may also overestimate the ability of firms to draw upon internal
labour reserves to restore production. According neoclassical theory, a firm would not hire
additional workers unless the value of their production would exceed or be equal to the gross
income of the workers.263 If a firm has a labour surplus, then the firm is not maximising
so
profits because the same level of production could be achieved with fewer workers.264 It is
more likely that an increase in short-term absence would mean that the firm either loses
production during absence or hires additional workers from the labour market where the price
of labour should not be assumed to be close to zero. Finally, the friction cost model does
provide the valid assumption that the sick worker may restore production levels after they
return or other workers may make up this work through increasing working time or capacity.
The model does not, however, take into account the opportunity cost of increasing working
time or capacity such as lost leisure time and ill-health effects due to increased stress
levels.262
This discussion of the human capital model and the friction cost model shows that there are
clear limitations of both estimation procedures. Whilst the human capital model
overestimates true lost production due to assumptions of achieving labour market
equilibrium, the theoretical basis for the estimation procedure is consistent with neoclassical
economic theory. Although, the friction cost approach attempts to address the reality of the
labour market, the issue of zero cost replacement of labour may not only result in the
underestimation of costs but is also based on an implausible assumption. As a result, this
thesis did not address a friction cost approach. In addition, there was less comparability to
existing studies and extremely limited data in the UK on friction periods at the employer-
level. The two friction cost studies found in this chapter's review used national-level data in
conjunction with assumptions on friction periods to estimate these costs as detailed data at the
employer-level is difficult to obtain. The limitations of the friction cost method does not
suggest this approach should not be utilised but rather it could be seen as an alternate costing
approach in perhaps a sensitivity analysis given data availability. Given available data, the
friction cost method can be used as a viable complement to the human capital model. This
method can be seen as an alternative approach to the human capital model providing an
additional perspective for cost-of-smoking studies.
2.5.3 Limitations
There were some limitations of the review. There are no published criteria for quality
assessment of population-level cost studies. Thus, an 8-point scale was created to assess the
methodological quality of population-level cost studies adapted from elements of the
Consensus on Health Economic Criteria (CHEC)211 checklist. However, the developed scale
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has neither been validated nor used before. Additionally, the methods of searching, screening,
quality assessment and data extraction of literature were conducted by only one reviewer
(SFW). Another limitation was the regression models involving indirect cost per capita and
smoking prevalence may have been underpowered to be able to detect a statistically
significant relationship. The regression analysis took into account a maximum of 17 studies.
Some of the multivariable models in the stepwise analysis showed a high level of
predictability but the association between smoking prevalence and cost per capita was not
significant at the 5% level most likely due to a lack of power. Also, the interpretation of the
regression results should not be utilised to describe causal relationships between smoking
prevalence and indirect costs per capita as the relationship is ecological and it is likely there
are other confounding factors that influence the relationship. Finally, it is known that there
are other potential indirect costs of smoking that have yet to be quantified or reported in
published literature. These costs include the loss of vacation time, effect on family and
friends, impact on motivation or teamwork and effects on co-workers.F? However, these
components are likely to have smaller impacts than the costs included in our models,
therefore their effects on the findings are likely to be marginal.
2.6 Conclusion
In this chapter, the relationship between smoking prevalence and indirect cost per capita was
found to be significant across 17 population-level cost-of-smoking studies. The findings
suggests that a 1% increase in smoking prevalence results in a 1.7% increase in cost per
capita across all population-level studies and a 2.1% increase in cost per capita across human
capital model studies only. In monetary terms (back-transforming), the results show that on
average a 1% increase in smoking prevalence results in a $5.42 usn (£3.55) increase in cost
per capita across all population level studies and an $8.17 usn (£5.36) increase in cost per
capita across human capital model studies only. The human capital model was the most
commonly used method of quantifying costs while less commonly utilised was the friction
cost method. While there are limitations of both methods, the human capital model provides a
framework for estimating costs consistent with neoclassical economic theory. However,
future research may involve the combination of both models but more empirical evidence is
needed to validate the precision of the cost estimates.
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Chapter 3
Productivity loss from foregone earnings due
to smoking-attributable premature mortality
in the UK
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3.1 Introduction
In Chapter 2, the human capital model had been established as the primary methodology for
conducting an indirect cost-of-smoking study in the United Kingdom due to its comparability
with other indirect cost-of-smoking studies and strong theoretical underpinnings. This chapter
describes the model methodology, results and potential limitations of such a model in the UK.
There is a direct causal association between smoking and premature mortallty.'' 9265 A 50-
year follow-up study of 34,439 male British doctors found that men who continued smoking
died on average 10 years younger than lifelong non-smokers.i As many of these deaths come
prematurely during working years, this creates a large economic burden for countries in terms
of loss of productive life years.
To date, most economic studies evaluating the cost of smoking have focused only on
healthcare costs. While many of these studies81-83 have found that the lifetime healthcare
costs of smokers (taking account of shorter life expectancy in smokers) are higher than those
of non-smokers, other studies84-86 have found the opposite. In the case of the UK, there have
been three previous studies'" 266 267 which have estimated direct health care costs due to
smoking. A recent study found that, despite a decline in adult smoking prevalence from 39%
in 1980 to 21% in 2009268, the direct healthcare costs to the UK NHS remained high at £5.2
billion/" This could be due a combination of factors such as healthcare cost inflation and
improvement of treatments of complex cases. While studies in the US 240241247269 and EU 242
244 250 270 have quantified productivity loss due to smoking, there are currently no studies in
the UK that have taken this approach. Without accounting for lost productivity. the overall
burden of smoking to society is likely to be underestimated.
3.2 Aims and Objectives
As there is a direct association between smoking and premature mortality, the aim of this
chapter was to estimate the lost productivity cost of smoking in the UK due to premature
mortality. This is the first study that has quantified the economic cost of lost productive life
years associated with smoking in the UK. This study attempts to complement existing direct
cost-of-smoking studies. These aims were achieved by completing the following objectives:
• Develop an economic model for productivity loss for the UK based on human capital
theory
• Identify and obtain relevant parameters needed to populate the economic model from
multiple UK data sources
• Quantify the productivity loss by implementing the developed model for the UK
• Conduct sensitivity analyses on the cost estimates obtained from the model
3.3 Methods
An economic model was developed based on Smoking-Attributable Mortality, Morbidity and
Economic Costs (SAMMEC) methodology?". SAMMEC was developed by the CDC to
permit the rapid calculation of deaths, years of potential life lost, direct health-care costs,
indirect mortality costs and disability costs associated with cigarette smoking. For the
mortality-related measures, age-specific and age-adjusted rates are also calculated. The
pivotal epidemiologic measure in these calculations is the smoking-attributable fraction to
calculate smoking-attributable mortality, years of potential life lost and smoking-attributable
productivity costs. Unfortunately, SAMMEC does not take into consideration important
labour market effects of unemployment and the full-time to part-time employment ratios in
the calculation of economic costs. The economic model developed in this chapter uses
SAMMEC equations to calculate smoking-attributable fractions (Section 3.3.1), smoking-
attributable mortality (Section 3.3.1) and years of potential life lost (Section 3.3.2).
SAMMEC equations were then modified to take into account age-adjusted employment rates
when calculating years of productive life lost (Section 3.3.2) and income was adjusted by the
full-time to part-time work ratios in the population (Section 3.3.3). The knock-on effect of
this modification was that the model reflected labour market characteristics in calculating
productivity loss which the original SAMMEC equations did not take into account.
This underlying approach is based on human capital theorl56 which views health as a
durable capital stock that yields healthy life years, and therefore loss of life years results in
lost production. The human capital model takes the perspective that income is related to the
individual's general health stock. This accounts for all future income lost from an individual
that leaves the workforce as result of death or disability. Therefore, negative behaviours such
as smoking will likely have an impact on health and transitively, income and earnings. The
cost of lost productivity due to premature mortality can be estimated by applying average
wage rates to lost years during productive life. This approach was taken because of the
comparability with previous cost-of-smoking studies240-242 244 247 250 269 270 which had used
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similar approaches in other countries and the availability of accurate population-level data to
facilitate this estimation in the UK.
To implement the model, age and gender-specific UK life tables for disease-specific
mortality72-274 were used to calculate the total number of premature deaths (i.e. deaths that
occurred before the average life expectancy) in the general population (irrespective of
smoking status). For each premature death, the total number of productive life years lost was
calculated as the difference between the age of death and the life expectancy in the general
population adjusted by the employment rate. To calculate smoking-attributable loss of
productive life years for each disease condition, epidemiological evidence on relative
mortality risk for smoking-related diseases and smoking prevalence in the UK were used to
generate mortality risk fractions. Following this, age and sex-specific gross earnings for men
and women were applied to each person-year of premature death. The costs across all disease
conditions were summed to estimate the total smoking-attributable loss of earnings due to
premature mortality.
The year 2010 was set as the base year and the most recent data on disease-specific mortality,
smoking prevalence, employment rate and annual income were used to populate the model.
The study population included adults aged 35 years and older as most deaths due to smoking
occur later in life and the risk of smoking attributable mortality is low in people under 35
years of age." Further details on all aspects of the methodology and data sources are
presented below.
3.3.1 Smoking-attributable mortality
The epidemiological approach to the economic model employs the use of smoking;
attributable risk fractions (SAFs). In order to quantify smoking-attributable mortality, SAFs
for both current and ex-smokers were calculated using a standard formula275 based on
smoking prevalence (p) and relative mortality risks (RR) for current, ex and never smokers:
56
SAFs were calculated for sex-specific age-bands from 35 to 100 years. This process was
repeated for 20 common smoking-related disease categories." These disease categories were
based on the International Classification of Diseases276 (lCD-tO). Smoking prevalence data
for adults aged 35 years or over in England and Wales were extracted from the 2010 Health
Survey for England_277 278Smoking prevalence data for adults in Scotland and Northern
Ireland were extracted using the 20tO Scottish Health Survey279 (SHS) and the 2010 Northern
Ireland Continuous Household Survey280 (CHS). The percentage of adult current, ex and
never smokers were stratified using the same age-bands and sex as used for SAF estimation.
The length of each age-band was governed by the data available in each survey. The relative
mortality risk parameters were used from the Cancer Prevention Study 1114(CPS-II), a US
prospective mortality study of over a million men and women enrolled in 1982. Data from the
CPS-II were used because it was the largest prospective cohort study in which mortality risks
from smoking was assessed in age, gender and ICD-I0 strata. In addition, relative risk
estimates from the CPS-II have been used extensively to estimate smoking-attributable
mortality in nearly 50 countries.26S 281282 The CPS-II provided relative mortality risk
estimates for 19 common smoking-related diseases (Table 5). The relative risk of mortality
for the 20th disease classification of "all other diseases" was based on Jha et al.283 for current
smokers and Jacobs et al.284 for ex-smokers. Subsequently, smoking-attributable mortality 28S
was calculated by multiplying age- and sex-specific SAFs by the number of deaths for each
smoking-related disease:
SAM = Number of deaths x SAF
The annual number of deaths by sex and age was obtained from the 20tO national death
registers286-288of England and Wales, Scotland, and Northern Ireland. The coding for
underlying cause of death in the registers were based on lCD-tO and given in sex and age-
specific categories.
3.3.2 Years of potential life lost
The SAM (discussed above) calculated the number of smoking-attributable deaths in each
age category, stratified by sex and grouped by underlying cause of death. To calculate years
of life lost (YLL), SAM was multiplied by the remaining life expectancy (RLE) at the age of
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death. RLE was calculated as the difference between life expectancy and the midpoint of
each 5 year age-band for both men and women:
Years of Life Lost (YLL) = SAM x RLE
Data for RLE was obtained from the most recent Office for National Statistics (ONS) life
tables_272-274The YLL values were calculated irrespective of employment status. To adjust for
the proportion of smokers in employment, YLL was multiplied by the age and sex-specific
smoking-employment rate extracted from population health surveys2n 279280to obtain the
years of productive life lost (YPLL):
Years of Productive Life Lost (YPLL) = YLL x Employment Rate
3.3.3 Cost of smoking-attributable productivity loss due to premature mortality
Smoking-attributable productivity loss was defined as the present value of future earnings
(PVFE) from paid labour. In order to quantify smoking-attributable productivity loss, 2010
gross annual income data were used for both full-time (FT) and part-time (PT) work from the
ONS Annual Survey of Hours and Earnings.289-291Earnings data from England and Wales
were provided in 5-year age-bands while data for Scotland and Northern Ireland were given
only as median income across all age-bands. The median income was used instead of the
mean income to take into account the positively skewed distribution (that is, a long thin tail
for those with high incomes). Therefore, the median income is necessarily correlated with
income inequality and in fact is a better representation of 'average' income.292 If median
income inequality increases, then median income would decrease while the mean income
would remain the same. Thus, the median income reflects both total income and income
distribution whereas mean income only represents total income.
The median annual income was adjusted by the percentage of full-time and part-time (Table
6, Table 7, Table 8) workers for each sex, age-band and UK country using data from the
2010 UK Labour Force Survey93:
S8
Adjusted Median Income = Median FT Income x % FT +Median PT Income x % PT
The PVFE for each age-band (b) was calculated by summing the adjusted annual median
gross income (discounted) from the midpoint of each age-band to life expectancy from the
midpoint of each age-band:
PVFEb = I(Adjusted median income)d
From t = (Midpoint of age-band) to (Life expectancy from mid-point)
The subscript d under adjusted median annual income represents the discounted PVFE.
Discounting was based on the HM Treasury294 recommended discount rate of 3.5% as the
base-case scenario. The PVFE was then adjusted by the sex and age-specific employment rate
for smokers in each age-band obtained from population health surveys277279280corresponding
to each UK country:
Adjusted PVFEb = PVFEbx Employment Rateb
Subsequently, PVFEb was then multiplied by age and gender-specific smoking-attributable
mortality271 to obtain smoking-attributable productivity loss for each age-band:
(Smoking attributable productivity lossh = SAMb x Adjusted PVFEb
The above calculation was repeated for each gender and age-group and each smoking-related
disease category. This adjustment by the employment rates in smokers allowed for the
estimation of earnings beyond the average age of retirement. The total smoking-attributable
productivity loss was then summed for each smoking-related disease category by male and
female strata. These costs were calculated for England and Wales, Scotland, and Northern
Ireland separately and then combined for the UK estimate.
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3.3.4 Sensitivity analysis
One-way sensitivity analysis was conducted to test the robustness of the results. Earnings loss
was quantified by varying the underlying assumptions: (i) undiscounted future earnings 182
using the previous HM Treasury recommended 6% discount rate (iii) 25th percentile of annual
income for low socio-economic status (iv) 75th percentile of annual income for high socio-
economic status (v) assuming low production (100% part-time work) (vi) assuming high
production (100% full-time work).
3.4 Results
3.4.1 Relative mortality risk parameters
The human capital model requires both epidemiological and economic components to
quantify productivity loss due to smoking. Relative mortality risks provided by the CPS-1I1\
Jha et al.283 and Jacobs et al.284 for 20 ICD-IO categories are shown in Table 5. Gender-
specific mortality risks were extracted for both current and ex-smokers compared to the
reference category of never smokers.
In males, the greatest mortality risk for smoking was due to cancer of the trachea, lung and
bronchus (RR = 23.26 for current smokers, RR = 8.70 for ex-smokers, Table 5). In females,
the greatest mortality risk from smoking was due to chronic obstructive pulmonary disease
(RR = 13.08 for current smokers, RR = 6.78 for ex-smokers, Table 5). For ischemic heart
disease and cerebrovascular disease, two separate relative risks were provided in individuals
aged from 35-65 and individuals aged 65 or over due to significant differences in mortality
risks between these age-groups. Ex-smokers generally had a reduction in relative risk of
mortality compared to current smokers for most disease categories; however, the risks were
almost always higher than that of never smokers.
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Table 5. Relative mortality risks for 20 disease categories for current and ex-smokers
compared to never smokers
Male Female
Disease Category ICD·tO Code Current Ex Current Ex
Smoker Smoker Smoker Smoker
Malignant Neoplasm'
Lip, Oral Cavity, Pharynx COO-CI4 10.89 3.40 5.08 2.29
Oesophagus CIS 6.76 4.46 7.75 2.79
Stomach C16 1.96 1.47 1.36 1.32
Pancreas C25 2.31 1.15 2.25 1.55
Larynx C32 14.60 6.34 13.02 5.16
Trachea, Lung, Bronchus C33, C34 23.26 8.70 12.69 4.53
Cervix Uteri C53 1.59 1.14
Kidney and Renal Pelvis C64,C65 2.72 1.73 1.29 1.05
Urinary Bladder C67 3.27 2.09 2.22 1.89
Acute Myeloid Leukaemia C92.0 1.86 1.33 1.13 1.38
Cardiovascular Disease!
Ischemic Heart Disease
Aged 35-64 120-125 2.80 1.64 3.08 1.32
Aged 65+ 1.51 1.21 1.60 1.20
Other Heart Disease 126-152 1.78 1.22 1.49 1.14
Cerebrovascular Disease
Aged 35-64 160-169 3.27 1.04 4.00 1.30
Aged65+ 1.63 1.04 1.49 1.03
Atherosclerosis 170 2.44 1.33 I.S3 1.00
Aortic Aneursym 171 6.21 3.07 7.07 2.07
Other Arterial Disease 177 2.07 1.01 2.17 1.12
Respiratory Disease!
Pneumonia, Influenza J09-JIS 1.75 1.36 2.17 1.10
Bronchitis, Emphysema J40, J43 17.10 15.64 12.04 11.77
Chronic Obstructi ve
J44 10.58 6.80 13.08 6.78Pulmonary Disease
All Other Disease AOO-B99, D50-
(infection, endocrine, blood, D89, EOO-E90,
nervous, digestive, GOO-G99, KOO- 1.302 1.003 1.702 1.003
musculoskeletal, skin, K93, LOO-L99,
genitourinary) MOO-M99, NOO-
N99
'Relative mortality risks from CPS-III4
2Relativemortality risks from Jha et al.283
3Relativemortality risks from Jacobs et al.2M
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3.4.2 Demographic parameters
3.4.2.1 England and Wales
In Table 6, population-level demographic variables were provided for England and Wales
from multiple data sources. Smoking-prevalence rates, annual gross earnings, remaining life
years (life expectancy at midpoint of age-band), full-timelpart-time work rates and
employment rates in smokers were stratified by gender-specific age-groups. Men between the
ages of 35-39 had the highest proportion of current smokers (27%) and lowest proportion of
ex-smokers (21%). There was a sharp decrease in proportion of current smokers and a sharp
increase in proportion of ex-smokers in men 60 years or over. In men aged 80 or over, only
3% were current smokers while 58% were ex-smokers. In women, current smoking
prevalence was highest between the ages of 40-44 (21%) and then gradually declined
thereafter. There were fewer ex-smokers in middle-aged females between 45-54 years. In
terms of the economic component of human capital, annual gross earnings showed clear
discrepancies in income levels between males and females across age-groups. For full-time
work, the median income was highest in women between 35-59 years (£25,925 per annum)
while the highest median income in men occurred between 40-49 years (£31,778 per annum).
For part-time work, the median income was highest in women and men between 35-39 years
(women: £9,776 per annum; men: £10,825 per annum). In men, the employment rate in
smokers was highest between 35-39 years at 83.7% and dropped sharply after 65 years to
17.8%. In women, employment rates in smokers were lower than the employment rates in
men across all age-groups peaking at 73.7% between 50-54 years. There were also gender
discrepancies between the ratios of full-time to part-time workers. In men, the proportion of
full-time workers was much higher than the proportion of part-time workers until 65 years. In
women, the proportion of full-time workers was more similar to the proportion of part-time
workers until 65 years.
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3.4.2.2 Scotland
In Table 7, population-level demographic variables were provided for Scotland from multiple
data sources. Smoking-prevalence rates, annual gross earnings, remaining life years (life
expectancy at midpoint of age-band), full-time/part-time work rates and employment rates in
smokers were stratified by gender-specific age-groups. Men between the ages of 35-44 had
the highest proportion of current smokers (32%) and lowest proportion of ex-smokers (17%).
As age-bands increased, there was a steady decline in the proportion of current smokers and
increase in the proportion of ex-smokers in men. In women, current smoking prevalence was
highest between the ages of 45-54 (28%) and then gradually declined thereafter. In terms of
the economic component of human capital, annual gross earnings showed clear discrepancies
in income levels between males and females. For full-time work, the median income in men
was £27,331 per annum while the median income in women was £21,879 per annum. For
part-time work, the median income in men was £7,976 per annum while the median income
in women was £9,076 per annum. The employment rate in smokers was highest in men aged
45-54 years at 75.3% and dropped sharply after 65 years to 11.2%. In women, the
employment rate in smokers was highest between 34-44 years at 69.9% and dropped sharply
after 65 years to 5.4%. There were also gender discrepancies between the ratios of full-time
to part-time workers. In men, the proportion of full-time workers was much higher than the
proportion of part-time workers until 65 years. In women, the proportion of full-time workers
was more similar to the proportion of part-time workers until 65 years.
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3.4.2.3 Northern Ireland
In Table 8, population-level demographic variables were provided for Northern Ireland from
multiple data sources. Smoking-prevalence rates, annual gross earnings, remaining life-years
(life expectancy at midpoint of age-band and productive life years remaining (midpoint of
age-band to retirement age) were stratified by age-groups and sex. Smoking prevalence
figures were only able to be obtained for three age-bands of 35-49, 50-59 and 60-95 due to
the coding structure of the Continuous Household Survey295. The overall smoking prevalence
in Northern Ireland was 24% for men and 23% for women.295 In terms of the economic
component of human capital, annual gross earnings showed clear discrepancies in income
levels between males and females. For full-time work, the median income in men was
£23,364 per annum while the median income in women was £20,710 per annum. For part-
time work, the median income in men was £7,361 per annum while the median income in
women was £7,905 per annum. The employment rate in smokers was highest in men aged 35-
49 years at 74.9% and dropped sharply after 60 years to 15.3%. In women, the employment
rate in smokers was highest between 35-49 years at 68.6% and dropped sharply after 60 years
to 11.3%. There were also gender discrepancies between the ratios of full-time to part-time
workers. In men, the proportion of full-time workers was much higher than the proportion of
part-time workers until 60 years. In women, the proportion of full-time workers was more
similar to the proportion of part-time workers until 60 years.
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3.4.3 SAM, YPLL and productivity loss
Using the parameters provided in Table 5, Table 6, Table 7 and Table 8, the SAM, YPLL,
and productivity loss were calculated. Results of smoking-attributable lost productivity costs
for England and Wales, Scotland, and Northern Ireland in 2010 by sex and disease category
are presented in the subsequent sections.
3.4.3.1 England and Wales
There were 493,242 deaths286 (all ages) registered in England and Wales in 2010 due to all
causes. There were a total of 329,461 deaths in adults aged 35 years and over from 20 disease
categories that have been known to carry higher risk in smokers. Of the total deaths, smoking
was estimated to be responsible for 80,601 deaths annually (Table 9). The most common
smoking-attributable deaths in both men and women were related to cancer of the trachea,
lung, bronchus (males: 14,404 deaths; females: 10,296 deaths), ischemic heart disease
(males: 7,073 deaths; females: 3,305) and COPD (males: 9,232 deaths; females: 8,123
deaths). Lung cancer, ischemic heart disease and COPD were responsible for 65% of all
smoking-related deaths. Smoking was estimated to be responsible for 204,254 years of
productive life lost in men and 96,513 years of productive life lost in women. Productivity
lost was valued at £4.1 billion (£3.2 billion for men; £858 million for women). Men had
higher values of productivity loss than women due to a higher prevalence of current smokers,
higher income level, higher employment rate and larger proportion of full-time workers
relative to part-time workers.
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3.4.3.2 Scotland
There were 53,967 deaths287 (all ages) registered in Scotland due to all causes. There were a
total of 36,324 deaths in adults aged 35 years and over from 20 smoking-related disease
categories in 2010; of which smoking was estimated to be responsible for 12,397 deaths
(Table 10). The most common smoking-attributable deaths in both men and women were
related to cancer of the trachea, bronchus, lung (males: 1,847 deaths; females: 1,572 deaths),
ischemic heart disease (males: 1,685 deaths; females: 936) and COPO (males: 899 deaths;
females: 1,119 deaths). Lung cancer, ischemic heart disease and COPO were responsible for
64% of all smoking-related deaths. Smoking was estimated to be responsible for 24,040 years
of productive life lost in men and 13,742 years of productive life lost in women. Productivity
loss was valued at £564 million (£417 million for men; £ 146 million for women).
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3.4.3.3 Northern Ireland
There were 14,457 deaths288 (all ages) registered in Northern Ireland due to all causes. There
were a total of 9,539 deaths in adults aged 35 years and over from 20 smoking-related disease
categories in 2010; of which smoking was responsible for 3,107 deaths (Table 11). The most
common smoking-attributable deaths in both men and women were related to cancer of the
trachea, lung, bronchus (males: 471 deaths; females: 369 deaths), ischemic heart disease
(males: 460 deaths; females: 249) and COPO (males: 326 deaths; females: 236 deaths). Lung
cancer, ischemic heart disease and COPO were responsible for 63% of all smoking-related
deaths. Smoking was estimated to be responsible for 12,785 years of productive life lost in
men and 6,496 years of productive life lost in women. Productivity loss was valued at £265
million (£200 million for men; £65 million for women).
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3.4.3.4 United Kingdom
The number of combined deaths in the UK from all causes totalled 561,666. Smoking was
estimated to be responsible for 96,105 (58% male) in adults aged 35 years and over in 2010
(Table 12). This amounted to 17% of all deaths resulting in l.2 million years of life lost. For
individuals who were in the workforce, premature deaths resulted in 357,831 years of
productive life lost. The productivity cost of lost earnings due to smoking was valued at
£4.93 billion per year (discounted 3.5%) after combining the estimates from England and
Wales, Scotland, and Northern Ireland.
Table 12. Smoking-attributable mortality, years or potential lire lost and productivity
loss in the by UK country (2010)
Country SAM! YLL1 YPLL3 Productivity Loss' (OOOs£)
England and Wales 80,601 999,714 300,768 4,101,694
Scotland 12,397 139,749 37,782 563,600
Northern Ireland 3,107 66,483 19,281 265,256
United Kingdom 96,105 1,205,946 357,831 4,930,550
ISmoking-attributable mortality = deaths x smoking-attributable fraction
2Years of life lost = smoking-attributable mortality x remaining life expectancy
3Years of productive life lost = years of life lost x employment rate
"Productivlty loss = smoking-attributable mortality x adjusted present value of future earnings (discounted 3.5%)
Figure 7 shows the proportion of smoking-attributable productivity loss in the UK by
category of disease. Ischemic heart disease and cancer of the trachea, bronchus and lung
made up of 53% total productivity loss. Oesophageal cancer, COPD and cerebrovascular
disease made up of 21% of total productivity loss. Even though COPD was responsible for
21% of all smoking-attributable deaths, the monetary impact was only 7.4% of total
productivity loss because deaths occurred in older individuals, many of whom were past the
average age of retirement when employment rate dropped sharply.
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Figure 7. Proportion of smoking-attributable productivity loss (£) in the UK (2010) by
category of disease
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One-way sensitivity analysis is shown in Figure 8 by varying the parameter assumptions
from the base-case productivity loss of £4.93 billion. By altering discount rates, the values
ranged from £3.84 billion (0%) to £7.63 billion (6%). Using a low income level (25th
percentile) resulted productivity loss of £3.55 billion while using a high income level (75th
percentile) resulted productivity loss of £7.09 billion. By altering employment activity, the
values ranged from £2.02 billion (low productivity) to £5.73 billion (high productivity).
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Figure 8. One-way sensitivity analysis for UK productivity loss (£) with
varying parameter assumptions from baseline
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3.5 Discussion
3.5.1 Summary of findings
The analysis in this chapter demonstrates smoking was responsible for 96,105 deaths (17% of
all deaths) in adults aged 35 years and over (58% male) in the UK in 2010. These deaths
resulted in l.2 million life years lost and 357,831 years of productive life lost. The analysis
estimated that productivity loss was £4.93 billion discounted at the base-case rate of 3.5%.
When combined with a recent estimate of the cost of smoking to the NHS (£5.2 billionj'" and
costs to the economy due to absenteeism (£l.46 billion)296, the cost to the society from these
components alone was estimated to be £1l.6 billion due to smoking in 2010-2011. This
amount is more than the total revenue generated of £9.1 billionl88 from tobacco duties in
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2010-2011. The analysis suggests that reduction in smoking prevalence would result in fewer
smoking-attributable deaths, increase in life-years saved and significantly reduce the
productivity loss in the workforce.
3.5.2 Implications
This was the first study to quantify productivity loss due to smoking in the UK. The human
capital model was used in this study due to its comparability with existing studies24o-24244247
250269270,availability of parameter data to populate the model and its appropriateness in the
context of lost productivity analysis from its strong theoretical underpinnings.P" 256
Moreover, this study used the proportion of full-time to part-time workers and the current rate
of employment in the UK to reflect the probability of being in employment if smoking-
related premature mortality was avoided.
While the baseline costs reflect the current labour market, the results from the sensitivity
analysis imply that economic activity may in fact have a large impact on productivity costs.
Larger estimates were obtained when the following parameter values were assumed (instead
of the conservative base-case assumptions): 0% discount rate, high income earners and higher
proportions of full-time employment. This suggests that productivity costs may be reduced
during periods of low growth, high unemployment and high proportions of part-time workers.
This has ramifications for policy-makers as these costs are not only dependent on the
estimation method but also economic activity.
To validate the death estimates from the model, smoking-attributable mortality estimated in
this study was compared with previous studies conducted in the UK. The estimated number
of 80,601 smoking-attributable annual deaths in England and Wales was similar to 81,700
deaths reported in the NHS report on smoking statistics_297In addition, the proportion of total
deaths attributable to smoking in this study (17%) was similar to the 18.6% provided by
Allender et al.87 in 2005 and the 17.2% annually reported in Twigg et al.s for the period
between 1998 to 2002 for the UK. This comparison suggests that our estimates are consistent
with previous studies. Also, as in previous studies, this study has utilised population-
attributable fractions (PAFs) to calculate the number of deaths. An important strength of this
study is that the PAFs were based on the largest prospective cohort study that investigated the
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mortality risks due to smoking. Moreover, the stratification of mortality estimates at the level
of sex, age and disease condition was unique to the cohort.
3.5.3 Limitations
There are also some limitations of the study. First, productivity loss has only been quantified
as lost earnings due to premature mortality. Hence, the estimates did not include other
components of indirect costs such as absenteeismf", presenteeismr", smoking breaks'", lost
leisure time202, fire damage245 and passive smoking248. Including these costs in future studies
will increase the costs of smoking. Second, the human capital approach taken in this study
does not represent the employer's perspective of lost productivity. Calculating productivity
loss from an employer's perspective would require a friction cost approaclr'" taking into
account employment costs and friction periods for restoring levels of initial production. Since
the human capital model does not take into worker replacement as described in Section 2.5.2,
the cost estimates in this chapter overestimate productivity loss. The alternate friction cost
method was not utilised because of its implausible assumptions on zero-cost labour
replacement (Section 2.5.2) and there was also substantial difficulty in obtaining valid
population-level data on both the frequency and length of friction periods in the UK.
Although human capital model overestimate costs, it was the current best practice method of
estimating productivity loss due to the limitations of the friction cost method. Third, the
relative risk in ex-smokers in the model was assumed to be constant and not a function of
years of quitting due to data limitations. Previous evidence298-3oohas shown that the risk of
smoking-related mortality declines in ex-smokers with longer durations of abstinence.
Moreover, the analysis assumed that smokers dying early would most likely be in
employment in the future had they survived. However, this assumption was strengthened by
using the current employment rate in the UK to adjust for the probability of being in
employment by age (conditional on survival). Fourth, the relative mortality risk from the final
ICD-IO category of "all other diseases" was obtained from two case-control studies.283 284
While a significant association was found in these studies, a causal relationship could not be
determined due to the limitation in the study design. Fifth, the economic model in this chapter
utilised median gross annual income for the estimation of costs to take into account the
income distribution of the population. The costs estimates using this approach will
underestimate costs when compared to using the mean income. However, the use of the
median income provides a more robust estimate, having a breakdown point of 50% which is
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resistant towards giving arbitrarily large results due to outliers. Finally, the economic model
developed in this chapter estimates the costs of premature mortality in the workforce. It must
be acknowledged, however, that significant cost-savings can arise from premature mortality
in health and social care settings. Some modelling studies84-86 have shown that although
healthcare costs for smokers are on average higher than that of non-smokers, long-term costs
savings for the health and social care services can result from smokers dying prematurely and
not using health services in old age. Additionally, premature mortality may in fact increase
the number of job vacancies and reduce unemployment rates when firms replace workers
which may be especially relevant during economic recessions. Despite these limitations, a
comprehensive and recent estimate has been provided for productivity loss in the UK using
best practice methodology. These results will further facilitate the estimation of net societal
costs of smoking to inform UK tobacco control policy.
3.6 Conclusion
In this chapter, smoking was found to be responsible for 96,105 deaths in adults aged 35
years and over (17% of all deaths) in the United Kingdom in 2010. These deaths resulted in
nearly 1.2 million years of life lost and 357,831 years of productive life lost. The cost of
productivity loss due to premature mortality was £4.93 billion discounted at base-case rate of
3.5%. These results suggest that reducing smoking prevalence is likely to result in substantial
gains in economic productivity in the workforce. The scale of the cost burden stresses the
importance of strong tobacco control policy at the national level.
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Chapter 4
Smoking and absenteeism: Systematic review,
meta-analysis of occupational studies and cost
of absence in the UK
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4.1 Introduction
In Chapter 3, the primary component of smoking-related indirect costs (productive life lost
due to premature mortality) was estimated for the UK. Since the causal link between smoking
and premature mortality has been well established in the UK8 9 and globally6S, the indirect
costs as a result of premature mortality could be estimated directly using the human capital
model. In Chapter 2, the literature review found that absence from work due to illness was
the second largest component of indirect costs of smoking. Absenteeism costs identified in 13
studies in Chapter 2 were direct measures of foregone income due to short-term sick leave or
temporary disability. These costs may provide motivation for employers to support smoking
cessation programmes as potential near-term benefits may be gained by a reduction in
absenteeism.
However, contrary to consistent evidence providing a causal association between smoking
and premature mortality, there is limited review evidence to suggest smoking is associated
with absenteeism." 191-195 To date, the epidemiological literature has not been systematically
reviewed, evaluated for publication bias, assessed for quality or synthesised in a meta-
analysis.
4.2 Aims and Objectives
The aim of this study was to evaluate and quantify the relationship between smoking and
work absenteeism through a systematic review and meta-analysis of longitudinal and cohort
studies. Establishing an epidemiological association between smoking and workplace absence
provides stronger justification for the estimation of absenteeism costs in the UK. By
providing this justification, the secondary aim of this study was to provide the parameters and
estimate the recent absenteeism costs for the UK. These aims were achieved by completing
the following objectives:
• Adhere to PRISMA197 and MOOSE29 guidelines to ensure a high level of quality
assurance with regards to selecting and extracting data for the systematic review
• Develop search strategy and eligibility criteria
• Quality assessment of occupational cohort studies
• Summarise, extract and synthesize the evidence
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• Conduct meta-analysis to quantify the association between smoking and absenteeism
• Assess for publication bias
• Use the results of the meta-analysis to estimate costs of absenteeism in the UK
4.3 Methods
4.3.1 Search strategy
A comprehensive search of electronic databases was conducted in MEDLINE (1948 to
February 2012), EMBASE (1980 to February 2012), PubMed (1950 to February 2012),
Science Direct (1950 to February 2012), NHS Economic Evaluation Database (1980 to
February 2012). Grey literature were searched for in CAB Abstracts (1910 to February 2012)
which includes all relevant conference proceedings. In addition, reference lists from included
studies were checked for further potential studies. Keywords relating to "smoking" and
"absenteeism" were used to search for all relevant articles (Search Terms: Appendix 9.3).
Keywords were developed through group discussion and consensus (SFW, JLB, CQ, SA) and
piloted in each individual database before the formal search process. Where available in the
database, medical subject headings (MeSH) were used to identify related terms.
4.3.2 Inclusion criteria
Studies meeting all of the following key criteria were included in the review (Detailed
eligibility checklist shown in Appendix 9.4):
(1) Study design - The designs included in the review were longitudinal studies,
prospective cohorts or retrospective cohorts in order to evaluate the temporal
relationship between smoking and absenteeism.
(2) Population - The studies including subjects who were full-time, part-time or self-
employed adult wage earners in any occupation were included in the review.
(3) Exposure - Studies that established the primary exposure of smoking (cigarette, pipe,
cigar) through one of the following methods were included: self-reported interview,
self-reported survey, medical/employee records or validated biomarker such as
cotinine or carbon monoxide.
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(4) Outcome - The primary outcomes of interest were the following measurements of
absenteeism established through self-reported interview, medical/employee records or
self-reported survey: duration of absence (days, hours, percentage of work time lost)
or risk of absence (risk, odds, hazard, rate).
4.3.3 Data extraction
Two authors (SW and JLB) independently selected studies based on titles and abstracts.
Titles were excluded on the basis of subject matter while abstracts were excluded when
inclusion criteria for study design or population were not met. Full-text articles were retrieved
from the remaining studies. The full-text articles that were not written in English were
translated using both a human translator (TL) and electronic language translator. Full-text
articles were screened and independently selected for inclusion by two reviewers (SW and
JLB; SW and CQ; or SW and SA) using a designed checklist based on eligibility criteria. The
data extraction form was developed and independently piloted on five initial studies. Two
reviewers (either SW and JLB; or SW and SA) independently extracted the data from the
studies using a standardised form (Appendix 9.6) including data on study design, study
population, location, sample size and reported results.
4.3.4 Quality assessment
To assess the methodological quality of selected studies, the Newcastle-Ottawa Scale301
(NOS) was used. According to the NOS, studies were judged according to three domains i)
selection of the study groups ii) comparability of the groups iii) ascertainment of the outcome
of interest; with a maximum total score of nine. The original scale was modified slightly to
account for specific aspects of the review (Appendix 9.6). The domains are described below:
i. The selection of the study groups (0-4): a score of four represents high
representativeness of the cohort, validated assessment of the exposure and
demonstration that the outcome of interest was not present at the start of the study,
11. The comparability of the groups (0-2): a score of two represents high
comparability due to controlling or stratifying for confounding factors.
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lll. The ascertainment of the outcome of interest (0-3): a score of three represents
validated assessment of the outcome, adequate duration of follow-up and low
attrition rates « 20%).
The quality assessment took into account most aspects of quality in epidemiological studies
such as control of confounding variables, adequate sample size, minimisation of selection
bias and clear definitions of exposures. Two reviewers (either SW and JLB; or SW and SA)
independently assessed the quality of the included studies. Any disagreements were resolved
by discussion and consensus.
4.3.5 Statistical analysis
Random effects meta-analysis was conducted to evaluate the following outcomes i) relative
risk (RR) of absence and ii) mean difference in days absent per year (annualised). The
extracted data for the effect size outcomes were in several formats: odds ratio, rate ratio,
hazard ratio and mean difference. The difference in mean duration of absenteeism between
the exposed (smokers) and non-exposed (non-smokers) groups was also reported in several
different formats: days, hours and percentage of working time lost. The data transformation
for mean duration of absenteeism was performed by annualising the data into days per year in
both exposed and non-exposed groups. However, the transformations for the effects reported
as odds ratios, rate ratios or hazard ratios were more complex. The most comparable method
of comparison between the ratio measures was through risk ratios. While hazards and rate
ratios are essentially special cases of risk ratios, odds ratios are fundamentally different. Rate
ratios and hazard ratios were used directly as estimates of relative risk ratios302 while odds
ratios were transformed to risk ratios using the correction method303• Detailed methodology
on the data transformation of reported effects from the studies to relative risk ratios is
provided in Appendix 9.10.
Separate analyses were conducted to assess the effects of smoking by comparing current
smokers versus non-smokers, ex-smokers versus never smokers and current smokers versus
ex-smokers. Random effects meta-analysis models were used to analyse the data from
different studies and to account for differences in population characteristics, geography and
study year. The heterogeneity between the studies was assessed using the i statistic which
measures the percentage of total variation across studies, derived from the Cochran's Q-
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statistic304• Detailed methodology on the random effects meta-analysis and analysis of
heterogeneity is provided in Appendix 9.7. All the analyses were completed in STATA 11
(Stata Corp, College Station, TX, USA).
4.3.5.1 Primary and sensitivity analyses
Three meta-analyses were performed using the extracted data: relative risk of absence for
current smokers versus non-smokers (Modell); mean difference in duration of absence for
current smokers versus non-smokers (Model 2); and relative risk of absence for ex-smokers
versus never smokers (Model 3). In addition, indirect comparison meta-analysis was
performed using inverse variance weighting305 to analyse the risk of absence between current
smokers and ex-smokers to test for true effect of quitting smoking.
Figure 9. Diagram for indirect treatment comparison for meta-analysis
Current
Smokers
Direct Indirect
Direct
Ex-
Smokers
Never
Smokers
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An adjusted indirect comparison30S was utilised because all study results used never smokers
or non-smokers as the reference group. Figure 9 describes the process in which the indirect
comparison was calculated based on smoking status. The solid lines represent direct
relationships in which data was reported based on the reference group of never smokers while
the dotted line describes the calculated indirect relationship based on meta-analysis results
from the direct relationships. The detailed methodology on the adjusted indirect comparison
is provided in Appendix 9.9.
Where available, adjusted relative risk estimates extracted from the studies were used
opposed to unadjusted results to take into account additional individual-level covariates. The
only outcome that was not able to be pooled using meta-analysis was the mean difference in
duration of absence between ex -smokers and never smokers due to a limited number of
studies (n = 4) and no reported measures of dispersion. Since none of the studies provided
any measures of dispersion or test statistics to calculate the measures of dispersion,
imputation procedures could not be utilised.
4.3.5.2 Missing parameters
Some studies in the meta-analysis had missing data for measures of dispersion (e.g. standard
deviations or 95% confidence intervals). For some of these studies (n = 5), it was possible to
obtain the measure of dispersion from the p-values or using the exact t-statistic or F-statistic.
For other studies (n = 6) with insufficient data to enable estimation of dispersion, the measure
of dispersion was imputed by first running an initial meta-analysis model with only those
studies that had a measure of dispersion available and then imputing dispersion measure for
the studies with insufficient data from the pooled standard error. Detailed imputation
procedures on missing parameters are provided in Appendix 9.11. To evaluate the impact of
the imputed dispersion parameters, sensitivity analysis was conducted by excluding the
studies with imputed measures of dispersion.
4.3.5.3 Subgroup analyses and meta-regression
To explore reasons for heterogeneity, subgroup analyses were conducted using the above
random effects models to evaluate effect size based on sex, work sector, type of absence and
methodological quality of the study (based on the selection, comparability and ascertainment
domains). The work sectors were sub-grouped by private, public or unclassified sector of
work. The unclassified workers were usually from nationally representative samples or a
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state-run company. Due to the diversity of the pooled workforce, the best classification was
by public or private sectors. In terms of duration of absence, the NICE definltionsl'" were
used to define short- and long-term absence. The cut-offs were specified as < 4 weeks per
year for short-term absence and z 4 weeks per year for long-term absence.l'"
To evaluate statistical significance of difference in effect size based on subgroups, random
effects meta-regression+" was conducted for subgroups that appeared to have large
differences in effect sizes. Gender, type of absence, work sector and quality score could be
incorporated as dummy variables into multivariate models. Detailed meta-regression
methodology is provided in Appendix 9.S.
4.3.5.4 Publication bias
Publication bias or "small-study bias" was assessed visually by funnel plot307 and
statistically by Egger's test for asymmetry'l" based on the distribution of effect sizes against
standard errors. Funnel plots were used as a visual tool to investigate publication bias in
meta-analysis. Funnel plots are scatter plots of the measure of effects estimated from
individual studies on the horizontal axis against a measure of standard error on the vertical
axis. In the absence of bias, results will scatter widely at the bottom of the graph (small
studies, large standard error) and the spread narrowing among larger studies (large study,
small standard error) resembling a symmetrical, inverted funnel.307 Smaller studies without
statistically significant effects can remain unpublished resulting to an asymmetrical funnel
plot.
Asymmetry in the funnel plot was evaluated using Egger's test.308 The method uses linear
regression of the study effect estimates on their reciprocal of standard errors (precision).
Under the null hypothesis of "no asymmetry", the line would be completely horizontal and
the intercept term would be at zero. The greater the association between effect estimate and
the standard error, the more the slope moves away from horizontal and the intercept term gets
further away from zero309 which results in greater asymmetry.
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4.4 Results
4.4.1 Description of studies
The electronic database search yielded a total of 3,080 studies (Figure 10).After removing
duplicates (n = 993) and excluding studies based on relevance of titles and abstracts (n =
1,906), 181 full-text articles were retrieved for evaluation. After screening full-text articles
for eligibility, 29 studies31O-338were identified for inclusion in the systematic review. The
most common reason for exclusion was non-cohort or non-longitudinal study design (56
studies excluded) or smoking status was not reported (54 studies excluded). Other reasons for
exclusion included no definition of absenteeism (18 studies), duplicates of the same
participants (8 studies), non-adult participants (7 studies), unavailable full-text articles (7
studies) and protocols only (2 studies).
The study characteristics and study-effect estimates are presented in Table 13. The year of
publication for the studies ranged from 1960328to 2011335with a median year of publication
of 2003. Most studies were conducted in Western countries; though three studies321 322326
were from Eastern Europe; two studies325330from Japan; and one study318was from Israel.
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Figure 10. Search flow chart and selection process
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4.4.2 Quality assessment
The quality scores on NOS ranged from the lowest score of three to the highest score of eight
with a median of six (InterQuartile Range: 5 to 7) (Table 13). There were no studies with the
maximum score of nine because no studies achieved the maximum score of four in the
"selection" criteria. To achieve this, studies must have assessed smoking status using a
validated biomarker such as cotinine or a device such as a carbon monoxide reader. All 29
studies relied on self-reported smoking status either through interview or survey responses.
Lower scores were generally related to studies not taking into account confounding variables
and/or having high attrition rates (> 20%) without providing descriptions of those lost.
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Figure 11. Improvement in quality score by publication year for 29
studies included in the systematic review
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The relationship between quality and publication year was evaluated by scatter plot and linear
regression. There was an upward trending relationship shown a scatter plot (Figure 11)
between quality scores and year of publication where quality improved over time. On
average, quality improved by 0.06 points per year from 1960 to 2011 (fJ = 0.06,95% Cl 0.03
to 0.10; p = 0.001).
4.4.3 Current smokers versus non-smokers
4.4.3.1 Risk of absenteeism
Seventeen studies'" 3ll 314-317320323-327330-332334335 compared the risk of work absenteeism for
current smokers; of which 8 studies'!" 315 317 327 330 331334 335 compared the risk between current
smokers and never smokers and 9 studies'"" 311 316320323-326332 compared the risk between
current smokers and non-smokers (including ex-smokers). The follow-up duration ranged
from 3 monthsi'" to 144 months320 with a median duration of 24 months. There were 71,516
workers in the sample with an over-representation of men (60%) compared to women (40%).
To test for the overall effect of current smoking, never smokers and non-smokers were
combined in a single "non-smoking" group. The pooled meta-analysis showed that current
smokers were 33% more likely to take work absence than non-smokers (RR = 1.33,95% Cl
1.25 to 1.41; i = 62.7%; 17 studies; Figure 12). When meta-analysis was stratified based on
whether or not study-level covariates such as age, sex and lifestyle factors were adjusted for,
the pooled estimates were similar to the overall relative risk (adjusted RR = 1.35 [95% Cl:
1.25 to 1.45]; unadjusted RR = 1.25 [95% Cl: 1.17 to 1.35]).
In the subgroup of 8 studies comparing the risk of absence between current and never
smokers, almost identical results (RR = 1.36,95% Cl 1.27 to 1.47; 12 = 68%; 8 studies) to the
overall analysis comparing the risk between current and non-smokers were obtained.
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4.4.3.2 Duration of absenteeism
Thirteen studies312 313 318 319321322326328329333336-338 compared the duration of work absence
between current smokers and non-smokers. There were a total of 30,978 workers in these
studies. The follow-up duration ranged from 3 monthsl'" to 120 months336 with a median of
24 months. The continuous outcome of duration of absence was not adjusted for any
additional study-level covariates in the extracted data. Most studies included in the meta-
analysis of duration of absenteeism reported the results separately for men and women;
hence, the results were stratified by gender. The overall mean annual difference in absence
between current smokers and non-smokers was 2.74 days (95% Cl 1.54 to 3.95 days; i =
89.6%; 13 studies; Figure 13). In men, current smokers were absent on average 1.18 more
days per year than non-smokers (95% Cl 0.51 to 1.84 days; f = 28.4%; 8 studies); whereas in
women, the difference between current and non-smokers was not significant (days/yr = 0.75;
95% Cl -0.63 to 2.12; i = 69%; 6 studies). When the results from the meta-analysis were
applied to the UK population with an adult smoking prevalence of 21%339, employment rate
of 70.5% (29.17 million)l90 and an average pay of £434 per weekl90, the estimated total cost
of absenteeism due to smoking was £1,457 million (95% Cl £819 million to £2,100 million)
in 2011.
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4.4.4 Ex-smokers versus never smokers
4.4.4.1 Risk of absenteeism
Eight studies314 31S 317 327 330 331 334 33S compared the risk of absenteeism for ex-smokers and
never smokers comprising a total pooled sample of 48,645 workers with an over-
representation of men (59%) compared to women (41%). The duration of follow-up ranged
from 12 months31S 331 to 96 months330 with a median of 30 months. Overall. ex-smokers were
14% more likely to take work absence than never smokers (RR = 1.14.95% Cl 1.08 to 1.21;
i = 62.4%; 8 studies; Figure 14). The average risk of absenteeism (14%) for ex-smokers
compared to never smokers was substantially less than the risk of absenteeism (33%) for
current smokers compared non-smokers. The majority of the studies provided relative risks
that were adjusted for additional individual-level lifestyle covariates while only one studl31
provided crude effects.
4.4.4.2 Duration of absenteeism
Four studies?" 322329336 compared the duration of work absence between ex-smokers and
never smokers. These studies provided incomplete measures of dispersion and therefore
meta-analysis could not be performed. The largest difference in work absence was reported in
a study by Lundborg" where ex-smokers took 4.5 more days off per year than never
smokers. When occupational and health variables were controlled for. the difference was not
statistically significant. The smallest difference in work absence was reported in Tsai et al.336
where female ex-smokers took only 0.20 more days off per year than never smokers but the
difference was not statistically significant. Neither Halpern et al.319 nor Jedrychowski et al.322
found statistically significant differences in duration of absenteeism between ex-smokers and
never smokers. Therefore, there was no evidence from the available studies that ex-smokers
were significantly absent longer than never smokers.
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4.4.5 Current smokers versus ex-smokers (indirect comparison)
By using the meta-analyses comparing current smokers to never smokers (RR = 1.36,95% Cl
1.27 to 1.47; 12 = 68%; 8 studies) and ex-smokers to never smokers (RR = 1.14,95% Cl 1.08
to 1.21;i= 62.4%; 8 studies), indirect comparison meta-analysis was conducted (Appendix
9.9) using an inverse variance weighting. The analysis showed that current smokers were
19% more likely be absent from work compared to ex-smokers (RR = 1.19,95% Cl 1.09 to
1.32; n = 8 studies; p < 0.01) suggesting that quitting smoking would in fact reduce the risk
of work absence.
4.4.6 Subgroup analysis
Table 14 presents subgroup analyses using random effects models for relative risk of
absenteeism (Modell) and duration of absenteeism (ModeI2) in current versus non-smokers
and relative risk of absenteeism in ex-smokers versus non-smokers (Model 3). The analysis
was stratified by sex, work sector and duration of absence. For subgroups based on sex, all
three models showed only small, non-significant differences in pooled effects between males
and females (Modell: meta-regression p = 0.940; Model 2: meta-regression p = 0.431,-
Model 3: meta-regression p = 0.906). When studies were grouped by work sector, public
sector workers on average were more at risk of being absent from work than private sector
workers in both current and ex-smokers (Models 1 and 3). However, the difference was not
statistically significant in either model (Modell: meta-regression p = 0.745; Model 3: meta-
regression p = 0.709). In terms of duration, current smokers were on average more at risk of
long-duration absence (~4 weeks) than short-duration absence « 4 weeks) (Modell) but the
difference was also not statistically significant (meta-regressionp = 0.632).
The methodological quality of the studies had a marginal impact on the pooled effects of the
meta-analyses when comparing the relative risk of absenteeism in current versus non-
smokers (Modell) and ex-smokers versus never smokers (Model 3). However, the impact
that methodological quality had on pooled effects was most apparent in Model 2 When
comparing the duration of absence between current and non-smokers. For the selection
domain of the quality assessment, the average difference in pooled effects between studies
with high scores and studies with low scores was 2.42 days per year (meta-regression p :::
0.406). For the comparability domain, the average difference in pooled effects between '
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studies with high scores and studies with low scores was 2.67 days per year (meta-regression
p = 0.401). In terms of the ascertainment domain, the average difference in pooled effects
between studies with high scores and studies with low scores was 3.52 days per year (meta-
regression p = 0.133). Overall, the analysis in Model 2 showed that low quality studies may
have biased the average estimates downwards as high quality studies tended to demonstrate
much stronger effect sizes.
4.4.7 Sensitivity analysis
The sensitivity analysis excluded studies that did not report a measure of dispersion. The
results (Table 14) showed that imputation of measures of dispersion generally had marginal
effects on the meta-analyses for the relative risk of absenteeism between current smokers and
non-smokers (Modell) and ex-smokers and never smokers (ModeI3). However in Model 2,
the mean difference of absence duration demonstrated that current smokers were absent 3.3
more days per year than non-smokers in the sensitivity analysis (compared to 2.74 days per
year in the primary analysis). This suggests that data imputation procedures had a small
impact weighting the estimate downwards when in fact the mean difference in absence
between current and non-smokers may have been even greater.
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Table 14. Summary relative risk ratios from primary and stratified random effects
meta-analyses between smoking and absenteeism
Stratification Pooled Effect Size Heterogeneity
Modell: Current vs. Relative Risk of 95% Confulence Interval No. of studies rNon-smokers absenteeism
Primary analysis 1.33 1.25,1.41 17 62.7%
Sex
Male 1.36 1.24,1.49 9 62.2%
Female 1.32 l.l9,1.45 7 70.4%
Non-stratified 1.26 1.05,1.52 7 63.6%
Work sector
Private 1.25 1.20, 1.31 7 0.0%
Public 1.41 1.27,1.57 6 62.8%
Unclassified 1.34 l.l1, 1.62 4 67.1%
Type of absence
Short « 4 wks) 1.33 l.l6,1.52 4 91.2%
Long (~4 wks) 1.55 1.37,1.77 4 23.1%
Undefined 1.31 1.27,1.43 13 62.3%
Selection
High (~3) 1.42 1.29,1.56 6 66.2%
Low « 3) 1.27 l.l9,1.36 11 43.2%
Comparability
High (= 2) 1.33 1.23,1.45 13 70.7%
Low « 2) 1.30 1.21,1.38 4 6.1%
Ascertainment
High 1.40 1.29, 1.52 9 70.6%
Low 1.25 l.l7,1.33 8 12.4%
Sensitivity analysis" 1.38 1.27,1.50 12 70.7%
Current vs. never 1.36 1.27, 1.47 8 68.0%
Model2: Current vs. Mean difference 95%CI No. of studies i
Non-smokers (days per yr)
Primary analysis 2.74 1.54,3.95 13 89.6%
Sex
Male 1.18 0.51,1.84 8 28.4%
Female 0.75 -0.63,2.12 6 69.0%
Non-stratified 6.60 2.37,10.83 5 95.2%
Selection
High 4.48 -0.13,9.09 3 97.2%
Low 2.06 0.99,3.13 10 78.1%
Comparability
High 4.83 -0.72, 10.37 2 98.1%
Low 2.16 1.17,3.16 11 76.4%
Ascertainment
High 5.04 1.52,8.57 6 93.7%
Low 1.52 0.59,2.45 7 76.8%
Sensitivity analysis" 3.30 1.51,5.09 8 92.7%
Model 3: Ex- vs. Never Relative Risk of 95%CI No. of studies i
smokers absenteeism
Primary analysis 1.14 1.08, 1.21 8 62.4%
Sex
Male l.l4 1.08, 1.21 5 0.0%
Female l.ll 1.01, 1.22 5 73.3%
Non-stratified 1.37 0.83,2.26 2 88.0%
Work sector
Private 1.10 1.03,1.16 4 55.8%
Public 1.23 1.09,1.39 4 45.6%
Unclassified
Selection
High l.l4 1.04, 1.25 3 80.1%
Low 1.15 1.06, 1.24 5 21.8%
Comparability
High l.l6 1.09,1.24 6 45.7%
Low l.l0 0.99,1.22 2 64.8%
Ascertainment
High l.l7 1.08, 1.27 6 70.0%
Low l.l2 1.05. 1.20 2 0.0%
Sensitivity analysis. 1.18 1.10. 1.27 6 49.0%
*Only included studies with reported measures of dispersion
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4.4.8 Publication bias
No significant evidence of publication bias was found in the meta-analyses for the relative
risk of absenteeism between current smokers and non-smokers (Figure 15; Egger's
asymmetry test, p = 0.951); the mean difference in absenteeism between current smokers and
non-smokers (Figure 16; Egger's asymmetry test, p = 0.132); and the relative risk of
absenteeism between ex-smokers and never smokers (Figure 17; Egger's asymmetry test, p =
0.104).
Figure 15. Funnel plot of the log relative risk of absence and corresponding
standard error between current smokers and non-smokers
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Figure 16. Funnel plot of the mean difference of absence and corresponding
standard error between current smokers and non-smokers
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Figure 17. Funnel plot of the log relative risk of absence and corresponding
standard error between ex-smokers and never smokers
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4.5 Discussion
4.5.1 Summary of findings
There was consistent evidence from this systematic review and meta-analysis that smoking
increased both the risk and duration of work absenteeism. This is the first systematic review
assessing the impact of smoking on the risk and duration of absenteeism. In current smokers,
the risk of work absenteeism was 33% greater than that of non-smokers. In terms of the
duration of absence, current smokers were absent 2.74 days per year more than non-smokers.
For ex-smokers compared to never smokers, the relative risk of absenteeism was 14% higher.
For the mean duration of absence in ex-smokers compared to never smokers, there were only
four studies available. There was no evidence in those four studies that smoking was
significantly associated with absenteeism. The average number of days absent per year
ranged from 0.2 days to 4.5 days but the study effects could not be pooled due to incomplete
parameters. By comparing current smokers to ex-smokers indirectly, the relative risk of
absenteeism was found to be 19% higher. Overall, the results were conservative in nature as
quality assessment and sensitivity analysis showed that low quality studies and data
imputations procedures weighted the pooled effect size downwards, suggesting that the
strength of association between smoking and risk or duration of absenteeism may in fact be
stronger.
4.5.2 Exploration of heterogeneity
High levels of heterogeneity (p > 60%) were generally seen in the meta-analyses as the
studies differed in time periods, geographic location and population demographics.
Additional reasons for heterogeneity were explored through further subgroups presented.
When workers were stratified by sex, the relative risk and duration of absenteeism due to
smoking were similar in men and women. Public sector workers had on average higher risk
of absenteeism than private sector workers; however, the result was not statistically
significant at the 5% level. The lack of significance could be due to a lack of power in the
meta-regression analysis from a limited number of studies. A survey of 241 public and
private sector organisationsr" found that absence was on average 2.5 days higher in the
public sector than in the private sector. One of the reasons suggested was that public sector
employees were in more challenging public-facing roles such as social work, policing,
teaching and nursing where they often have to deal with people in difficult and emotionally
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charged situations, putting pressure on their time and resilience.?" Another reason may be
that public sector workers have better job security than private sector workers. While the
results were not statistically significant, there may be some indication to support the survey
literature suggesting public sector workers on average were more at risk of absence.
Compared to non-smokers, current smokers were on average at higher risk of taking longer
durations of absence than shorter durations. However, this result was not statistically
significant. Again, this lack of statistical significance could be due to a lack of power in the
meta-regression as there were only four outcomes'"" 317 327 332 that could be classified as short-
duration and four outcomesi'" 314327334 that could be classified as long-duration. In many of
the included studies in the review, the reason for long-term absence was consistently due to
chronic health problems while the reasons for short-term absence were due to short-term
illness. Many of the' smokers in the sample were persistent long-term smokers. Health
problems related to smoking tend to be long-term and chronic conditions such as COPD and
CVD where illness periods were longer and more frequent. This is further supported by a 19-
year follow-up study in Finland which estimated that the smoking resulted in 2.6 productive
work-years lost per person due to smoking-related chronic health problems.182
4.5.3 Implications
The results of this study suggest that smoking cessation in the workplace could potentially
result in cost savings for employers from reduced absenteeism. Using the results of the meta-
analyses, smoking was estimated to cost UK employers on average £1.46 billion in 2011
from absenteeism in the workplace. This large economic impact of smoking on absenteeism
suggests that there is potentially great value in workplace smoking cessation programmes.
This view is supported in several cost-of-smoking studies.89 237 251342
• • 343 344th h d'There have been two systematIc reviews at ave explore the Impact of smoking
cessation interventions in the workplace. A review of 22 prospective studies on the impact of
work environment on smoking cessation by Albertsen et al.343 found that highly demanding
jobs were associated with higher amount smoked while social support at work was positively
associated with cessation. In addition, a Cochrane Review by Cahill et al.344 of 51 quasi-
randomised controlled trials evaluated workplace interventions and found strong evidence
that interventions directed towards individual smokers (such as individual or group
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counselling and pharmacological treatment) increased the likelihood of quitting more than
unassisted, self-help or social support interventions alone.344 In both these reviews, the
general conclusion was that workplace interventions aided employees to quit smoking. The
number of quitters could be potentially increased by improving awareness of the workplace
programmes. In order to improve quit rates, it would be necessary to increase participation by
providing easier access and raising awareness of successful forms of workplace smoking
cessation interventions.
4.5.4 Limitations
There were some limitations of the systematic review. The review found no significant
evidence of publication bias in any of the meta-analyses; however some visual evidence of
asymmetry was seen in the funnel plots. Asymmetry in the funnel plots could have been a
result of poor methodological quality of the studies rather than publication bias.345
Furthermore, there were only a limited number of studies which had reported results by sub-
groups, thus limiting the power of the subgroup analysis. As a result, meta-regression did not
detect significant differences between gender subgroups, absence duration subgroups, work
sector subgroups or quality assessment subgroups at the 5% level. This was most noticeable
in quality assessment subgroups in Model3 where the average pooled effects resulted in large
effect sizes but wide 95% confidence intervals.
There were also limitations in terms of the quality of evidence and design of studies
identified in the systematic review. Cohort studies may be the best type of evidence in terms
of observational studies but some studies were subject to a high risk of attrition bias and
confounding. A few of the studies experienced higher attrition rates and lacked description of
those lost to follow-up. Many of these studies were retrospective and limited to what
information was collected at the time. Some multivariate models included many covariates
(e.g. demographics, lifestyle, health, work-related variables) and others included only a few
(e.g. age and sex).
Additionally, relative risks ratios were computed from odds ratios in several studies for the
meta-analysis using a common transformation method; however, this is known to overstate
significance levels when outcomes are common.t'" Finally, there were seven studies which
had old publication dates (1950-1970) where access full-text articles in print or electronic
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form was unavailable. Several of these papers were in journals that have stopped circulation
and contact with the study authors was not achievable. These studies presented findings
within the range of the pooled results in this chapter and were unlikely to have a substantial
impact on the pooled results due to small sample sizes.
4.6 Conclusion
The systematic review found that smoking increases both the risk and duration of
absenteeism. Current smokers were on average 33% more likely to be absent from work than
non-smokers. When current smokers did take absence, they were absent on average 2.74
more days per year than non-smokers. Ex-smokers were also on average 14% more likely to
be absent from work than never smokers. There was no evidence to suggest there was a
significant difference in duration of absence between ex-smokers and never smokers. Using
an indirect comparison, current smokers were on average 19% more likely to be absent from
work than ex-smokers. The increased risk and duration of absence was estimated to cost UK
employers on average £1.46 billion in 2011. The results of this systematic review implicate
that quitting smoking may reduce absenteeism and result in substantial cost-savings for
employers.
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Chapter 5
Validation of UK indirect cost estimates using
population-level indirect cost-of-smoking
studies
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5.1 Introduction
One of the primary limitations of cost-of-illness studies is that there are no obvious methods
in which to validate the cost estimates. This is due to methodological heterogeneity as
described in Chapter 2. Whilst published guidance347-349has provided a conceptual
framework for cost-of-illness methodology, many studies suffer from conceptual deficiencies
and lack transparency in reporting. Most cost-of-smoking studies use some variant form of
the 1960s framework347of combining 'direct' costs of medical care with 'indirect' costs of
lost production from reduced working time. The differences in methodology were apparent in
the 17 indirect cost-of-smoking studies identified in Chapter 2. Despite this, there was some
degree of consistency across the studies. In Chapter 2, it was hypothesized smoking
prevalence was directly proportional to indirect costs across populations. The ecological
relationship between smoking prevalence and indirect cost was tested and found to be
significant. The significant association was not surprising because in spite of methodological
heterogeneity, prevalence was in fact the primary driver of all 17 cost-of-smoking studies.
The multiplicative effects of individual-level costs (Le. lost productive life years,
absenteeism) were propagated to population-level estimates by the degree of smoking within
a population. In other words, the greater the number of people in a population who smoke the
more indirect costs the population incurs.
Chapter 2 also identified the primary components of indirect costs. The two major
contributors to indirect costs were foregone income due to productive life lost and
absenteeism from work. This was the rationale for quantifying the indirect costs of foregone
income due to productive life lost (Chapter 3) and indirect costs of absenteeism from Work
(Chapter 4). The results in those chapters showed that smoking resulted in £4.93 billion in
foregone income due to productive life lost and £1.46 billion in absenteeism in the UK in
2010-2011. These two primary components of indirect costs totalled £6.39 billion in 2010-
2011.
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5.2 Aims and Objectives
In this chapter, the aim was to validate the calculated indirect costs of smoking in the UK.
The aim was achieved by completing the following objectives:
• Derive regression equations from the ecological analysis of 17 population-level cost-
of-smoking studies identified in Chapter 2.
• Include the thesis estimate of indirect costs into the ecological regression analysis
• Compare the predicted indirect cost estimate to the observed indirect cost estimate
5.3 Methods
The methodology for validating the UK indirect cost estimate involved transforming the UK
indirect cost estimate to reflect the common US dollar currency in the base-year of 2010
similar to the methods used in Chapter 2. Since the UK cost estimate reflected the year
2010-2011, itwas not necessary to inflate the amount by the labour cost index. The combined
indirect cost of £6,387,550,000 in foregone income from productive life lost (Chapter 3) and
absence from work (Chapter 4) was first converted to indirect cost per capita. From a UK
population of 62,231,336 in 2010203, the indirect cost-per-capita was calculated to be
£102.64. This value then had to be exchange rate adjusted to US dollars to coincide with the
regression analysis in Chapter 2 in which the cost estimates were based on 2010 US dollars.
Using the 2010 annual dollar to pound exchange rate of 1.55 (USD:GBP) provided by the
IMF207, the indirect cost per capita was converted to $159.10 USD. Subsequently, the
exchange rate adjusted indirect cost per capita was compared to the indirect cost per capita
derived from published studies in Chapter 2.
Regression analysis was conducted on smoking prevalence in the study year and indirect cost
per capita with the inclusion of the UK estimate. Previously in Chapter 2, the 'best-fit'
logarithmic model was specified using stepwise regression analysis for the multivariate
association between smoking prevalence and indirect cost per capita. The results of that
particular analysis included the covariate of GDP per capita and found that a 1% increase in
smoking prevalence resulted in a 1.7% (95% Cl 0.21 to 3.16, p = 0.028) increase in cost per
capita across all studies and a 2.1% (95% Cl 0.46 to 3.81, P = 0.017) increase in cost per
capita across human capital model studies only. The results of this regression analysis yielded
two logarithmic functions:
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Function 1. All studies (17 studies):
Ln(CostperCapita) = 1.69 * Ln(Prevalence) + 0.59 * Ln(GDPperCapita) - 6.66
Function 2. Human capital studies (15 studies):
Ln(CostperCapita) = 2.13 * Ln(Prevalence) + 1.35 * Ln(GDPperCapita) - 0.38 *
Ln(Unemployment Rate) - 14.76
Using the logarithmic functions, a predicted logarithmic value of indirect cost per capita
could be calculated using the log of smoking prevalence, log of GDP per capita and log of the
unemployment rate (human capital studies only). To predict indirect cost per capita in the
UK, the smoking prevalence of 20%7, GDP per capita (2010) of USD $36,356203 (£25,886)
and annual (2010) unemployment rate of 7.8%350 were substituted in the logarithmic
functions. The predicted indirect cost per capita for the UK was then back-transformed from
the logarithmic scale to reflect the monetary amount:
Function 3. All studies (17 studies):
CostperCapita = exp[1.69 * Ln(Prevalence) + 0.59 * Ln(GDPperCapita) - 6.66]
Function 4. Human capital studies (15 studies):
CostperCapita = exp[2.13 * Ln(Prevalence) + 1.35 * Ln(GDPperCapita) - 0.38 *
Ln(Unemploymen Rate) - 14.76]
The predicted monetary values were then compared to the observed indirect cost-per-capita
amount for the UK of $159.10 USD (£102.64).
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5.4 Results
When compared to other studies, the indirect cost per capita due to smoking for the UK in
2010 reflected the lower half of the cost spectrum as shown in Figure 18.
Figure 18. Comparison of indirect costs per capita due to smoking inflated to 2010 US
dollars by location
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This was due to the UK adult smoking prevalence of 20% in 2010 was below the median
prevalence rate of 27% among all studies. Since smoking prevalence was the primary driver
of the estimates and it was not surprising the UK cost estimate for the most part was less than
that of populations with higher smoking prevalence. The ecological relationship between
indirect cost per capita and smoking prevalence was examined using a regression model
(Figure 19).
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Figure 19. Ecological relationship between smoking prevalence and indirect cost per
capita for population-level studies
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With the inclusion of the UK cost estimate, the slope of the regression line was found to be
$8.70 (95% Cl -$5.44 to $22.83, p = 0.21; Figure 19) [£5.73, 95% Cl -£3.60 to £15.05] for
every 1% increase in adult smoking prevalence. In Chapter 2, without the inclusion of the
UK cost estimate, the slope of the regression line was found to be $8.57 (95% Cl -$6.60 to
$23.59, p = 0.24; Figure 6) [£5.62 95% Cl -£4.33 to £15.48] for every 1% increase in adult
smoking prevalence. The inclusion of the UK cost estimate only slightly changed slope of the
regression line. In addition, the estimate seemed was consistent with other population-level
cost estimates seen visually in Figure 19. Similar to the association found in Chapter 2,
there seemed to be an overall positive relationship between adult smoking prevalence and
cost per capita; however, this relationship was not linear, nor statistically significant.
Therefore, logarithmic transformations were used for the validation functions.
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By substituting the 2010 UK adult smoking prevalence of 20%, 2010 GDP per capita of
$36,356 USD (£25,886) and 2010 unemployment rate of 7.8% into the logarithmic functions
provided in the methods, the predicted value of indirect cost for the UK could be estimated.
Using regression function derived from all studies (Function 1 and Function 3), the
predicted cost per capita was $99.33 USD (£65.47). When the regression function derived
only from human capital model studies was used (Function 2 and Function 4), the predicted
cost per capita was $150.93 USD (£99.49). When the predicted costs were compared to the
observed cost per capita of $159.10 USD (£102.64), there was a 5% difference between
predicted and observed costs across human capital studies and a 34% difference between
predicted and observed costs across all studies. The predicted value was similar to the
observed value when only human capital studies were included in the prediction function.
However, with the inclusion of friction cost studies, the predicted value decreased as these
estimates tended to be more conservative. The friction cost estimates negatively affected
(towards horizontal) the slope of the prediction line. This was not surprising as the
productivity loss estimates were derived from the human capital model in Chapter 3.
Therefore, the observed values converged well with the predicted values derived from
validation Function 2 and poorly with the predicted values derived from validation Function
1. This does show, however, that there was some degree of consistency and validity in the
thesis estimates with other published studies which had utilised the human capital method.
5.5 Discussion and Conclusion
This validation study showed that cost methodology used in this thesis provided a level of
consistency and validity when compared to other published studies which had used the
human capital method. This study employed an ecological approach to validate the UK cost
estimates. The main limitation of this approach was that there was no method of
incorporating the effects of methodological heterogeneity into the regression analysis. A
random-error term could have been included in the regression analysis to try to capture
differences among studies; however, there were doubts regarding whether the methodological
heterogeneity was completely random. All the included studies used variant forms of
prevalence-based approaches to estimate indirect costs. Dummy variables were also
considered to group potentially similar studies; however, the analysis lacked power due to the
limited number of studies. Furthermore, no clear, defensible grouping of the studies could be
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made. Finally, weighting the cost outcomes by the number of cost components was
considered but this process only decreased the predictability of the model. Thus, the final
model chosen was based on the log-log transformation function between smoking prevalence
and indirect cost per capita with one covariate (GDP per capita) for all studies and two
covariates for human capital studies (GPD per capita and unemployment rate). Ultimately,
this approach provided the 'best-fit' model suitable for validation.
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Chapter 6
Economic evaluation of workplace smoking
cessation interventions: Markov model from the
employer's perspective
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6.1 Introduction
On the basis of current consumption patterns, 450 million adults will be killed by smoking
between 2000 and 2050 where over half of these deaths will occur between the ages of 30
and 69 years losing years of productive life.4 The analysis in Chapter 3 found smoking was
responsible for 96,105 deaths (17% of all deaths of adults aged 35 and over) in the UK in
2010. As many of these deaths come prematurely during working years, this creates a large
economic burden in terms of loss of productive life years. The cost-of-smoking study
conducted in Chapter 3 showed that smoking cost the UK economy £4.93 billion in foregone
income due to productive life lost. Smoking has also been established to be associated with a
higher probability of absenteeism from work. The systematic review conducted in Chapter 4
found that smokers were estimated to have 33% more risk of being absent from work than
non-smokers due to sick leave and absent on average 2.74 days a year more than non-
smokers, costing UK employers £1.46 billion per year. When the cost of smoking to the NHS
(£5.2 billion)", costs to the employers due to absenteeism (£1.46 billion)351 and costs of
foregone income due to productive life lost (£4.93 billion)" are combined, the cost to the
society from these components alone was estimated to be £11.6 billion in 2010-2011.
The large economic burden suggests that smoking cessation would lead to fewer lives lost,
fewer productive years lost, less foregone income and fewer absences at work resulting in
large cost-savings for both employers and the wider society. A potential solution is for
employers to adopt smoking cessation interventions in the workplace. Previous systematic
reviews352 353 have found there is strong evidence that interventions directed towards
individual smokers increase the likelihood of quitting smoking including advice from a health
professional, individual and group counselling and pharmacological treatment. It has been
established that smoking cessation interventions are cost-effectivef'" 354355for increasing life
years or quality adjusted life years (QAL Ys) in individuals. However, previous studies have
only taken a health service perspective on costs and outcomes. In order for employers to
adopt smoking cessation interventions, any proposed model must analyse the cost-benefits
from a firm's perspective to maximise profits and minimise absenteeism-related costs
(induding labour turnover, disability and mortality) by increasing quit rates in the workforce.
These costs have been established in well-known business surveys356-358as contributing
significantly to operating expenses.
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Cost-benefit analysis is commonly used to measure all positive or negative consequences of
interventions including the effects on users and non-users, externality effects and other social
benefits. The analysis in this chapter measures the positive and negative consequences of the
smoking cessation interventions with regards to the employer and employees. This is
technically a cost-offset analysis because this analysis does not measure the effects on non-
users, externality effects and other social benefits. However, the analysis retains the cost-
benefit terminology due to it being commonly used in reporting monetary outcomes for costs
and benefits in evaluating investment decisions.
6.2 Aims and Objectives
The aim of this chapter was to conduct a cost-benefit analysis of several common workplace
smoking cessation interventions from the employer's perspective for minimising costs and
maximising returns on investment. A secondary aim was to conduct cost-effectiveness
analysis of workplace smoking cessation interventions if the employer valued maximising
quitting instead. The aims were achieved by completing the following objectives:
• Develop the decision analytic framework for comparing cost-benefits and cost-
effectiveness of workplace interventions from the employer's perspective: no
intervention, brief advice, individual counselling, individual counselling with nicotine
replacement therapy (NRT)
• Construct a Markov model to simulate a cohort of workers taking into account
smoking cessation interventions, smoking status, absenteeism, labour turnover, death
and disability
• Conduct deterministic analysis to obtain total costs incurred and return on investment
• Conduct probabilistic sensitivity analysis taking into account parameter uncertainty
• Conduct additional sensitivity analysis on costs and alternate discount rates
• Re-sample the Markov model using cost-effectiveness analysis to determine the
employer's optimal smoking cessation strategy for maximising quitting
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6.3 Methods
6.3.1 Decision analysis
The study used a decision analytic frameworkr'" based on a Markov model360 to assess the
effects of workplace interventions for smoking cessation to reduce absenteeism and labour
turnover (due to disability and death). Four workplace smoking cessation strategies were
evaluated based on prior comprehensive reviews344 361 and NICE guidance/'" on the
effectiveness of workplace smoking cessation interventions:
I. Strategy 1: No intervention (base-case scenario)
II. Strategy 2: Brief advice from an occupational health nurse
III. Strategy 3: Individual counselling with an occupational health nurse
IV. Strategy 4: Nicotine replacement therapy (patch) and individual counselling with
an occupation health nurse
Other forms of pharmacotherapy such as varenic1ine and buproprion were not evaluated as
there is limited evidence on the practicality and effectiveness of these interventions in a
workplace setting. Each strategy was evaluated using a Markov state transition model
simulating a cohort of adult smokers (aged 35 and older) participating in a particular
workplace smoking cessation strategy. The decision analysis framework involved comparing
the total costs (TC) incurred and returns on investment (ROI) derived from each individual
strategy simulated from the Markov models in reducing absenteeism, disability and death in
the workplace cohort (Figure 20).
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Figure 20. Decision analytical framework for evaluating workplace smoking
cessation interventions from the employer's perspective
Workplace Smoking Cessation Interventions
Strategy 1: No Strategy 2: Brief Strategy 3: Individual Strategy 4: NRT +
Intervention Advice Counselling Individual Counselling
~7
Cohort Simulation Model
Markov Cohort Simulation Model
~7
Outcome Measures
Total Costs (Te) Return on Investment (TC)
Two outcomes were presented to allow the decision-maker (employer) to decide on which
outcome to use. The strategy with the lowest total cost and largest return on investment was
considered to be the optimal choice in the primary analysis. Many economic evaluation
studies use net benefits (net monetary benefit, net health benefits) to determine optimal
strategies from a health services perspective. Cost-effectiveness analysis from this
perspective often use outcomes such as QALYs or life years where the most cost-effective
strategy is usually determined by the maximisation of the effects (QALYs or life years) and
minimisation of the costs, often times given a willingness-to-pay threshold. However, from
an employer's perspective, it is common to evaluate alternate investment options using total
cost (TC) incurred and return on investment (ROI).362 Total cost (TC) incurred is simply the
combined expected value of expenditure from smoking cessation intervention, absence costs
and labour turnover costs. The optimal strategy selection for the employer would be the
strategy which minimised total costs.
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ROI can be interpreted as the amount of additional money an employer gains per pound
spent. In the calculation below, the net present value (NPV) of benefits gained is quantified
as the monetary value saved from a reduction of absence and labour turnover costs while the
net present value (NPV) of costs is the investment expenditure of adopting a particular
smoking intervention strategy:
(NPV of benefits - NPVof costs)
Return On Investment = NPV f
o costs
Both NPV of costs and NPV of benefits are incremental values calculated from the baseline
strategy of no intervention. Strategies with positive ROI compared to a baseline strategy will
offer a better investment for the employer while strategies with negative ROI will offer a
worse investment. Investment choices made on the basis of 'I'C and ROI are identical
(strategy with the lowest Te incurred results with the highest ROI). Both outcomes were
utilised in the primary analysis.
In a secondary analysis, cost-effectiveness analysis was used to determine whether the
employer's optimal selection strategy would differ if the employer valued maximising
quitting. In this scenario, the outcome used was cost per quitter and the evaluation of
intervention strategies were ranked based in the incremental cost-effectiveness ratio (leER):
Total Costsstrategy i-Total Costsstrategy i-1
IeER= ------------~~-=~----~--~--~~------Number of Quittersstrategy i-Number of Quittersstrategy i-1
The leER was calculated as the ratio of the change in costs (from current strategy to previous
strategy) to the change in number of quitters (from current strategy to previous strategy). The
leER allows for the ranking of all four intervention strategies according to cost-effectiveness.
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6.3.2 Markov state transition model
A Markov model was constructed which simulated a hypothetical cohort of 1,000 current
smokers in the workplace (Figure 21). The direction and likelihood of a worker moving
between states was governed by transition probabilities. Solid lines describe forward
progressions, dotted lines describe return progressions and circular arrows represent
remaining in the same state.
There were two 'present at work' states: current smokers and ex-smokers; and four 'absence
from work' states: long-term absence for current smoker, long-term absence for ex-smokers,
leaving work due to disability and leaving work due to death. In Figure 21, the smoking
cessation intervention can be visualised as a rectangle to illustrate the probability of
participation in the intervention by current smokers who subsequently had either a successful
or unsuccessful quit attempt. For the 'no intervention' strategy, cessation interventions were
removed from the model and the transition between current and ex-smokers was shown as a
successful unassisted quit attempt.
Figure 21. Markov state transition model for smoking cessation interventions
Short-term Absence (CS)
Intervention
Short-term Absence (EX)
Transitiqm
Black"' to forward state
Dotted = to previous state
Circular. remain in current state
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The key characteristics of the model are summarised below:
• The workers were followed up from 35 years until the average age of retirernenr'f in the
UK (64.6 years for men and 62.3 years for women).
• Cycle lengths of six months (26 weeks) were implemented corresponding to sustained
smoking cessation quit rates at six months because smokers who can quit and remain
abstinent for six months are likely to have a very high probability of remaining long-term
ex-smokers. 364
• When an individual left work due to disability or death, it was assumed that the individual
would not be able to return to work as a member of the original cohort.
• Short-term absences were defined as absent workers who did not qualify for long-term
statutory sick pay in the UK.
• Long-term absences were defined as absences that qualified for long-term statutory sick
pay by the employer (up to 26 weeks).
• Current and ex-smokers are allowed to have short-term absences without having to leave
the state as short-term absences are usually much shorter than the cycle length
• Transition to the disability state could only happen from long-term absence (i.e. workers
cannot directly enter disability state from long-term absence) because the UK labour
market definition of disability365 was applied where individuals must be on long-term
absence greater than 26 weeks to be able to qualify for disability or incapacity benefits.
• Costs were taken from the employer's perspective as companies and firms behave to
minimise the costs of absenteeism and labour turnover.
• All future costs were discounted by 3.5% in accordance to HM Treasury recommended
guidelines.i"
The simulation was conducted separately for men and women as there were gender
differences in costs, absence rates, death rates and disability rates. The cohort simulation
results took into account all probabilistic parameters for transition probabilities (methodology
in Section 6.3.3) in conjunction with baseline costs (methodology in Section 6.3.4).
Probabilistic analysis employed random sampling technique of 1,000 Monte Carlo
simulations (methodology in Section 6.3.5.2). One-way sensitivity analysis was also
conducted to take into account the maximum and minimum values of costs and alternate
discount rates of 0% and 6% (methodology in Section 6.3.5.1). The analyses were conducted
using TreeAge Pro 2012 Decision Analytic Modelling Software.
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6.3.3 Transition probabilities
Transition probabilities governed movement between states during cycles. The Markov
model in Figure 21 is shown in a linear cycle tree in Figure 22 which shows all the possible
transitions between states. The total time for all the possible transitions to occur was exactly
three cycles (18 months). Cycle zero had relatively few pathways as all individuals in the
cohort started as current smokers (base cohort). Cycle one was the first cycle in which ex-
smokers could transition to other states and cycle two was the first full cycle where all
possible transitions could be made. In order to simulate the hypothetical cohort, the model
required the following probabilities corresponding to a six-month cycle length: quit attempts,
intervention specific quit rates, relapse rates, mortality rates, absence rates and disability
rates. Most transition parameters in the literature were given as proportions over a particular
study period or rates over a period of time. If a proportion was given over a study period of
six months, then it was used directly as a six-month probability. However, if a proportion was
given over study or follow-up periods other than six months, then a transformation was made
using two formulae366; one which converts probabilities (corresponding to the length of
particular study periods) to an instantaneous event rate and another which converts the
instantaneous event rate into a six-month probability:
-In(l - Probability)
Rate = .
Tlmeyears
where Timeyears is the study period or length of follow-up
6 month probability = 1- e( -Rate x Timeyears)
where Timeyears is 0.5 corresponding to a six-month cycle length
Details about how specific transition probabilities were obtained are provided in the
subsequent sections.
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6.3.3.1 Probability of making a quit attempt
The probability of making a quit attempt varied between intervention strategies. Evidence
from a review of smoking cessation interventions in the workplace352 suggests that the
availability of assisted interventions in the workplace increases participation rates among
workers. For strategy one (no intervention), the Omnibus Survey165 informed that the
proportion of unassisted quit attempts made in a random sample of 950 UK smokers in 2008
was 26%, which was transformed (Section 6.3.3) into a six-month probability of 14%. For
strategies two through four (brief advice, individual counselling, NRT with individual
counselling), the pooled probability was calculated for using intervention participation rates
from five randomised control trials367-371identified in a Cochrane Review of workplace
smoking cessation interventions352 shown in Table 15.
Table 15. Participation in workplace smoking cessation interventions
Participants Total Smokers Proportion Reference
844 1,592 0.53 Jason et al.367
59 137 0.43 Jeffery et al.368
486 136 0.28 Klesges et al.369
/"
143 1,193 0.12 Sorensen et al.37O
172 681 0.25 Sutton et al.371
For each study, the raw proportions were calculated using the number of participants divided
by the total number of smokers in each study. The variances of the raw proportions were
stabilised using the Freeman-Tukey variant of the arcsine square root transformation.Y'' The
pooled analysis was conducted using the random effects model to allow for heterogeneity
between studies. In Figure 23, results of the meta-analysis of proportions show that the six-
month probability of participation in workplace interventions was 31% (95% Cl 15% to 51%)
from a pooled sample of 3,739 workers. There was a large amount of heterogeneity seen due
to the outcomes being absolute (rather than relative) and worksite interventions differed
across locations. Detailed methodology on the meta-analysis of proportions is provided in
Appendix 9.12.
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Figure 23. Random effects meta-analysis for workplace
smoking cessation intervention probability of participation
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6.3.3.2 Probability of quitting smoking
The baseline probability of sustained quitting at six months was obtained by pooling the
proportion of quitters from the control/no intervention groups identified in three separate
Cochrane Reviews9798 JOlon the effectiveness of smoking cessation interventions. For each
study, the raw proportions were calculated using the number of quitters at six months divided
by the total number of smokers in the control arm of the trial. The variances of the raw
proportions were again stabilised using the Freeman- Tukey variant of the arcsine square root
transformation.372 There were 18 total studies373-390 extracted from the Cochrane Reviews
where the outcome reported was a six-month sustained quitting outcome validated by
biomarker.
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Table 16. Baseline proportion of sustained quitters at six months follow-up from no
intervention groups (controls)
Sustained Quitters Total Smokers (N) Proportion Reference(6 mo. validated)
12 106 0.113 380
5 68 0.074 383
4 90 0.044 384
20 234 0.085 389
0 19 0.000 374
22 576 0.038 377
18 201 0.090 381
4 447 0.009 382
27 308 0.088 385
2 173 0.012 387
24 205 0.117 373
4 52 0.077 375
16 401 0.040 376
34 260 0.131 378
8 54 0.148 379
31 271 0.114 386
2 80 0.025 388
4 49 0.082 390
The proportions were then pooled using random effects meta-analysis using the methodology
detailed in Appendix 9.12 to obtain the probability of unaided sustained quitting at six-
months. In Figure 24, the results of the meta-analysis show that the sustained six-month
probability of unaided quitting was 6.9% (95% Cl 4.7% to 9.5%) from an aggregate pool of
studies with a total sample of 3,594 smokers.
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Figure 24. Random effects meta-analysis for sustained six-month
probability of unaided quitting
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Once the baseline probability of quitting was calculated, the treatment effect of each smoking
cessation intervention was applied by multiplying the risk ratios to the baseline probability of
quitting smoking. Cochrane Reviews provided the treatment effects through meta-analysis for
brief advice'", individual counselling'" and NRT patches with individual counselling'?',
However, the risk ratios could not be directly used as too much methodological heterogeneity
was detected between studies. The reviews pooled together multiple types of smoking
cessation endpoints and intervention groups. To solve this problem, only studies from the
Cochrane Reviews that closely mirrored the smoking cessation interventions evaluated in this
particular study and reported a six-month sustained quit rate validated by biomarker (carbon
monoxide and salivary cotinine) were re-extracted. Random effects meta-analysis was used to
re-pool together the extracted studies to obtain weighted treatment effects for brief advice.
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individual counselling and NRT (patches) with individual counselling while accounting for
heterogeneity between studies. Both male and female participants were combined in the
meta-analyses as most of the extracted studies did not report sex-specific quit-rates.
Figure 25. Random effects meta-analysis for the risk ratio of sustained smoking
cessation at six months for brief advice compared to no intervention (reference)
"10
Study AA (95"10 Cl) Weight
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1.59 (0.94, 2.69) 46.26
1.43 (0.99, 2.06) 100.00
Janz 1987
Page 1986
Porter 1972
Overall (I-squared = 0.0"10, P = 0.833)
NOTE: Weights are from random effects analysis
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decreased cessation increased cessation
In the pooled analysis for smokers who received brief advice, the level of sustained quitting
at six months was 43% greater than in smokers who received no intervention (RR = 1.43,
95% Cl 0.99 to 2.06, n = 4 studies, 12 = 0%; Figure 25).
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Figure 26. Random effects meta-analysis for the risk ratio of sustained smoking
cessation at six months for individual counselling compared to no intervention
(reference)
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For smokers who received individual counselling, the level of sustained quitting at six
months was 70% greater than in smokers who received no intervention (RR = 1.70, 95% Cl
1.05 to 2.75; n = 5 studies, 12 = 56.6%; Figure 26).
For smokers who received NRT patches and individual counselling, the level of sustained
quitting at six months was 86% greater than in smokers who received a placebo or no
intervention (RR = 1.86, 95% Cl 1.41 to 2.45, n = 8 studies, e = 37.7%; Figure 27).
Applying the average treatment effects of the smoking cessation interventions to the baseline
probability of quitting of 6.9%, the probability of quitting at six months was calculated as
9.9% for brief advice, 11.7% for individual counselling and 12.8% for NRT with individual
counselling.
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Figure 27. Random effects meta-analysis for the risk ratio of sustained smoking
cessation at six months for NRT patches with individual counselling compared to
placebo or no intervention (reference)
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6.3.3.3 Probability of relapse
For smokers who made a successful quit attempt, a probability of relapse after six months
was estimated. Because of the cycle length, the model assumed that smokers can only relapse
after six-months sustained quitting. Relapse rate used in the Markov model was obtained
from a cohort study of 1,266 ex-smokers who had recently quit smoking after six months.f"
The study found that only 7.3% of smokers who had abstained from smoking for a
continuous six months had actually relapsed.
133
6.3.3.4 Probability of mortality
To obtain gender-specific mortality for current and ex-smokers, smoking-attributable risk
fractions (SAPs) were calculated for all-cause mortality in five-year age-bands from 35-64
years. Smoking-attributable fractions for current smokers (SAFes) and ex-smokers (SAFEx)
were calculated separately using the following equations'":
prevalencecsCRRes - 1)
SAFes = ----------
1+ prevalencecsCRRcs -1)
prevalenceEXCRREX - 1)SAFEX = ___;;------:------:- ...........----:-:-
1+ prevalenceEXCRREX - 1)
.:
Gender and age-specific prevalence of current and ex-smoking was obtained from the 2010
Health Survey for England278• The prevalence figures were grouped in five-year age-bands
from 35-64 years. Age and sex-specific adjusted relative risks for all-cause mortality due to
current and ex-smoking were provided by Doll et al.8 for British men and Pirie et al.9 for
British women. These were used to calculate SAFs in five-year age-bands. SAFs were then
multiplied by total number of deaths in each five-year age-band to obtain smoking-
attributable mortality 285. The total number of deaths in England and Wales required to
calculate SAM was obtained from the 2011 Death Register392 provided by the Office for
National Statistics (ONS). SAM was in tum used to calculate the annual probability of
mortality (as explained below).
The annual probability of mortality for current and ex-smokers required SAM and
population-level estimates for the population of current and ex-smokers using the ONS 2011
Mid-Year Population Estimates=" of England and Wales. These population estimates were
obtained by multiplying smoking prevalence with the number of current and ex-smokers in
the population in each 5-year age-band. The annual probabilities of mortality were then
obtained by dividing SAM from current smoking by the number of current smokers and SAM
from ex-smoking by the number of ex-smokers. Finally. annual probabilities were converted
to the six-month probabilities using transformation equations'i" (Section 6.3.3). This process
described above is shown in Table 17 for men and Table 18 for women.
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Table 17. Probability of all-cause mortality in men from current and ex-smoking
Total Annual 6-MonthAge Prevalence! SAF Deaths' SAM Smokers' Probability Probability
Mortality Mortality
Current Smokers
35-39 0.27 0.18 2,197 405 504,266 0.0008 0.0004
40-44 0.23 0.16 3,514 555 460,127 0.0012 0.0006
45-40 0.19 0.13 5,005 664 376,383 0.0018 0.0009
50-54 0.25 0.17 6,878 1,197 458,412 0.0026 0.0013
55-59 0.25 0.17 9,726 1,679 398,092 0.0042 0.0021
60-64 0.13 0.09 15,766 1,488 208,405 0.0071 0.0036
Ex-Smokers
35-39 0.21 0.05 2,197 109 389,685 0.0003 0.0001
40-44 0.25 0.06 3,514 203 504,904 0.0004 0.0002
45-40 0.26 0.06 5,005 301 529,377 0.0006 0.0003
50-54 0.29 0.07 6,878 459 522,975 0.0009 0.0004
55-59 0.32 0.07 9,726 701 497,575 0.0014 0.0007
60-64 0.51 0.11 15,766 1,768 848,166 0.0021 0.0010
IHSE 2010394
20NS Death Register 2011 for England and Wales395
3Prevalence x ONS Mid-Year Population Estimates for England and Wales396
Table 18. Probability of all-cause mortality in women from current and ex-smoking
Total Annual
6-Month
Age Prevalence! SAF Deaths' SAM Smokers
3 Probability Probability
Mortality Mortality
Current Smokers
35-39 0.17 0.23 1,219 282 317,718 0.0009 0.0004
40-44 0.21 0.27 2,201 593 433,702 0.0014 0.0007
45-40 0.20 0.26 3,369 873 412,938 0.0021 0.0011
50-54 0.19 0.25 4,736 1,185 346,506 0.0034 0.0017
55-59 0.19 0.25 6,480 1,598 300,204 0.0053 0.0027
60-64 0.14 0.19 10,736 2,087 235,003 0.0088 0.0044
Ex-Smokers
35-39 0.24 0.05 1,219 55 442,761 0.0001 0.0001
40-44 0.24 0.05 2,201 102 505,054 0.0002 0.0001
45-40 0.19 0.04 3,369 123 395,274 0.0003 0.0002
50-54 0.23 0.04 4,736 210 422,858 0.0005 0.0002
55-59 0.27 0.05 6,480 326 428,033 0.0008 0.0004
60-64 0.31 0.06 10,736 621 526,400 0.0012 0.0006
IHSE 2010394
20NS Death Register 2011 for England and Wales395
3Prevalence x ONS Mid-Year Population Estimates for England and Wales396
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The Markov model also needed to be populated with the probability of mortality of workers
who were on long-term absence. The Whitehall Study 11397of British civil servants provided
estimates of long-term absence as a predictor of all-cause mortality. The study compared
number of deaths over a three year period for workers who had a spell of long-term absence
to number of deaths for workers who had not had a spell of long-term absence over a three
year period. There were 127 deaths during 3-year follow-up of 1,906 British workers who
had a spell of long-term absence. Therefore, the 3-year probability of mortality for those
workers who were on long-term absence was 6.7%. The 3-year probability was converted
using transformation equationst'" (Section 6.3.3) to a six-month probability of 1.14%.
6.3.3.5 Probability of disability
The parameter which dictated the transition of workers on long-term absence to leaving work
due to disability was obtained from a large population-based cohort study98 predicting
disability pension in workers who were on long-term absence. Over a five-year period, there
were 2,318 cases of disability pension in 8,283 men and 3,122 cases of disability pension in
11,096 women. Therefore, the five-year probability of disability in individuals on long-term
absence was 28.0% for men and 28.1% for women. The five-year probability was converted
to six-month probabilities (Section 6.3.3) of 5.3% for men and 5.4% for women.
6.3.3.6 Probability of absence from work
Both short-term and long-term probabilities of absenteeism in current and ex-smokers were
obtained from a population-based cohort of workers followed-up over 12 months.327 The
study provided person-years for the length of follow-up. Therefore, the absence rates could
be calculated over a 12-month period for 375 male current smokers and 498 male ex-
smokers. Similarly, absence rates were calculated for 1,242 female current smokers and 1,182
female ex-smokers. The annual rates were converted using transformation equations366
(Section 6.3.3) to six-month probabilities. These parameters are illustrated in Table 19 for
men and Table 20 for women.
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Table 19. Probability of short-term and long-term absence from work in men by
smoking status
Smoking Status Absence Person- Years Absence Rate Annual 6-MonthIncidence Probability Probability
Short-term Absence
Current Smoker 285 1,434 0.199 0.180 0.095
Ex-Smoker 86 1,907 0.045 0.044 0.022
Long-term Absence
Current Smoker 167 1,434 0.116 0.110 0.057
Ex-Smoker 57 1,907 0.030 0.029 O.oI5
Table 20. Probability of short-term and long-term absence from work in women by
smoking status
Smoking Status Absence Person- Years Absence Rate Annual 6-MonthIncidence Probability Probability
Short-term Absence
Current Smoker 400 4,822 0.083 0.080 0.041
Ex-Smoker 166 4,590 0.036 0.036 O.DlS
Long-term Absence
Current Smoker 232 4,822 0.048 0.047 0.024
Ex-Smoker 90 4,590 0.020 0.019 0.010
6.3.4 State costs
Transitioning from states in the Markov model shown in Figure 21 may incur state costs. The
expected value of these costs can be characterised as the sum-product of the state cost and the
proportion of the cohort in each cycle. There are several transition states in the Markov model
that incurred costs (discussed below). The year 2011-2012 was set as the base-year for the
model to reflect the most recent costs derived from literature. Details about how the state
costs were obtained from existing literature are provided below.
6.3.4.1 Costs of smoking cessation interventions
The duration and intervals for brief advice and individual counselling for the interventions
were based on similar interventions used in other workplace smoking cessation studies.352
Brief advice was modelled to be given in the first month while individual counselling was
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modelled to be given over two months (2 sessions per month). Nicotine replacement therapy
(NRT) was modelled in accordance with NICE guidance399 on recommended usage and
duration based on a maximum three month supply. NICE guidance399 has also suggested that
it is possible to give combination NRT therapy to heavy smokers; however there was
uncertainty on length of usage, type of NRT combinations and adherence in the workplace
setting. Existing workplace interventions have all relied on single therapy NRT and therefore,
there was considerable difficulty modelling the usage of combination therapy accurately.l'"
Therefore, single therapy nicotine patches were modelled as they are commonly used in
workplace interventions344 known to be effective and one of the cheapest forms of NRT
available.4OO The descriptions of each strategy are presented in Table 21.
Table 21. Routine workplace smoking cessation interventions
Strategy Description Costs
No Intervention None None
Brief Advice 10 minute session with an
occupational health nurse
(Initial consultation in first month)
Individual counselling Four 10 minute sessions with an
occupational health nurse
(Initial consultation and every two
weeks for two months)
Nicotine Replacement
Therapy + Individual
Counselling
Four 10 minute sessions with an
occupational health nurse and NRT
(Initial consultation and every two
weeks for two months + NRT supply
for three months)
Consultation time, wages/salary,
national insurance, qualifications,
overheads, travel and working time
Consultation time, wages/salary,
national insurance, qualifications,
overheads, travel and working time
Consultation time, NRT patches,
wages/salary, national insurance,
qualifications, overheads, travel and
working time
The human resource cost elements for each smoking cessation strategy were consultation
costs for nurse-led smoking cessation counselling obtained from Table 10.7 of the 2011
PSSRU report401 for unit costs of health care use in the UK and unit costs for nicotine
patches. Nurse-led counselling cost £1.45 per minute in 2011. For one 10-minute session of
brief advice, this amounted to £14.50 per person. For individual counselling, four sessions
amounted to £58 per person. These costs include wages/salary, national insurance,
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qualifications (training), overheads (management, administration, non-staff and capital
expenses), travel and working time (including annual leave, sick days, study days).
For NRT patches, data provided in the 2012 British National Formulary400 were used. The
unit costs were calculated for 13 well-known branded patch products manufactured by
McNeill, Novartis and aSK (Table 22). The average unit cost of one 24-hour nicotine patch
was £1.34. There was little variation in unit costs between products and dose strengths. A
standard adherence model402 was implemented where 50% of individuals were likely to use
NRT for only 4 weeks and 50% of individuals were likely to use NRT for a full 12 weeks.
Further sensitivity analyses were conducted using a low adherence model where all
individuals use NRT for only 4 weeks and a high adherence model were individuals use NRT
for the full 12 weeks. A worker was given one 24-hour patch per day (dose strength
dependent on amount smoked) over the intervention period. The average cost per worker of
NRT usage totalled £75.17 with standard adherence, £37.58 with low adherence and £112.75
with high adherence.
Table 22. Baseline costs of NRT patches from well-known branded products (2012) ,_.,-
Product Costs Units Unit Cost Cost Per Worker •
Nicorette"
5 mg patch £9.07 7 £1.30 £72.56
10 mg patch £9.07 7 £1.30 £72.56
15 mg patch £9.07 7 £1.30 £72.56
Nlconnelt"
7 mg patch £9.12 7 £1.30 £72.96
14 mg patch £2.57 2 £1.29 £71.96
14 mg patch £9.40 7 £1.34 £75.20
21 mg patch £2.85 2 £1.43 £79.80
21 mg patch £9.97 7 £1.42 £79.76
21 mg patch £24.51 21 £1.17 £65.36
NiQuitin®
7 mg patch £9.97 7 £1.42 £79.76
14 mg patch £9.97 7 £1.42 £79.76
21 mg patch £9.97 7 £1.42 £79.76
21 mg patch £18.79 14 £1.34 £75.16
Average £1.34 £75.17
*Standard adherence for 12 weeks40l [50% of individuals use for 4 weeks; 50% of individuals use for 12 weeks]
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By combining NRT costs with nurse-led counselling costs, total intervention costs were
calculated in Table 23. An employer would incur no intervention costs if they elected not to
have a smoking cessation intervention. Brief advice was relatively cheap at £14.50 per
worker while individual counselling costs the employer £58 per worker. NRT combined with
individual counselling was the most expensive strategy at £133.17 per worker.
Table 23. Baseline intervention costs per worker who choose to join a smoking cessation
strategies
Strategy Description Costs Per Worker
Brief Advice 10 minute session with an
occupational health nurse
(Initial consultation in first month)
£0
£14.50
No Intervention None
Individual counselling Four 10 minute sessions with an
occupational health nurse
(Initial consultation and sessions
every two weeks for two months)
£58.00
Nicotine Replacement
Therapy + Individual
Counselling
Four 10 minute sessions with an
occupational health nurse and NRT
(Initial consultation and sessions
every two weeks for two months +
NRT supply for three months)
£133.17
6.3.4.2 Costs of absenteeism
In Chapter 4, a meta-analysis was conducted on the duration of absence between current
smokers and non-smokers. The results of the meta-analysis showed the mean annual
difference in absence between current smokers and non-smokers was 2.74 days (95% Cl 1.54
to 3.95 days; i = 89.6%; 13 studies; Figure 13) from a pooled sample of 30,978 workers.
This particular meta-analysis provided the mean difference in annual duration of absence
which informed the costs of absenteeism needed to populate the Markov model. Instead of
mean difference in absence, the raw number of days absent was needed to populate the
model. This was done by specifying the random effects meta-analysis to output the pooled
average mean for current smokers and non-smokers separately instead of mean difference.
The output showed that current smokers were absent 12.53 days per year from a pooled
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sample of 14,267 current smokers and non-smokers were absent 9.79 days per year from a
pooled sample of 16,711 non-smokers. Section 4.4.4.2 (Chapter 4) found no evidence of a
significant difference in the number days of absence per year between ex-smokers and never
smokers; hence, the mean absence days from the overall non-smoking group was used for
days of absence in ex-smokers. The absence days per six months (corresponding to the model
cycle length) combined with UK gender-specific wage rates were used to calculate the
productivity loss for the employer due to short-term absence. The wages during the short-
term absence period which an employer pays to a worker was used to value for productivity
lost in the workplace. The 2012 UK Annual Survey of Hours and Eamings403 was used to
obtain median gross hourly wages (Men: £12.6 per hour; Women: £10.05 per hour) and hours
worked per day (Men: 7.76 hours per day; Women: 7.46 hours per day). The median hourly
wage was used to estimate baseline costs due to having heavily skewed distribution. This
process is illustrated in Table 24.
Table 24. Baseline costs of short-term absence days in the workplace
Annual Absence
Hours fer Hourll Daily ForegoneSmoking Status absence days per 6 Earnings3 production4days' month day wage
Men
Current Smoker 12.53 days 6.27 days 7.76 £12.60 £97.78 £612.57
ExlNon Smoker 9.79 days 4.90 days 7.76 £12.60 £97.78 £478.71
Women
Current Smoker 12.53 days 6.27 days 7.46 £10.05 £74.97 £469.71
ExlNon Smoker 9.79 days 4.90 days 7.46 £10.05 £74.97 £366.99
'Weng et aJ.2013351
2AnnualSurveyof Hours and Earnings 2012404
3Hoursper day x hourly wage
4Absenceper 6 month x daily earnings
In men, the cost of short-term absence was valued at £612.57 for current smokers and
£478.71 for ex/non-smokers. In women, the cost of short-term absence was valued at £469.71
for current smokers and £366.99 for ex/non-smokers. Sensitivity analyses was also conducted
using the inter-quartile range of hourly wages403 to determine short-term absence costs if
individuals were in the lowest 25th percentile of hourly wage (Men: £8.7 per hour; Women:
£7.4 per hour) or highest 75th percentile of hourly wage (Men: £19.17 per hour; Women:
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£15.47 per hour). If a male worker was in the bottom 25th percentile of wage earners. the cost
of short-term absence would be £423.90 for current smokers and £331.20 for ex/non-smokers
while for female workers in the bottom 25th percentile. the cost of short-term absence would
be £344.90 for current smokers and £269.50 for ex/non-smokers. If a male worker was in the
top 75th percentile of wage earners, the cost of short-term absence would be £931.98 for
current smokers and £728.18 for ex/non-smokers while for female workers in the top 75th
percentile. the cost of short-term absence would be £723.02 for current smokers and £564.91
for ex/non-smokers.
To obtain costs for long-term absence (absences up to 26 weeks). the 2012 weekly rate of
£85.85 for statutory sick pay in the UK405 was combined with the median cost of temporary
vacancy cover provided by a survey of 124 UK businesses.358 The cost of vacancy cover is
provided in Table 25 for several occupational groups.
Table 25. Costs of vacancy cover and other costs per employee due to absence
Occupation Group 2012 Cost (per worker absence)
Manufacturing and production
Private sector services
Public services
Non-profit
All employees
£456
£513
£647
£700
£600
The responsibility of statutory sick pay in the UK lies with the employer.t'" Many employers
have higher payment amounts per week with privately managed sick pay schemes.F" 358
However. the UK government scheme provides the lowest amount per week. A worker can
qualify for statutory sick pay if they are absent greater than 4 days per spell up to a maximum
of 26 weeks. Since the Markov model has a 26 week (6 month) cycle length. workers Who
transition to long-term absence states incur the full 26 week costs of statutory sick pay before
they can transition back to work or out of work. Therefore. the cost of statutory sick pay for
the full 26 weeks was £2.232.10 per person. The cost of statutory sick pay (£2.232.10) was
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then added to the median cost of temporary vacancy cover (£600, Table 25). This resulted in
the total baseline cost of long-term absence to be £2,832.10 per worker. Additional sensitivity
analysis was conducted using the lowest vacancy cost occupational group (manufacturing and
production) and the highest vacancy cost occupational group (non-profit). Therefore, total
long-term absence costs ranged from £2,688.10 per worker to £2,932.10 per worker.
6.3.4.3 Cost of labour turnover
For individuals who transitioned from long-term absence to leaving work through death or
disability, the employer incurred the cost of replacing the labour. The costs of labour turnover
were obtained from the annual survel56 of 308 UK businesses in 2009. Table 26 shows the
costs of labour turnover by occupational group.
Table 26. Costs of labour turnover per employee
Occupation Group 2009 Cost
2011 Cost
(per worker) (per worker)·
Senior managers/directors £9,000 £9,375
Managers and professionals £6,500 £6,771
Administrative, secretarial and technical £3,445 £3,589
Service(customer, perspective, protective, sales) £3,723 £3,878
Manual and craft workers £3,150 £3,281
All employees £6,125 £6,380
·Inflated to 20111evels by UK labour cost index406
The costs of labour turnover included vacancy cover, redundancy, recruitment, selection,
training and induction. The cost of labour turnover in 2009 for all occupational groups was
£6,125 per worker. The 2009 cost was inflated to 2011 levels with the most recent labour cost
index406 for the UK. The 2011 cost of labour turnover totalled £6,380 per worker. Sensitivity
analysis was conducted using the lowest cost occupational group (manual and craft workers)
and the highest cost occupational group (senior manager/directors). Therefore, the cost of
labour turnover ranged from £3,281 per worker to £9,375 per worker.
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6.3.5 Sensitivity analysis
6.3.5.1 One-way sensitivity analysis for costs
The process in which state costs were obtained to populate the Markov model was detailed in
Section 6.3.4. The baseline, minimum and maximum state costs summarised in Table 27
were used to populate the Markov model for the calculation of total costs (TC) and return on
investment (ROD. The baseline cost values were used as the primary parameters in the
Markov model. All future costs were discounted at a base-case rate of 3.5%. The maximum
and minimum values of costs were used for one-way sensitivity analyses in a secondary
analysis. The only possible distribution that could be fit with maximum and minimum values
was the triangular distribution.l'" Due to limitations described in Appendix 9.13.1, the
triangular distribution was not utilised. Instead, one-way sensitivity analysis was conducted
because costs obtained from literature provided little information on sample moments (mean
and variance) and therefore could not be fit with a more informed distribution (Le. gamma or
log-normal). The one-way sensitivity on the cost parameters was modelled in conjunction
with the probabilistic probability parameters. In addition, alternate discount rates of 0% and
6% for future costs were utilised to examine the robustness of the results.
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6.3.5.2 Probabilistic sensitivity analysis
The methods for obtaining transition probabilities to populate the Markov were described in
Section 6.3.3. Table 28 shows the summary of all transition probabilities. Probabilistic
sensitivity analysis (PSA) is essentially a Bayesian process. The primary purpose of PSA was
to incorporate parameter uncertainty into the model by specifying prior probability
distributions for the purpose of generating posterior distributions of total costs (TC) incurred.
PSA was conducted using transition probabilities and their respective distribution parameters
provided in Table 28 combined with base-line state costs provided in Table 27. With the
exception of all-cause mortality in current smokers and ex-smokers, all transition
probabilities parameters were obtained from studies which had provided finite sample sizes.
Distributions for the probabilities of all-cause mortality in current and ex-smokers were not
required as the probabilities were obtained from UK aggregate population-level sources. The
remaining parameters were from finite and often small sample sizes. Therefore, those
probabilities were fit with beta distributions using the method of moments approach.f"
Detailed methodology and justification for using the beta distribution is described in
Appendix 9.13.2. The random sampling was conducted using 1000 Monte Carlo simulations.
The Monte Carlo method recalculates expected values in the Markov model multiple times
by randomly sampling of the probability density function of individual parameter
distributions. The advantage of this technique is that any number of parameter uncertainties
can be incorporated into the analysis allowing for the estimation of the total impact of
uncertainty on the model. PSA was conducted using TreeAge Pro 2012 Decision Analytic
Modelling Software.
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Table 28. Summary transition probabilities with beta distribution parameters for
probabilistic sensitivity analysis
Parameter Probability N StD Error a p Source
Quit Attempt
No Intervention 0.140 950 0.011 133 816 165
Strategy 2-4 0.310 3,739 0.008 1159 2579 352
Sustained Quit
No Intervention 0.069 3,831 0.004 264 3566 9798101
Brief Advice 0.099 596 0.012 59 536 97
Individual Counselling 0.117 1,898 0.007 223 1674 98
NRT + Counselling 0.128 2,218 0.007 285 1932 101
Relapse 0.073 1,266 0.007 92 1173 364
Mortality: CS
Men 8394-396
35-39 0.0004
40-44 0.0006
45-49 0.0009
50-54 0.0013
55-59 0.0021
60-64 0.0036
Women 9394-396
35-39 0.0004
40-44 0.0007
45-49 0.0011
50-54 0.0017
55-59 0.0027
60-64 0.0044
Mortality: EX
8394-396Men
35-39 0.0001
40-44 0.0002
45-49 0.0003
50-54 0.0004
55-59 0.0007
60-64 O.OOJO
Women 9394-396
35-39 0.0001
40-44 0.0001
45-49 0.0002
50-54 0.0002
55-59 0.0004
60-64 0.0006
Mortality: LT Absence 0.011 1,906 0.002 22 1883 397
ST Absence: CS 327
Men 0.095 375 0.015 35 338
Women 0.041 1,242 0.006 50 1190
ST Absence: EX 327
Men 0.022 498 0.007 11 486
Women 0.018 1,182 0.004 21 1159
LT Absence: CS 327
Men 0.057 375 0.012 21 353
Women 0.024 1,242 0.004 29 1211
LT Absence: EX 327
Men O.oI5 498 0.005 7.37 489.39
Women 0.010 1,182 0.003 11.52 1169.00
Disability 398
Men 0.053 8,283 0.002 441 7841
Women 0.054 11,096 0.002 594 10501
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6.3.5.3 Maximisation of quitting: cost-effectiveness analysis
One of the key assumptions in the primary analysis is that the employer will optimise strategy
selection based on total costs incurred and return on investment as described in Figure 20.
Decision making based on these financial metrics233362 are the most commonly employed
strategy for businesses and employers for evaluating investments such as workplace
interventions. However, there are other metrics which are also considered when businesses
make investments. To address the secondary aim in this chapter, an assumption was made
that the employer may value maximising quitting instead of minimising total costs. This was
a plausible assumption as smoking cessation interventions are implemented in some
workplaces with the primary purpose of maximising quit rates.344 Therefore, cost-
effectiveness analysis was conducted by re-assessing the Markov model using number of
quitters as the primary outcome. Cost per quitter was utilised instead of cost per quality
adjusted life-year (QALYs) due to having more relevance in an employer-based setting for
smoking cessation interventions. The method of ranking interventions by QALYs implies a
quasi-utilitarian perspective which is commonly used to determine who will or will not
receive certain treatments.f'" This metric is extremely useful from a health services
perspective in the provisioning of healthcare based on willingness-to-pay per QALY. From
an employer-based perspective of workplace interventions, QALYs may be less intuitive for
decision-making as the valuation of how much a QALY is worth is not standard practice.
This is supported in a review409 evaluating the cost-effectiveness of workplace policies for
smoking cessation where all of the included studies used a cost per quitter metric.
Each strategy was ranked based on ICERs as described in Section 6.3.1 calculated as the
ratio of incremental costs over the incremental number of quitters of each workplace
intervention compared to the previous intervention. ICERs were utilised because the
workplace interventions were mutually exclusive options in this analysis. The ICER allows
for the ranking of these mutually exclusive strategies to determine optimal strategy given a
specific budget constraint (Willingness- To-Pay). However, in this analysis, there was no
specified budget constraint as willingness-to-pay differs among employers (due to differences
in size, overheads, efficiency). In addition, there was no literature to specify what UK
employers were currently willing to pay per quitter. Therefore, an optimal strategy selection
was provided for different scenarios of budget constraints.
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6.4 Results
6.4.1 Effectiveness of interventions
The Markov model simulation was conducted using a cohort of 1,000 men and 1,000 women
separately starting at the age of 35 and followed until the average age of retirement, disability
or death (whichever occurred first) for each smoking cessation strategy.
Table 29. Cumulative number of current smokers, quitters, dead or disabled and total
number of absence spells incurred for each workplace smoking cessation intervention
Strategy
Current Total Death or Absence
Smokers Quitters Disability Spellsl
Men (N = 1000)
No Intervention 685 80 235 7,186
Brief Advice 574 214 212 6,474
Individual Counselling 550 243 207 6,314
NRT + Individual Counselling 537 260 204 6,224
Women (N = 1000)
No Intervention 761 98 141 3,195
Brief Advice 630 245 125 2,930
Individual Counselling 591 288 121 2,872
NRT + Individual Counselling 575 306 119 2,839
'Short-term absence, long-term absence, leaving work through death or disability
The number of workers in each state at the average age of retirement is reported in Table 29
for separate smoking cessation strategies. In both men and women, the number of current
smokers decreased while the number of quitters increased for more comprehensive smoking
cessation strategies. NRT with individual counselling provided the highest number of
sustained quitters (260 men; 306 women), lowest number of workers who left work due to
death or disability (204 men; 119 women) and fewest absence spells incurred (men: 6,224
cases; women: 2,839 cases). The baseline 'no intervention' strategy resulted in the lowest
number of sustained quitters (80 men; 98 women), highest number of workers who left work
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due to death or disability (235 men; 141 women) and most absence spells incurred (7,136
men; 3,195 women). Brief advice and individual counselling were ranked between the
effectiveness of 'no intervention' and NRT with individuals counselling in terms of
increasing number of sustained quitters and reducing death, disability or absence spells. If
strategy selection was purely based on effectiveness of increasing the number of quitters and
reducing the number of deaths, disabilities or absence spells, then NRT with individual
counselling was the optimal choice for an employer without budget constraints.
6.4.2 Cost-benefit analysis
6.4.2.1 Deterministic
Despite being the most effective strategy for increasing quitting and reducing death, disability
or absenteeism, NRT with individual counselling was not the optimal choice when
effectiveness was evaluated alongside cost implications for the employers (Le. the cost of
intervention, absence and labour turnover). The cost-benefit analysis based on the total cost
(TC) incurred and return on investment (ROI) for each smoking intervention strategy were
provided in Table 30.
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Total cost (TC) was the combined expected value of absence, labour turnover and
intervention for each workplace intervention over the productive lifetime. According to
Table 30, brief advice for both men and women was the optimal strategy if the strategy
selection was based on the minimisation of total costs (men: £4,875,484; women:
£2,196,534). NRT with individual counselling had the largest total costs incurred for both
men and women compared to all other strategies (men: £5,253,219; women: £2,743,785) due
to having the most expensive intervention costs (men: £626,706; women: £694,165).
In terms of the monetary returns on investment, brief advice also provided the largest returns
on investment (ROI) for men and women. For every £1 the employer expends, brief advice
resulted in additional returns of £5.08 for men and £1.19 for women. Individual counselling
provided positive but smaller return than brief advice for men with a RO! of £1. However, in
women, individual counselling provided a negative RO! of -£0.28. NRT with individual
counselling provided the employer with negative ROIs for both men (-£0.02) and women (-
£0.28). For the employer, brief advice resulted in the lowest TC and highest RO! compared to
all other strategies for both men and women.
6.4.2.2 One-way cost sensitivity analysis
Maximum and minimum values for state costs were used to calculate the change in total costs
incurred from baseline for men in Figure 28 and for women in Figure 29. The graphs
illustrate the monetary change from baseline estimates of total cost in thousands of GBP.
Sensitivity in NRT adherence costs only affected the total costs for the smoking cessation
strategy which provided NRT. There was no difference in total costs for other smoking
cessation strategies which did not provide NRT.
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Figure 28. Tornado diagram showing the change in total costs incurred from baseline
due to one-way sensitivity analysis of state costs for male workers (£ Thousands)
Sensitivity Strategies
Labour NRT -£259 £272
Turnover
Costs Indlvldual Counselling -£263 £254
Brief Advice -£268 £259
No Intervention -£293 £284
Long-Term NRT -£156 £109
Absence Individual Counselling -£158 £110Costs
Brief Advice -£162 £112
No Intervention -£176 £123
Short-Term NRT -£17 • ~ £29
Absence Indlvldual Counselling -£16 I• £27
Costs (EX)
Brief Advice -£14 I~ £24
No Intervention -£5 £8
NRT -£300 £505
Short-Term Individual Counselling
-£306 £514Absence
Costs (CS) Brief Advice
-£316 £531
No Intervention
-£359 £603
NRT
-£174 £179
NRT Individual Counselling £0
Adherence
Costs Brief Advice £0
No Intervention £0
Minimum Baseline Maximum
Figure 29. Tornado diagram showing the change in total costs incurred from baseline
due to one-way sensitivity analysis of state costs for female workers (£ Thousands)
Sensitivity Strategies
Labour NRT
-£149 £144
Turnover
Costs Individual Counselling -£151 £146
Brief Advice
-£154 £149
No Intervention
-£171 £165
Long-Term NRT -£70 £48
Absence Individual Counselling
-£70 £49Costs
Brief Advice
-£72 £50
No Intervention
-£77 £54
Short-Term NRT -£10 Iill £20
Absence Individual Counselling
-£9 I
~£19Costs (EX)
Brief Advice
-£8 I
~£17
No Intervention
-£3 £6
NRT
-£89 £180
Short-Term
Individual Counselling £184Absence -£91
Costs (CS) Brief Advice
-£94 £191
No Intervention
-£109 £220
NRT
-£193 £198
NRT Individual Counselling £0
Adherence
Costs Brief Advice £0
No Intervention £0
---r--
Minimum Baseline Maximum
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For both men and women, short-term absence costs for current smokers resulted in the largest
variations in total costs across all four strategies. This was because there was a substantial
risk of short-term absence in current smokers resulting in a large number of these individuals
incurring state costs. Differences in the minimum and maximum costs of short-term absence
were exacerbated by the large number of individuals incurring this cost. There were also
substantial variations in labour turnover costs across strategies for both male and female
workers due to a large discrepancy in turnover costs for different occupation groups. The cost
of labour turnover ranged from £3,281 for manual and craft workers to £9,375 for senior
managers and directors. In terms of long-term absence costs, there were moderate variations
in total costs across strategies due to relatively small discrepancies between maximum and
minimum state costs. For short-term absence costs in ex-smokers, although there were
discrepancies in maximum and minimum state costs, these differences were mitigated by a
lower risk of short-term absence in ex-smokers. Therefore, fewer ex-smokers incurred short-
term absence costs resulting in only small variations in total costs across strategies.
Sensitivity analysis using alternate discount rates is shown in Figure 30. For both men and
women, total costs were smallest for all strategies when costs were undiscounted. Total costs
were largest when discounted by 6%. Despite the variations in total costs due to differences
in state costs and discount rates, the strategy ranking remained the same where brief advice
resulted in the least total cost incurred for both men and women. This showed that the results
from the model were robust in nature.
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Figure 30. Total costs (TC) incurred of smoking cessation strategies using alternate
discount rates
Brief Advice I
NRT
I
Individual Counselling
--,
c::
OJ
E --,
0 Brief Advice --..
~
No Intervention ~
------------------------------ -------- -------- -------- ---
NRT
Individual Counselling
1
No Intervention
£0 £3,000 £6,000
Thousands (£)
£9,000 £12,000
6% .3.5%
6.4.2.3 Probabilistic sensitivity analysis
Random sampling of 1,000 Monte Carlo simulations was conducted after distributions
parameters were specified for transition probabilities to evaluate the uncertainty in the results.
The results from probabilistic sensitivity analysis (PSA) are provided in Table 31.
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From the probabilistic results provided in Table 31, the optimal strategy selection did not
differ from the deterministic analysis. Brief advice for both men and women had the lowest
mean total costs incurred (men: £4,872,170; women: £2,196,910). NRT with individual
counselling had the largest mean total costs incurred for both men and women compared to
all other strategies (men: £5,259,400; women: £2,742,730). Similar to the deterministic
results, brief advice offered the largest mean RDI (men: £5.16; women: £1.20).
The mean RDI for brief advice from probabilistic analysis was similar to the RDI from
deterministic analysis (men: £5.08; women: £1.19). Table 31 also shows the 95% confidence
interval (Cl) of mean total costs incurred which was constructed using the standard deviation
of total costs incurred. The mean total costs and 95% Cl for each intervention strategy are
depicted in Figure 31 for men and in Figure 32 for women.
£5,400
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£5,200
III
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Figure 31. Mean total cost (TC) and 95% Cl for workplace smoking
cessation interventions for men
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Figure 32. Mean total cost (TC) and 95 % Cl for workplace smoking
cessation interventions for women
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In men (Figure 31), total cost incurred for brief advice (£4,872,170; 95% Cl £4,770,221 to
£4,974,119) was significantly different from total cost incurred for no intervention
(£5,255,400; 95% Cl £5,139,152 to £5,371,648) and NRT with individual counselling
(£5,259,400; 95% Cl £5,165,624 to £5,353,176) but was not significantly different from total
cost incurred for individual counselling (£4,977,110; 95% Cl £4,880,992 to £5;353,176). In
women (Figure 32), total cost incurred for brief advice (£2,196,910 95% Cl £2,155,681 to
£2,238,139) was significantly different from total cost incurred for no intervention
(£2,296,670; 95% Cl £2,251,384 to £2,341,956), individual counselling (£2,381,390; 95% Cl
£2,340,632 to £2,422,148) and NRT with individual counselling (£2,742,730; 95% Cl
£2,704,177 to £2,781,283). The results from PSA suggest that brief advice was the optimal
strategy for women and either brief advice or individual counselling could be the optimal
strategy for men.
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6.4.2.4 Average cumulative returns on investment over time
With the inclusion of parameter uncertainty in PSA, the total costs incurred for brief advice
was significantly different than all other interventions for women. Therefore, brief advice was
the single optimal option for women. In men, total costs incurred for brief advice and
individual counselling were significantly different than all remaining interventions. However,
brief advice and individual counselling did not differ significantly in total costs incurred.
Thus, either brief advice or individual counselling could be the optimal option. The results for
the optimal decisions were the result of cumulative costs incurred over a productive life time.
Consequently, it was unknown whether brief advice or individual counselling resulted in
positive returns on investment (ROI) in the short-term or long-term. In Figure 33, average
cumulative ROI (from PSA) for brief advice was plotted in years for women.
Figure 33. Average cumulative returns on investment (from
PSA) for brief advice in women over years of workplace smoking
cessation intervention
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The results in Figure 33 showed that positive returns on investment from brief advice in
women occurred after 5.5 years since the inception of the programme. Not only was brief
advice the optimal strategy over the productive lifetime of the intervention but was also the
optimal strategy in a relatively short amount of time. In Figure 34, a similar plot of average
cumulative ROI against intervention time in years was analysed for brief advice in men.
Figure 34. Average cumulative returns on investment (from
PSA) for brief advice in men over years of workplace smoking
cessation intervention
£6.00 -r-------------------------
&:::'
o
~ £5.00 • • • • • • • • • • • • • • • •
- .
- .....
c • • • •
QI £4.00 -• •+'-=--------------E • • •
~ ....
QI £3.00 • •<-------------------
~ ..
- ..g £2.00 • • ~--------------------
c •L.. •
:J •
Gj £1.00 .-----------------------
~ .
QI •
.~ £0.00 -+'------------------------
~ .
:; .
E -£1.00 .-------------------------
:J
U
-£2.00 ...1..-------------------------
o 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30
Years of Workplace Intervention
The results Figure 34 in showed that positive returns on investment from brief advice in men
occurred in a shorter time than in woman. Brief advice in men resulted in positive returns in
investment almost immediately after the inception of the programme from 1.5 years onwards.
Individual counselling was also analysed in men in Figure 35 due to the fact that the total
cost incurred was not significantly different than total incurred of brief advice.
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Figure 35. Average cumulative returns on investment (from
PSA) for individual counselling in men over years of workplace
smoking cessation intervention
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The returns on investment for individual counselling were on average less than that of brief
advice in men but did provide positive returns after 5 years since programme inception.
Overall, brief advice is likely to provide positive returns on investment in men at a much
faster and larger amount than individual counselling. However, this difference may not be
significant. Nevertheless, both options of brief advice and individual counselling provide
employers with good investment opportunities compared to current practice (no intervention).
In addition, the law of diminishing returns shapes all three figures in the long-term. Long-
term returns gradually decrease as the pool of current smokers becomes smaller as quitting
increases. Thus, incremental returns on investments decrease due to fewer numbers of current
smokers in the work cohort as time increases.
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6.4.3 Cost-effectiveness analysis
The secondary aim of this chapter was to examine whether the decision strategy changed had
the employer valued maximising quit rates as the primary outcome. The Markov model was
re-assessed using number of quitters as the primary outcome and each strategy was ranked
based on leERs. Table 32 shows the leERs of the Markov simulation model using number
of quitters as the primary outcome.
Table 32. leERs (£lQuitter) for each workplace smoking cessation strategy compared to
the previous strategy from Markov simulation modelling
Strategy Total Costs Total Incremental Incremental ICER(£) Quitters Costs (£) Quitters (£IQuitter)
Men (N = 1000)
No Intervention £5,255,400 80 £0 £0
Brief Advice £4,872,170 214 -£383,230 134
-£2,859.75
Individual Counselling £4,977,110 243 £104,940 29 £3,623.66
NRT + Individual Counselling £5,259,400 260 £282,290 16 £17,457.81;;::
Women (N = 1000)
No Intervention £2,296,670 98 £0 £0
Brief Advice £2,196,910 245 -£99,760 147
-£678.12
Individual Counselling £2,381,390 288 £184,480 43 £4,298.60
NRT + Individual Counselling £2,742,730 306 £361,340 18 £19,837.79
Table 32 shows that no intervention was the dominated strategy in both men and women.
Brief advice was less costly and more effective at maximising number of quitters than no
intervention. Therefore, the baseline strategy of no intervention was never cost-effective so
this could be excluded from as a decision option immediately. This can be easily visualised
using incremental cost-effectiveness planes (Figure 36 for men and Figure 37 for women).
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Figure 36. ICER plane for workplace smoking cessation strategies
compared to the previous strategy in men
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Figure 37. ICER plane for workplace smoking cessation strategies
compared to the previous strategy in women
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The origin of the incremental cost-effectiveness planes represents the baseline strategy of no
intervention. The incremental costs and quitters were plotted relative to the origin and ranked
based on the leER from the previous strategy. Brief advice and individual counselling
appeared in quadrant IV for men meaning that both strategies were less expensive and more
effective than no intervention (Figure 36). Brief advice was the only strategy that appeared in
quadrant IV for women which dominated no intervention (Figure 37).
In terms of ranking the cost-effectiveness of brief advice, individual counselling and NRT
with individual counselling, there was no clear dominated strategy. For individual
counselling compared to brief advice an additional male quitter costs £3,624 (Figure 36)
while an additional female quitter costs £4,299 (Figure 37). For NRT with individual
counselling compared to individual counselling, an additional male quitter cost costs £ 17,458
(Figure 36) while an additional female quitter costs £19,838 (Figure 37).
The most cost-effective strategy for these remaining interventions will be dependent on
budget constraints or willingness-to-pay. The current willingness-to-pay for employers in the
UK is unknown so therefore a hypothetical scenario analysis was implemented to rank the
remaining strategies. Budget constraints or willingness-to-pay can be determined based on
total costs shown in Table 32 per person (divided by N = 1,000). If the total budget constraint
was £4,872 per male worker and £2,197 per female worker then brief advice would the most
cost-effective option. If the total budget constraint was £4,977 per male worker and £2,381
per female worker then the more effective intervention of individual counselling would be the
most cost-effective option. If the total budget constraint was £5,259 per male worker and
£2,743 per female worker or if there was no budget constraint, then the most effective option
of NRT with individual counselling would be the most cost-effective option.
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6.S Discussion
6.5.1 Summary
The results of the simulation of workers over the course of a productive life-time showed that
NRT with individual counselling provided the highest number of quitters, the lowest number
of workers who left work due to death or disability and fewest cases of absence spells
compared to no intervention, brief advice or individual counselling alone. However, once
costs were factored in, brief advice was the optimal strategy for minimising the total costs
incurred and maximising return on investment for the employer. Probabilistic sensitivity
analysis showed that total costs incurred were significantly different from all other
interventions in women while brief advice and individual counselling were both viable
investment options in men (Figure 38). Brief advice in women resulted in average additional
returns of £l.20 per pound expended while brief advice in men resulted in average additional
returns of £5.16 per pound expended. Individual counselling in men resulted in average
additional returns of £1.00 per pound expended. Additionally, positive returns occurred only
a few years after the interventions were implemented suggesting the interventions did not just
provide long-term financial benefits. One-way sensitivity analysis of costs and alternate
discount rates (0% and 6%) did not change the strategy ranking process showing that the
results were robust.
One of the key assumptions for the primary analysis was that employers are optimising
decisions based on financial metrics such as total cost (TC) incurred and return on investment
(ROJ). Cost-benefit suited this analysis as investment decisions for cessation interventions
were based purely on financial benefits. However, there are other outcomes employers may
base decision making on. In the constructed decision flow chart in Figure 38, it was assumed
that employers may try to maximise number of quitters. Instead of cost-benefit analysis, cost-
effectiveness analysis was used to evaluate the workplace interventions.
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The decision options in the scenario analysis were dependent on budget constraints. If the
total budget constraint was £4,872 per male worker and £2,197 per female worker then brief
advice would the most cost-effective option. If the total budget constraint was £4,977 per
male worker and £2,381 per female worker then the more effective intervention of individual
counselling would be the most cost-effective option. If the total budget constraint was £5,259
per male worker and £2,743 per female worker or if there was no budget constraint, then the
most effective option of NRT with individual counselling would be the most cost-effective
option.
The large discrepancies in total costs, return on investment and budget constraints between
men and women were due to gender differences between absence costs and absence
probabilities. Average hourly wages (used to value short-term absence costs) for women were
less than that of men (described in Section 6.3.4.2). Additionally, absenteeism in women was
less problematic than absenteeism in men as there was less risk of short-term and long-term
absence (described in Section 6.3.3.6). Therefore, the transitions probabilities and state costs
of both short-term and long-term absenteeism reflected this difference in the Markov model
results.
6.5.2 Implications
This is the first study that has evaluated the cost-benefitlcost-effectiveness of smoking
cessation interventions in the workplace from an employer's perspective in the UK. The
results suggest that employers who adopt workplace smoking cessation programmes will in
fact save money assuming that turnover not shorter than 2-5 years per employee. From an
employer's perspective, not having a workplace intervention was not optimal for either
returns on investment or maximising quitting. This suggests there is common ground for
employers to contribute towards the net social welfare of society. The selection between brief
advice, individual counselling and NRT with individual counselling depends on a multitude
of factors such as outcome metrics or budget constraints as shown in Figure 38. From a
societal perspective, the maximisation of quit rates would contribute the most towards net
social welfare due to overwhelming health and economic benefits of smoking cessation
(Section 1.4). The employer's strategy selection, however, may not necessarily maximise
social welfare from a societal perspective. For instance, if an employer chooses to base the
decision process on financial metrics, then brief advice would be an optimal intervention
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from the employer's perspective offering the best returns on investment. While brief advice
certainly will contribute towards increasing the number of quitters, it would not be the
intervention that would maximise quitting. Even if employers valued maximising quitting,
the decision strategy will be largely dependent on individual budget constraints. However, if
budget constraints were maximised or eliminated, then the most effective intervention NRT
with individual counselling would be the optimal option resulting in the alignment of the
societal and employer's perspective. This has some potential policy implications.
This suggests that policy-makers could consider promoting or supporting employers that
choose to start a workplace smoking cessation intervention. Tax incentives, subsidies or
support for employers for setting up smoking cessation interventions in the workplace may
offer better returns on investments by cutting costs of more expensive yet more effective
interventions. A survey of 1,344 British workplaces'l'" found that only 40% undertook at least
one major health-related activity per year. However, activity was particularly low in small
and medium sized companies, lacked structure and organisation to be effective. One of the
reasons cited for smaller and medium sized companies was the overhead costs of setting up
interventions were proportionally more than that of larger corporations.t'" Another key issue
which may affect whether or not employers adopt smoking cessation interventions is
workforce turnover rates. The economic model presented in this chapter was modelled on a
stable population of workers. However, workforce turnover rates can significantly differ
between employers. For employers with low turnover rates (employees stays greater than 2-5
years), the model shows that there are clear benefits of smoking cessation interventions. For
employers with high turnover rates (employees stays less than 2-5 years), it may not be cost-
effective to implement a smoking cessation intervention as the long-term benefits of reducing
absenteeism, disability and death may not be realised by the employer.
In addition, there are several reasons why interventions in the workplace can contribute to the
net social welfare of society which the model does not consider due to using an employer's
perspective352: (i) protection of non-smokers from the harmful effects of tobacco smoke 182
reduced direct costs of health care (iii) reduced costs of life insurance (iv) reduced cleaning
costs (v) reduced risk of fires (vi) increased productivity. There are also several potential
advantages of interventions in the workplace. First, more people may be reached and thereby
participation and cessation may be increased.352 Second, the workplace provides access to
relatively large number of people who make up a stable population.P" Third, there is a good
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opportunity to target young men who traditionally have low general practitioner visiting
rates.344 Finally, many workplaces (apart from small businesses) already have occupational
health staff and travel time is minimal. 344
While this study is particularly relevant to UK employers and policy makers, the results are
transferable to other developed countries where the smoking prevalence, labour costs and
mortality rates are similar. The key parameters in the model are the treatment effects of
smoking cessation interventions obtained from randomised clinical trials which are likely to
be similar across populations. The model itself is extremely flexible and can be used at an
aggregate-level or individual employer-level. The model can be easily populated with
country-specific parameters or even employer-specified parameters.
6.5.3 Limitations
There were several limitations of the study - most of which involve model assumptions
around parameter or structural uncertainty. First, the baseline unassisted quit rate of 6.9%
pooled from the control groups of the clinical trials may be higher than the general
population. The unassisted quit rate from the control groups was used so individuals from the
control groups could be compared to the treatment groups which allowed for the pure
treatment effect to be obtained. In clinical trials outcomes tend to be optimistic due to
individuals knowing they are in a clinical trial. Survey estimates of six-month quit-rates from
other studies ranged only between 3_5%166.However, the probabilistic analysis took into
account this discrepancy as the beta distribution for the baseline quit rate of 6.9% ranged
from 3% to 9%. Second, the random-effects meta-analysis which provided baseline cessation
rates combined the control arms of brief advice, individual counselling and NRT with
individual counselling to generate a larger pooled sample from which estimates could be
obtained. The pooled baseline quit rate of 6.9% (95% Cl 4.7% to 9.4%, N = 18 studies) was
then applied to risk ratios from meta-analysis to determine quit rates for brief advice (9.9%),
individual counselling (11.7%) and NRT with individual counselling (12.8%). In order to
determine if the pooling of all control arms in a meta-analysis affected the quit rates for each
smoking cessation strategy, meta-analyses were conducted separately for each smoking
cessation strategy. The baseline quit rate for brief advice was 6.6% (95% Cl 4.1% to 8.0%, N
= 4 studies); for individual counselling was 6.8% (95% Cl 5.5% to 7.8%, N = 6 studies); and
for NRT with individual counselling was 7.1% (95% Cl 5.8% to 8.4%, N = 8 studies). The
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baseline quit rates for individual smoking cessation strategies were very similar to the pooled
baseline quit rate of 6.9%. Therefore, the effects of using the quit rates from the individual
smoking cessation strategies would have only marginally changed the results of the analysis.
Third, the treatment effects from the random effects meta-analysis of brief advice, individual
counselling and NRT with individual counselling were combined for both men and women.
Men and women may in fact have different treatment effects which the Markov model did
not capture. Individual studies in the meta-analysis did not report gender subgroups and
therefore could not be pooled separately. Fourth, the probability of mortality, disability and
absence was not dependent on time since an individual became an ex-smoker due to Markov
memory limitation and parameter uncertainty. For probability of mortality, the model could
not determine how long an individual had become a non-smoker. A way around this is to
build multiple ex-smoking states; however, this would have made the model overly complex
with little added value. For probability of disability and absence, there were no parameters in
the literature which addressed time dependency. Fifth, the structural assumption was made
that individuals would remain in the cohort until they retire or exits due to disability or death.
It is likely that individuals in the workplace could quit or leave for other employment. There
was no literature around how long individuals typically remained at one employer at the
population-level. Sixth, distributions for state costs could not be fit due to limited data.
Although sensitivity analysis was conducted using maximum and minimum costs, the
probabilistic analysis assumed infinite probability density for cost parameters. Finally, there
were no parameters in the literature which could inform a sensitivity analysis on size of the
employer. Financial outcome metrics such as return on investment may depend on size as
smaller business may have relatively larger overheads compared to larger businesses.
6.6 Conclusion
In this chapter, the economic evaluation of workplace interventions resulted in brief advice
being the optimal decision strategy for women and both brief advice and individual
counselling were the optimal decision strategies for men in terms of minimising total costs
and maximising return on investment. If the employer valued maximising quitting, then NRT
with individual counselling was the most cost-effective strategy given a budget constraint
greater than or equal to £5,259 per worker. These results, however, are dependent on
employer workforce turnover rates. Nevertheless, this analysis shows that employers can
contribute to net social welfare of society. Policy which aligns employers' interest to societal
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interest may maximise net social welfare to society. Future research also needs to examine
the cost-benefitlcost-effectiveness of other forms of pharmacotherapy (varenic1ine or
bupropion) and financial incentives for smoking cessation.
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Summary Conclusions and Future Research
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7.1 Introduction
The overall aims of this thesis were to quantify the economic impact of indirect costs of
premature mortality and absenteeism in the UK and to evaluate possible solutions to decrease
the burden of smoking in the workforce.
This concluding chapter summarises the key findings from the research presented in the
thesis and how these findings fulfil the objectives described in Section 1.6.3. In addition,
there were several key lessons learned relating to the methods which were applied to
evaluating the impact of smoking in the workforce. Finally, this chapter also highlights
impact of the work and avenues of future research relating to evaluating the impact of
smoking in the workforce.
7.2 Summary of findings
7.2.1 Objective 1: Review of indirect cost-of-smoking methodology
In Chapter 2, the aim was to review cost-of-smoking methodology on the estimation of
population-level productivity loss or indirect costs. An electronic database search was
conducted in MEDLINE, EMBASE, CRD, Science Direct and EconLit. Included in the
analysis were population-level economic studies that had quantified the indirect costs of
smoking. Stepwise regression analysis determined the association between adult smoking
prevalence and cost per capita with the inclusion of population-level covariates.
Seventeen economic studies were included in the review; of which 15 studies used the human
capital model while only two studies used the friction cost method to quantify the indirect
costs of smoking. After adjusting for covariates, regression analysis showed that a 1%
increase in smoking prevalence resulted in a 1.7% (95% Cl 0.21 to 3.16, P = 0.028) increase
in cost per capita across all studies and a 2.1% (95% Cl 0.46 to 3.81. p = 0.017) increase in
cost per capita across human capital model studies only.
The findings in Chapter 2 suggest that on average a 1% increase in smoking prevalence
results in a $5.42 USD (£3.55) increase in cost per capita across all studies and an $8.17 USD
(£5.36) increase in cost per capita across human capital model studies only. Despite
methodological differences among studies, there was a degree of consistency. In terms of
comparability, the human capital model serves as the most common template for indirect
174
cost-of-smoking studies but tends to overestimate the consequence of disease. The friction
cost method is not as widely used and there are questions on the assumptions on zero-cost
labour replacement.
7.2.2 Objective 2: Quantify productivity loss of smoking in the UK
In Chapter 3, the aim was to quantify productivity loss (indirect costs) due to smoking using
cost-of-smoking methodology for the UK. An epidemiological approach was taken to
calculate disease-specific smoking-attributable risk fractions for mortality from national-level
data. The risk fractions were then combined with UK death register data to calculate
smoking-attributable mortality. Based on age and sex-specific earnings data, the monetary
value of future foregone income was estimated (discounted at 3.5%) due to smoking-
attributable mortality.
Smoking was found to be responsible for 96,105 deaths in adults aged 35 years and over
(17% of all deaths) in the United Kingdom in 2010. These deaths resulted in nearly 1.2
million years of life lost and 357,831 years of productive life lost. The cost of productivity
loss due to premature mortality was £4.93 billion discounted at base-case rate of 3.5%.
The results in Chapter 3 suggest that there may be large gains in productivity of the
workforce by reductions in smoking prevalence. The sheer scale of the financial loss stresses
the importance of strong tobacco control policy at the national level.
7.2.3 Objective 3: Evaluate the association between smoking and absenteeism
In Chapter 4, the aim was to evaluate the epidemiological association of smoking and
absence from work by systematic review and meta-analysis. A systematic review and meta-
analysis was performed by electronic database searches in MEDLINE, EMBASE, CAB
Abstracts, PubMed, Science Direct and National Health Service Economic Evaluation
Database. Longitudinal, prospective cohorts or retrospective cohorts were included in the
review. Summary effect estimates were calculated using random effects meta-analysis.
Heterogeneity was assessed by P and publication bias was investigated.
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A total of 29 longitudinal or cohort studies were included. Compared with non-smokers,
current smokers had a 33% increase in risk of absenteeism. Current smokers were absent for
an average of 2.74 more days per year compared with non-smokers. Compared with never
smokers, ex-smokers had a 14% increase in risk of absenteeism; however, no increase in
duration of absence could be detected. Current smokers also had a 19% increase in risk of
absenteeism compared with ex-smokers. There was no evidence of publication bias. The
results in Chapter 4 showed that there was in fact a strong epidemiological association
between smoking and absence from work. Therefore, these findings could be used to quantify
the monetary costs of absence due to smoking.
7.2.4 Objective 4: Quantify costs of absence in the UK
A secondary aim in Chapter 4 was to quantify the cost of absenteeism in the UK using the
results from the meta-analysis comparing the duration of absence from current smoker and
ex-smokers. Smoking was estimated to cost UK employers on average £1.46 billion in 2011
/ from absenteeism in the workplace. This large economic impact of smoking on absenteeism
suggests that there is potentially great value in workplace smoking cessation programmes.
7.2.5 Objective 5: Validate indirect costs of smoking
In Chapter 5, the aim was to validate the indirect costs or productivity loss estimates using
an ecological model. The method for validation used the regression equations derived from
the ecological analysis of 17 population-level cost-of-smoking studies identified in Chapter
2. When the regression function derived from human capital model studies was used, the
predicted cost per capita was $150.93 USD (£99.49). When the predicted costs were
compared to the observed cost per capita of $159.10 USD (£102.64), there was only a 5%
difference between predicted and observed values. This validation procedure in Chapter 5
showed that the results of the cost estimates in this thesis were consistent with the results of
other published human capital studies.
7.2.6 Objective 6: Cost-benefit analysis of workplace interventions
In Chapter 6, the primary aim was to evaluate the cost-benefit of workplace smoking
cessation interventions to reduce absenteeism and labour turnover from the employer's
perspective via decision analysis and Markov simulation model. A simulated cohort of UK
176
workers was analysed using Markov modelling techniques. Decision analysis was used to
optimise strategy selection based on minimising total costs and maximising return on
investment for the employer.
Cost-benefit analysis of workplace interventions resulted in brief advice being the optimal
decision strategy for women and both brief advice and individual counselling being the
optimal decision strategies for men in terms of minimising total costs and maximising return
on investment. Brief advice in women resulted in average additional returns of £1.20 per
pound expended while brief advice in men resulted in average additional returns of £5.16 per
pound expended. Individual counselling in men resulted in average additional returns of
£1.00 per pound expended.
The results in Chapter 6 suggest that employers who adopt workplace smoking cessation
programmes will in fact save money. However, this may largely depend on workforce
turnover rates. There are clear benefits for employers with low labour turnover rates for
adopting smoking cessation interventions but the results are unclear when labour turnover is
high. In addition, the strategies selection may not necessarily maximise social welfare from a
pure societal perspective. If employers choose to base the decision analysis on financial
metrics, then brief advice would be an optimal intervention from the employer's perspective
offering the maximum returns on investment. While brief advice certainly will contribute
towards increasing quitters, it would not be the intervention that would maximise quitting
from a pure societal perspective.
7.2.7 Objective 7: Cost-effectiveness analysis of workplace interventions
A secondary aim of Chapter 6 was to explore if the decision strategy changes if the
employer valued maximising the number of quitters. In this cost-effectiveness analysis, the
selection between brief advice, individual counselling or NRT with individual counselling
was dependent on budget constraints. If the total budget constraint was £4,872 per male
worker and £2,197 per female worker then brief advice would be the most cost-effective
option. If the total budget constraint was £4,977 per male worker and £2,381 per female
worker then the more effective intervention of individual counselling would be the most cost-
effective option. If the total budget constraint was £5,259 per male worker and £2,743 per
female worker or if there was no budget constraint, then the most effective option of NRT
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with individual counselling would be the most cost-effective option. Maximising budget
constraints would align the societal and employer's perspective by selecting the most
effective smoking cessation strategy.
Policy-makers could consider promoting or supporting employers that choose to start a
workplace smoking cessation intervention. Tax incentives, subsidies or support for employers
for setting up smoking cessation interventions in the workplace may offer better returns on
investments by reducing costs for more expensive yet more effective interventions. This
suggests there is common ground for employers to contribute towards the net social welfare
of society.
7.3 Key lessons learned
The methods used in this thesis span a range of statistical, epidemiology and health economic
methods. Through the research process several key lessons were learned.
7.3.1 Flexibility and focus
The overarching theme of the thesis revolves around the economic impact of smoking in the
workforce. When this topic was in its inception, there were several avenues of research which
could have been pursued. The thesis had to be focussed on specific areas of research due to
the broadness of the economics of smoking while simultaneously allow flexibility due to
limitations in data availability.
In this thesis, quantifying the indirect costs of smoking was limited to the monetary value of
productivity loss from premature mortality and the cost of absenteeism. While these two
components are two primary components, indirect costs are theoretically comprised of many
other components as described in Chapter 2. However, quantifying the non-health related
components (i.e. presenteeism, smoking breaks, lost leisure time, lost household production)
require detailed data and complex econometric methods beyond the scope of public health.
Therefore, the research objective was focussed on the primary cost components of premature
mortality and absenteeism. Once the idea was devised to examine indirect costs due to
premature mortality and absenteeism, flexibility was also needed. In these particular areas of
research, there were a multitude of methods. The methodology used was largely dependent
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on data availability in the UK. In Chapter 2, the methodological review identified the human
capital model and friction cost model as possible methods for estimating productivity loss
due to premature mortality. Research into data availability showed that it was possible to use
the human capital model for estimating costs in the UK using a prevalence based approach.
However, the friction cost methodology required survey instruments from employers to
determine exact turnover times (friction periods). This data was not available and therefore,
this avenue of research could not be pursued.
Another instance where the balance between flexibility and focus was vital was in the
construction of the Markov model in Chapter 6. The building the model was dependent on
perspective. The idea was proposed to focus on employers as this was an area which research
gaps exist on the economic evaluations of workplace interventions. Once the perspective was
decided, flexibility was needed in the model building phase. The construction of the model
was an iterative process. For instance, the initial model constructed included the idea of
having time varying components based on duration of ex-smoking. However, time varying
parameters on absence and labour turnover risk by smoking status did not exist. Therefore,
assumptions had to be made about the model structure.
7.3.2 Impact of thesis work
The ultimate goal of research in public health, epidemiology or health economics is to
influence public policy and provide solutions to prevent ill-health and improve the health of
the individual or population. This is the most important lesson learned - the research
questions addressed in the field of public health should be translational and have the potential
to benefit the welfare of the individual or society. The research in this thesis attempts to add
to tobacco control economics. The economic arguments for and against tobacco control need
to be examined using an evidence-based approach to strengthen the research base around
tobacco control policy. While it was impossible to address all areas of research on the
economics of smoking, this thesis does provide a clearer picture about indirect costs,
productivity loss, absenteeism and workplace smoking cessation interventions. The
implications of the research provided in the thesis are particularly relevant for UK smoking
policy and has already contributed towards tobacco control policy in the UK.
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Parts of this thesis have been published in peer-reviewed journals. Chapter 3 has been
submitted to The European Journal of Health Economics. Chapter 4 was published in
Addiction. Chapter 6 will soon be submitted to the Journal of Health Economics for peer-
review. The publication in Addiction was fortunate enough to receive press coverage in media
outlets such as Reuters, New York Post, Daily Mail, The Guardian and The Telegraph. In
addition, the findings in Chapter 4 have been requested by the Department of Health for an
on-going budget impact assessment.
Furthermore, most of the research conducted in this thesis has been disseminated at
international conferences and University seminars. Chapter 3 has been presented at Tackling
Smoking in zr Century Britain which took place in York in November 2012. Chapter 4
has been presented at the ISh World Conference on Tobacco or Health in Singapore in
March 2011 and also presented as a seminar for the Epidemiology, Public Health and
Primary Care Joint Seminar Series at the University of Nottingham in September 2011. The
economic model in Chapter 6 has been presented as a seminar for The Department of
Health Sciences Spring Seminar Series at the University of York in January 2013.
7.3.3 Developing transferable research skills
The range of methods used in this thesis helped me develop research skills which were
transferable to other areas of public health. During my time as a PhD student at the UK
Centre for Tobacco Control Studies, I simultaneously worked as a NIHR- CLAHRC funded
research associate in developing risk prediction models for paediatric obesity with an
interdisciplinary team based at the Institute of Mental Health (University of Nottingham).
After completing Chapter 4 and publishing the contents of the systematic review, I applied
the transferable skills in meta-analysis and indirect treatments to my paediatric obesity
research which investigated the risk factors of childhood obesity. I subsequently was able to
publish the systematic review and meta-analysis in Archives of Disease in Childhood with
substantial press interest. In Chapter 3, the economic models relied on obtaining many
parameters from large population-level surveys in the UK which required a substantial
amount of large database management. I applied those database management skills to the UK
Millennium Cohort Study; from which I developed a risk prediction algorithm for paediatric
obesity based on predictors in infancy. I wrote a publication disseminating this research
which has now been accepted by Pediatrics for publication. I have since conducted a
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validation study of my risk prediction algorithm using the Avon Longitudinal Study of
Parents and Children which will soon be submitted to The British Medical Journal.
7.4 Future research
As mentioned earlier, the economic impact of smoking in the workforce is extremely broad.
The research in this thesis provided aspects that can contribute to the evidence-base.
However, there are several areas in which there is potential for future avenues of research.
InChapter 2, besides productivity loss due to foregone income and absence costs from work,
there were several other components of indirect costs identified such as presenteeism,
smoking breaks, lost leisure time, fire damage and passive smoking. These elements made up
of smaller proportions of total indirect costs. Furthermore, the methods around the
quantification of these costs are less developed and there is no consensus on best practice
methods due to a limited number of studies. Therefore, this thesis did not attempt to address
those elements. However, it must be acknowledged that future research should address these
components in order to facilitate the estimation of total societal costs of smoking.
In Chapter 3, productivity loss due to premature mortality was estimated using the human
capital method for the UK. The friction cost is not as widely used but if data is available from
UK employer-based surveys on friction periods (replacement time) it would possible to
quantify indirect costs due to premature mortality using this method. This method assumes an
employer's perspective and therefore costs would be reduced due to replacement of labour.
This would add an important perspective to complement the human capital method.
In Chapter 4, the epidemiological association was based on absence from work due to
sickness and illness. This type of absence was solely based on the health effects
consequences of smoking. Absenteeism related to behaviour was not excluded from the
review but there were no longitudinal studies identified which have investigated this effect.
There are some indications that in addition to the health effects of smoking, there may be
possible differences in behavioural characteristics associated with smokers that contribute
towards absenteeism, similar to perhaps the truancy effect observed in children who
smoke.l'! This link between smoking and absence related to behavioural effects could be
investigated in the future using an occupational cohort.
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In Chapter 6, the economic evaluation of four workplace strategies for smoking cessation
was conducted; of which only one form of NRT was tested. Other forms of NRT which could
be evaluated for cost-benefit or cost-effectiveness in the future include gum, inhaler,
lozenges, tablets or combination therapy. In addition, other forms of pharmacotherapy such
as varenic1ine and buproprion offer substantially higher rates of quitting103 107; however it is
unknown due to lack of evidence as to whether these therapies are effective or cost-effective
in the workplace setting. Another area of potential research is the effectiveness and cost-
effectiveness of financial incentives in the workplace for smoking cessation. A recent review
found that rewarding participation and compliance in cessation programmes may have the
potential to deliver higher absolute numbers of quitters, but long-term success of quitting
through financial incentives is mixed.412 This is an area that needs much more research into
types of programmes, scale and longevity of cash rewards within a variety of smoking
populations before cost-effectiveness can be assessed.
7.5 Overall conclusions
This thesis has used a range of methodology to quantify the impact of smoking in the
workplace. In addition, this research has provided possible solutions to decrease the burden
of smoking in the workplace. The results have highlighted that a variety of methodologies are
needed to evaluate the economics of smoking. Although significant research gaps still
remain, the research provided contributed towards narrowing this gap. In particular, this
thesis has provided the first indirect cost-of-smoking study quantifying the productivity loss
due to premature mortality in the UK; the first systematic review and meta-analysis which
has explored the association between smoking and absence from work; and the first cost-
benefit and cost-effectiveness analysis of workplace interventions for smoking cessation in
the UK. The findings are particularly relevant for UK policymakers and employers for
justifying stronger tobacco control and promoting cessation. However, these methods are not
unique to the UK. The research in this thesis has provided the framework and methodology
for studies that can strengthen the evidence on the economics of smoking in other countries
as well. Finally, these methods are also not unique to tobacco control field. The burden-of-
illness and economic evaluation methodologies can be translated for research in other disease
epidemics.
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9.1 Chapter 2 Methods: Search terms
smoking
nicotine
tobacco
tobacco dependence
tobacco smoke
cigarette smoking
exp smoking
exp "smoking and smoking related phenomena"
smok$
tobacco$
cigarette$
cotinine$
cigar$
pipe$
adult smok$
former smok$
current smok$
ex smok$
non smok$
indirect
indirect cost$
mortality
morbidity
premature mortality
smoking-attributable$
life years lost
productive life years
absenteeism
sick$ absence
ill$ absence
sick$ absenteeism
ill$ absenteeism
work$ absence
prevalence approach
incidence approach
human capital
friction cost
work$ absenteeism
product$ lost
product$ loss
presenteeism
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9.2 Chapter 2 Methods: Health economic quality assessment form
Checklist Questions (Max = 8 points) Yes (1 point) No (0 points)
1. Is a well-defined research question posed in an answerable form?
2. Is the study population clearly described?
3. Is the economic study design appropriate to the stated objective?
4. Are costs measured appropriately in physical units?
5. Are costs valued properly?
6. Are all future costs discounted appropriately?
7. Do the conclusions follow the data reported?
8. Are costs subject to additional sensitivity analysis?
Total Score
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9.3 Chapter 4 Methods: Search terms
Smoking
Nicotine
smoking cessation
Tobacco
tobacco dependence
tobacco smoke
cigarette smoking
Cotinine
exp smoking
exp tobacco smoke pollution
exp "smoking and smoking related phenomena"
exp parental smoking
exp passive smoking
exp smoking habit
exp smoking cessation
smok$
tobacco$
cigarette$
cotinine$
cigar$
pipe$
second hand smok$
environmental tobacco smoke
adult smok$
former smok$
current smok$
ex smok$
non smok$
smoking status
absenteeism
"period of absence"
sick$ absence
ill$ absence
sick$ absenteeism
ill$ absenteeism
sick$leave
sick$ day$
work$ absence
work$ absenteeism
employee absence
employee absenteeism
work$ ill$
work$ sick$
product$ lost
product$ loss
"risk of absenteeism"
"risk of absence"
presenteeism
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9.4 Chapter 4 Methods: Eligibility checklist
Area 1. Study Design
I. The article presents a study that is longitudinal in design, where participants were
recruited at the beginning of the study, and then reassessed at a later interval or
end of the study (YIN) __
II. The article presents a study that is a prospective cohort, where participants were
recruited in the beginning of the study, and followed-up over regular intervals
(YIN) __
III. The article presents a study that is a retrospective cohort, where participants were
recruited, and then data was gathered on the participants from previous records
(YIN)_
If the answer was "yes" to any of these (I-III) statements, then the study satisfies the
study design criteria (Area 1): _
Area 2. Population
I. The participants in the study are full time workers and wage earners in the any of
the following occupational categories below (YIN) __
II. The participants in the study are part time workers and wage earners in any of the
following occupational categories below (YIN) __
III. The participants in the study are self employed workers and wage earners in any
of the following occupational categories below (YIN) _
Agriculture and fishing Energy and waster
Manufacturing
Distribution, hotels, and restaurants
Banking, finance, and insurance
Other services
Construction
Transport and communication
Public admin, education, health
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If the answer was "yes" to any of these statements (I-III), then the study satisfies the
population criteria (Area 2): _
Area 3. Exposure of interest- Smoking
I. The study assesses the participant's smoking status absenteeism occurs (YIN)
II. The study assesses the participant's smoking dosage before absenteeism occurs
(YIN)_
If the answer was "yes" to any of these statements (I-II), then the study satisfies the
exposure criteria (Area 3): _
Area 4. Outcome of interest - Absenteeism
I. The study assesses the participants work absenteeism record after smoking status
has been established (YIN) __
II. The study assesses the participants work sickness/illness record after smoking
status has been established (YIN) __
III. The study assesses the participants work attendance records after smoking status
has been established (YIN) __
Ifthe answer was "yes" to any of these statements (I-III), then the study satisfies the
outcome criteria (Area 4): _
Overall Inclusion:
If the study satisfies Areas 1-4, then include study in the systematic review: __ Y~es:!!.lN~o:..,__
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9.5 Chapter 4 Methods: Data extraction form
DESCRIPTION OF STUDY
Title
Study Design Prospective Cohort Retrospective Cohort
Longitudinal
Timing of Study Duration of Study (days/months/years):
Study year(s):
Definition of Smoking
(Smoking Status) Yes/No:
Current:
ExlFormer:
Non:
Heavy:
Light:
Moderate:
Other:
Attainment of Smoking
Validated test (Cotinine, Blood test, CO test) Self reported
Employer reported Medical record Other:
Measurement of
Absenteeism Days:
Hours:
Ratio Measure:
Other:
Attainment of Absenteeism Self reported Employer reported Registry Not Stated
Other:
SettinglLocation
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PARTICIPANTS
General characteristics
(Descriptive statistics)
Inc1usionlExc1usion
Occupational Occupation as defined by study:
characteristics
Full-time (2: 30 hours/week) Part-time « 30 hours/week)
(Industry sector - LFS)
All Industries Agriculture & fishing Energy & water
Manufacturing Construction Distribution, hotels &
restaurants
Transport & communication Banking, finance & insurance
Public admin, education, health Other services
Initial Sample Size
Follow-up rate
Final Sample Size
RESULTS
Absenteeism Unadjusted Adjusted Adjusted
(Inc 95% Cl) (Inc 95% Cl) Significance
Time Element (Days/Hours)
Ratio
(Risk/Odds/Rate)
~
Other
Covariates:
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9.6 Chapter 4 Methods: Quality assessment form
Newcastle-
*
Ottawa Scale Cohort studies
Selection 1) Representativeness of the exposed cohort
(Max - 4 stars) a. Truly representative of the average worker in the field/industry *
b. Somewhat representative of the average worker in the field/industry*
c. Selected group of users (volunteers)
d. No description of the derivation of the cohort
2) Selection of the non exposed cohort
*
a. Drawn from the same field/industry as the exposed cohort
b. Drawn from a different source
c. No description of derivation of non exposed cohort
3) Ascertainment of exposure
a. Biomarker or validation test (CotininelBlood sample! CO test)*
b. MedicaVemployer/survey reported
c. Self report or interview
d. No description
4) Demons~on that the outcome of interest was not present at start of study
a. Yes
b. No
Comparability 1) Comparability of cohorts on basis of the design or analysis
(Max - 2 stars) a. Study controls/stratifies for age or sexf(
b. Study controls/stratifies for any additional factor (at least one more) *
Exposure/ 1) Assessment of absenteeism
Outcome a. GPlMedical record *
(Max - 3 stars) b. EmployerlNational record *
c. Self report or interview
d. No description
2) Was follow-up long enough for outcomes to occur
a. Yes (~1 year),*
b. No
3) Adequacy of follow up cohorts
a. Complete follow up - all subjects accounted for '*
b. Subjects lost to follow up unlikely to introduce bias (follow-up rate >80%) or
description provided of those lost *
c. Follow up rate < 80% and no description of those lost
d. No statement
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9.7 Chapter 4 Methods: Random effects meta-analysis
The random effects model was used to pool the effect sizes from the extracted data using
inverse variance weightingt':'. The study t of a total of n studies provided the estimated effect
of interest Yio such as the log odds ratio, log risk ratio or difference in means. The estimated
effect of interest Yt as a function of the effect size 8t was assumed to be distributed normally
with mean of 8t and study variance of al:
Y· I8·- N (8· a?-)l l l' l
Additionally, the random effects meta-analysis allowed the true effects 8t to vary between
studies assuming a normal distribution around the true mean effect 8 with variance T2:
Transitively, the effect size of interest Yt was normally distributed around a mean effect 8
with variance al + T2:
Equivalently in functional form:
Yt = 8 + Ut + Et where Ut - N(O, T2) and Et - N(O, al)
The variance T2 was estimated as the between-study variance through the method of
moments approachi'". Each effect size was given a weight, the reciprocal of its variance. In
effect, studies with smaller sample sizes resulted in larger variances, which translated into
smaller weights. The weight Wi was denoted by the following:
1
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Subsequently, the pooled estimate of the effect size y was calculated as the sum of the
weights multiplied by the estimated effect of each study Yi, divided by the sum of the weights
from all studies:
The variance 82 of the pooled effect size was given by:
To assess heterogeneity between studies, the ]2 statistic was calculated as a proportion of
total variability in the model:
]2 = _Q _-....;..(k_-_l_)
Q
The measure of heterogeneity Q was given by:
k
Q = LWi (Oi - 8)2
i=l
The component (Oi - 8) was the difference of the study effect and the pooled effect and
wi was the study weight. ]2 values lie between 0 to 100%, with higher percentage variation
suggesting more heterogeneity or differences among the studies.
217
9.8 Chapter 4 Methods: Random effects meta-regression
Random effects meta-regression extends random effects meta-analysis by replacing the mean
effect size (J with a linear predictor xi/i. This assumes that the true effects follow a normal
distribution around the linear predictor:
Therefore,
Written in functional form:
The model was extended into a multivariate form to incorporate covariates:
Using the equations directly above, the covariates of gender, type of absence and work sector
were incorporated as dummy variables for into three separate multivariate models. All
algorithms for random effects meta-regression first estimate the between study variance T2
and then estimate the coefficient P by weighted least squares using weight l/(ul+ T2). The
algorithm for meta-regression uses restricted maximum likelihood (REML) to estimate T2
based on maximisation of the residual log likelihood.306
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9.9 Chapter 4 Methods: Adjusted indirect comparisons
The random effects model in Chapter 4 makes two direct comparisons due to never smokers
as the reference group: (1) current smokers versus never smokers (2) ex-smokers versus
never smokers. It is possible to take an indirect comparison between current smokers and ex-
smokers from information available using adjusted indirect meta-regression methods305• The
natural log of the relative risk of absence between current and ex-smokers (LnRRcSvs EX) for
indirect comparison can be estimated as the exponential of the difference in log relative risk
of current smokers versus never smokers (LnRRcsvs NS) and ex-smokers versus never
smokers (LnRREX vs NS):
LnRRcSVSEX = exp(LnRRcsVSNS - LnRREXVSNS)
Furthermore, the standard error of the indirect comparison (SEes vs EX ) can be estimated from
the square root of the sum of the squared standard errors:
SEeSVSEX - .JSEesvsNs + SEEXVSNS
Using the indirect comparison results of the standard error and log relative risks, the 95%
confidence interval can be computed:
95% Cl = exp(LnRResvsEx) ± 1.96 x InSEcsVSEX
The above analysis produces inverse variance estimates. Alternative indirect meta-analysis
models can be obtained by using the Mantel-Haenszel fixed-effect model, the DerSimonian
and Laird random effects model, weighted linear meta-regression or random effects meta-
regression.i'" The differences between the methods resulted in less than 1% difference in
pooled indirect effects and standard errors. Therefore, the choice of methodology had a
marginal impact on the results so the most straightforward method was used.
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9.10 Chapter 4 Methods: Data transformations
9.10.1 Rate ratio to risk ratio
Rates ratios and incidence rates are specified by:
IncidenceExposedRate Ratio = ----....:.;.;:..:;,..;".;;".;,.;,;..-
IncidenceNonexposed
Event
Incidence = ------Person _ time
The Poisson distribution is the preferred method for calculation of rates as a discrete
probability distribution that expresses the probability of a given number of events occurring
in a fixed interval of time if these events occur with a known average rate. The rate ratio is a
consistent estimator of the risk ratio provided that the ratio of persons at risk between
exposed and non-exposed groups are constant over time.302 The theory suggests that the rate
ratio will converge to the risk ratio if size of the sample at the beginning of the study
approaches the size of the sample at the end of the study. The rate ratio can in effect be
considered a special case of the risk ratio taking into account individual follow-up time. Thus,
rate ratios were used as estimates of risk ratios due to sufficient sample sizes and follow-up
rates.
9.10.2 Hazard ratio to risk ratio
Hazard ratios are measurements of instantaneous risk. The hazard ratio is specified by:
HazardExposedHazard Ratio = ---_.;;;,;.,;,::",:,;:.:.::._
HazardNonexposed
The studies included in the systematic review used the Cox proportional hazards model. In
the Cox model, the hazard rate is the probability that if the event in question (absenteeism)
has not yet occurred, it will occur in the next time interval, divided by the length of the
interva1.28s As the time interval decreases, the rate becomes instantaneous. The hazard rano is
a ratio of hazard rates; the assumption in the Cox model being that the ratio remains constant
over time. In contrast to hazard ratios, the risk ratio is expressed as the proportion of events
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occurring in the exposed group compared to that of the non-exposed group calculated at the
end of the study having occurred over an average or median duration of the study.415When
the study is short in length, then hazard ratio converges on the risk ratio. When the study is
long in length, the hazard ratio becomes a more precise estimator of the risk ratio. In essence,
the hazard ratio is a special case of the risk ratio that takes into account length of time for the
event to occur. Therefore, the studies that reported hazard ratios as outcomes were used
directly as estimates of the risk ratio.
,
9.10.3 Odds ratio to risk ratio
Odds ratios, unlike hazards and rate ratios are structurally different from risk ratios. If the
prevalence of outcome is high (common outcome), odds ratios will overestimate the risk ratio
when the measure of effect is greater than one and will underestimate the risk ratio when the
measure of effect is less than one.416Even if the outcome is uncommon, the odds ratios may
not approximate the risk ratio well if adjustment are made for confounding variables.t'"
Therefore, odds ratios were transformed into relative risk using a correction method303•
Risk Ratio = Odds Ratio
(1- Po) + (Odds Ratio x Po)
Cases
Po= ~~~--------Total Nonexposed
This method has been used to estimate adjusted risk ratio using Po, the number of cases of
absenteeism events in the non-exposed group. For studies that did not provide enough
information to compute Po, the weighted average Po was used calculated from the known
studies with known Po:
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9.11 Chapter 4 Methods: Missing parameter imputation
In order to use meta-analysis to pool a measure of effect, several parameters are needed. For
categorical exposures, this required individual studies to provide: the relative risk (InRR),
lower confidence limit (InLCI), upper confidence limit (InUCI); or the standard error of the
relative risk (se[lnRR]). For studies that were missing the upper or lower confidence limit,
certain techniques were used to impute the values.
For continuous exposures, six parameters are needed. The pooled difference in means
estimation required individual studies to provide: the mean of the exposed group (XExposed),
sample size of the exposed group (nEXposed), standard deviation of the exposed group
(SdExposed); mean of the non-exposed group (XNonexposed), sample size of the non-exposed
group (nNonexposed), standard deviation of the non-exposed group (SdNonexposed); or
separately the difference in the means (XExposed - XNonexposed) and the standard error of
the mean difference. Studies that did not provide the sample sizes of the exposure groups
were excluded from the meta-analysis but not from the systematic review. For studies that
were missing standard deviations, certain techniques were used to impute the values.
9.11.1 Imputing 95% confidence interval
For studies that did not report a 95% confidence interval (Cl), it was possible to impute the
lower and upper bounds from exact p-values or p-value cut-offs. The reported p-value needed
either to be an exact or an upper bound cut-off. In studies that reported the exact p-value, the
exact values of the lower and upper bound 95% Cl were calculated. In studies that reported
an upper bound cut-off of the p-value, only a conservative estimate of the 95% Cl was
obtained. The z-score from the corresponding p-value was obtained from the normal
distribution. The log of the standard error (inSEt) was calculated from the z-score and study
effect size et, using the following formula:
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In some cases where rate ratios were reported as the effect size and p-values were not given,
studies providing number of absenteeism events in both exposed and non-exposed groups
could be used to compute the log of the standard error417:
lnSEt =
1 1
r----+-----
EExposed, ENonexposed,
The variable E Exposed, was the number of absence events in the exposed group and
ENonexpoSedt was the number of absence events in non-exposed group. Subsequently, the 95%
Cl of the effect size was obtained from the log of the standard error:
95% CIi = ei ± 1.96 x lnSEi
However, when p-values were not given, were insignificant or when information about the
number of absence events in exposure groups were not given, an alternative method was
used: the standard error from the pooled effect size of all the other studies with available
confidence intervals in the random effects meta-analysis could be used as a proxy for
individual study standard errors.418 In essence, the missing confidence intervals were given
the standard error of the entire pooled population, The log of the pooled standard error lnSE
could be obtained from the estimated pooled effect size {j and pooled 95% Cl:
l - 95% El - {jnSE=----
1.96
From a slight variation, the 95% confidence interval of the individual study could be imputed
from the log of the pooled standard error:
95% CIi = ei ± 1.96 x inSEt
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9.11.2 Imputing standard deviation
For studies that did not report standard deviations of the mean duration of absence in both
exposed and non-exposed groups, it was possible to impute standard deviations from the F-
statistic, t-statistic, or p_value.419 The F-statistic is derived from analysis of variance
(ANOV A), which tests for the equality of the means by the variance. The t-statistic was
derived from the F-statistic by:
If and only if:
df = k -1 = 1
This condition was only satisfied when k = 2 and the degrees of freedom was 1. Therefore,
the above process can only be used when comparing two means. In this case, the analysis was
based on comparison of mean difference of absence between the exposed and the non-
exposed group satisfying the assumption of two means. The t-statistic can also be derived
from the p-value using the student's t distribution and degrees of freedom. The degrees of
freedom for the t-statistic was derived by:
df = nEXposed + nNonexposed - 2
Once the t-statistic was obtained, the standard error was calculated where XEXpoSedt and
XNonexpoSedt were the mean absence durations of the exposed and non-exposed groups
respecti vel y:
XEXposedt - XNonexposedt
se. =
, t
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The within-group standard deviation was obtained from a standard error using the following
formula where nExposedt and nNonexposedt were the sample sizes of the exposed and non-
exposed groups respectively for study i:
1 + 1
nExposedt nNonexposedt
The standard deviation (SDi) was the average of the standard deviations of the both the
exposed and non-exposed group. Thus, the average standard deviation was used as a proxy
for the individual standard deviations from groups as shown:
For studies that did not provide a test statistic or p-value to impute standard deviations, an
alternative method was used to impute standard deviations from the pooled mean difference
using random effects meta-analysis of studies with known standard deviations.418 The degrees
of freedom could be computed for the entire pooled sample. The t-statistic was obtained from
the student's t distribution using the computed degrees of freedom and p-value cut-off of
0.05. From the pooled mean difference, t-statistic and 95% confidence interval; the standard
error of the pooled mean difference was calculated using:
__ (Xpooled - LC/pooled)
se =~:,__---_:;....:..;.~,;;_
t
The pooled standard error was used as a proxy for the standard error of each individual study.
From a slight variation of an above equation, the within group standard deviation was derived
from the pooled standard error:
Se
SDi = -;:::=======
1 + 1
NExposedi NNoneXposedj
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9.12 Chapter 6 Methods: Random effects meta-analysis of proportions
The process of pooling proportions across studies relied on similar meta-analytic techniques
used in previous sections. In Chapter 4, relative risks were pooled using inverse variance
weighting413• However, this process assumes a normal distribution for effect sizes as
described in Appendix 9.7. The assumption of normality cannot be assumed for proportions
as proportions have binomial characteristics.
In order to pool proportions, data transformations must be used. This is done by first
transforming the raw proportions into a quantity suitable for random effects meta-analysis.
Let ni be the sample size and Pi be the raw proportion of study t. The Freeman- Tukey372
variant Xi of the study proportion can be calculated by an arcsine square root transformation:
The aim behind this transformation is to use the arcsine function to create a new set of
variables such that the variability in the values do not relate to the mean value. The arcsine
transformation is a common transformation which applies to source data in the range from
[0,1] which naturally characterises binomial data. The transformation spreads the data across
the range from [-7tl2, 7tl2] which adjusts the data to make the distributions more similar to a
normal distribution. Next, the individual transformed proportions Xi can be pooled across
studies:
The DerSimonian-Laird weighr'!" Wi for each study t incorporates the random effects
variable T2 characterised as the between-study variance calculated by the method of moments
approacht'":
1
W'=---
t T2 + c:ri
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The variance u: of transformed study proportion Xi can be estimated as the square of the
standard error of study proportion xi using study sample size ni:
ui = se; = In. ~1)
Once the pooled transformed proportion X is calculated, the parameter can be back-
transformed to obtain the original pooled proportion p by using sine squared:
p = sin2 (~)
This analysis was carried out using the statistical software StatsDirect Version 2.
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9.13 Chapter 6 Methods: Probability Distributions
9.13.1 Limitations of the triangular distribution
Costs typically can be fit as gamma or log-normal distributions constraining costs to non-
negative values while also reflecting potential skewness in the data.407 However, fitting a
gamma or log-normal distribution requires sample moments (mean and variance) which none
of the literature which informed the cost estimates provided. In scenarios where only
maximum and minimum costs elements are provided, there are two possible solutions: (1) fit
a triangular distribution (2) or conduct one-way sensitivity analysis. The triangular
distribution is easily fitted as a unit area triangle which can be represented by three
parameters: a minimum, a maximum and a mode. Despite being easy to fit, the distribution is
extremely limited. The distribution is non-symmetric and the mean will not equal the mode.
The distribution also has three points of discontinuity at each of the minimum, mode and
maximum (zero probability of values above or below the minimum and maximum). Minima
and maxima are also poor statistics in that the range of the variation measured tends to
increase with sample size as there is more of a chance of observing and extreme value. This is
contrary to what is generally considered desirable for the variance of the parameter
distribution to decrease when greater information on the parameter of interest is provided.
These limitations bring more arbitrary uncertainty rather than informed uncertainty into the
model by using the triangular distribution. Therefore, the latter choice of conducting one-way
sensitivity analyses on the maximum and minimum values of transitions costs was the desired
strategy.
9.13.2 Fitting the beta distribution
When parameters are obtained from finite and small sample sizes, the natural probability
distribution for probability parameters is the beta distribution. The beta distribution was fit
using the method of moments approach 407:
il(l-il)
(a + P) = S2 -1
a = il(a +p)
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The system of equations requires two sample moments: the mean (u) and the standard error
(s) to solve for distribution parameters alpha (a) and beta (P). The mean was provided as the
six-month transition probability and the standard error (se) was calculated using the following
formula with known sample size (n):
se = Jp(l;P)
The beta distribution is the natural choice for representing uncertainty in a probability
parameter when the data informing the parameters is binomial as the beta distribution is
conjugate to binomial data.407 The selection of the beta distribution was an informed choice
as the beta distribution constrains probabilities to their natural endpoints - from zero to one.
Since many of the probabilities populating the Markov model in Chapter 6 were near zero
and had small sample sizes, standard errors were often large relative to the mean. If a normal
distribution was applied to those parameters, the tail ends of the distribution would have been
less than zero. This would have been problematic for probabilistic sensitivity analysis as
probabilities cannot be negative.
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